SlideShare une entreprise Scribd logo
1  sur  34
Télécharger pour lire hors ligne
Guideline irritable bowel syndrome 2012
1§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
§”·π–𔇰’ˬ«°—∫
‚√§≈”‰ â·ª√ª√«π
 ”À√—∫·æ∑¬å∑—Ë«‰ª
(·π«∑“߇«™ªØ‘∫—µ‘)
2012
‚¥¬
 ¡“§¡ª√– “∑∑“߇¥‘πÕ“À“√·≈–°“√‡§≈◊ËÕπ‰À« (‰∑¬)
2 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π
 ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
‚¥¬  ¡“§¡ª√– “∑∑“߇¥‘πÕ“À“√·≈–°“√‡§≈◊ËÕπ‰À« (‰∑¬)
æ‘¡æ§√—Èß∑’Ë 1 ‡¡…“¬π 2556
®”π«π 5,000 ‡≈à¡ 32 Àπâ“
 ß«π≈‘¢ ‘∑∏‘Ï
æ‘¡æå∑’Ë
PENTAGON ADVERTISING LTD., PART.
566/124 ´Õ¬°‘®æ“π‘™ ∂ππæ√–√“¡ 4 ·¢«ß¡À“æƒ≤“√“¡ ‡¢µ∫“ß√—° °√ÿ߇∑æœ 10500
566/124 Soi Kijpanich, Rama 4 Rd., Bangrak, Bangkok 10500
Tel : 235-6038, 633-3762 Fax 633-0334
Email: toon47@asianet.co.th
3§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
Irritable Bowel Syndrome (IBS) ‡ªìπªí≠À“∑’Ëæ∫∫àÕ¬„πª√–‡∑»‰∑¬·≈–
post infectious diarrhea Õ“®®–‡ªì𠓇ÀµÿÀπ÷ËߢÕß IBS ‰¥â ∑”„Àâ incidence
‡æ‘Ë¡¢÷Èπ„π∫â“π‡√“
Guideline π’È ™à«¬„Àâ·æ∑¬å∑’Ëæ∫ºŸâªÉ«¬¥â«¬ªí≠À“π’ȇ¢â“„®·≈– approach §π‰¢â
‰¥â‡À¡“– ¡¢÷Èπ
¢Õ¢Õ∫§ÿ≥Õ“®“√¬å∑ÿ°∑à“π∑’Ë ≈–‡«≈“ ·≈–µ—Èß„®∑”„À≥â guideline ¥’·≈–
practical ∑’Ë ÿ¥ ”À√—∫ª√–‡∑»‰∑¬
».πæ. ‘π Õπÿ√“…Æ√å
𓬰 ¡“§¡ª√– “∑∑“߇¥‘πÕ“À“√·≈–°“√‡§≈◊ËÕπ‰À« (‰∑¬)
§”π”
4 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
§”π”
IrritableBowelSyndrome(IBS)‡ªìπ°≈ÿà¡Õ“°“√∑’Ëæ∫∫àÕ¬„π∑“߇«™ªØ‘∫—µ‘
ºŸâªÉ«¬ IBS ¡’Õ“°“√§≈⓬°—∫‚√§Õ◊Ë𠇙àπ dyspepsia ∑âÕ߇ ’¬ ·≈–∑âÕߺŸ° À√◊Õ IBS
Õ“®‡°‘¥√à«¡°—π°—∫‚√§Õ◊Ë𠧫“¡√Ÿâ·≈–§«“¡‡¢â“„®‡°’ˬ«°—∫‚√§ IBS „πÀ¡Ÿà·æ∑¬å
‡«™ªØ‘∫—µ‘∑—Ë«‰ª¬—ß¡’πâÕ¬Õ¬Ÿà‚¥¬∑’˺ŸâªÉ«¬ IBS ¡—°®–‰¥â√—∫°“√«‘π‘®©—¬‡ªìπ‚√§Õ◊Ë𠇙àπ
dyspepsia ®ÿ¥¡ÿàßÀ¡“¬¢Õß guideline π’È §◊Õ ‡ªìπ°“√„ÀâÕߧ姫“¡√Ÿâ‡°’ˬ«°—∫ IBS
·π«∑“ß„π°“√µ√«®§âπ·≈–°“√√—°…“∑’ˇÀ¡“– ¡µ“¡ ¿“«–·≈–¢âÕ¡Ÿ≈∑’Ë¡’Õ¬Ÿà„πªí®®ÿ∫—π
§”·π–π”„π guideline π’È ‡ªìπ‡æ’¬ß·π«∑“ß„π°“√¥Ÿ·≈ºŸâªÉ«¬ IBS Õ¬à“߉√
°Áµ“¡·æ∑¬å∑’Ë¥Ÿ·≈ºŸâªÉ«¬Õ“®®–∑”°“√¥Ÿ·≈√—°…“ºŸâªÉ«¬·µ°µà“߉ª®“°§Ÿà¡◊Õπ’ȉ¥âµ“¡
§«“¡‡À¡“– ¡ ”À√—∫ºŸâªÉ«¬·µà≈–√“¬
∫∑ √ÿªµà“ßÊ ∑’ˇ°’ˬ«°—∫ IBS „π§Ÿà¡◊Õ©∫—∫π’ȉ¥â√«∫√«¡·≈–‡¢’¬π¢÷Èπ¡“
‚¥¬Õâ“ßÕ‘ß∂÷ߢâÕ¡Ÿ≈®“°µà“ߪ√–‡∑»‡ªìπ à«π„À≠à·≈–‡ªì𧫓¡‡ÀÁπ¢ÕߺŸâ‡™’ˬ«™“≠
„π°√≥’∑’Ë¢âÕ¡Ÿ≈‰¡à‡æ’¬ßæÕÀ√◊Õ‰¡à¡’ ‚¥¬‡©æ“–Õ¬à“߬‘ËߢâÕ¡Ÿ≈∑’ˇ°’ˬ«¢âÕß°—∫ IBS
„πª√–‡∑»‰∑¬ ´÷Ëß¡’§”∂“¡À≈“¬ª√–°“√∑’ˬ—߉¡à¡’§”µÕ∫∑’Ë™—¥‡®π ·≈–§ßµâÕß
∑”°“√»÷°…“‡æ‘Ë¡‡µ‘¡‡æ◊ËÕπ”¡“„™â„π°“√®—¥∑” guideline §√—ÈßµàÕ‰ª„Àâ ¡∫Ÿ√≥嬑Ëߢ÷Èπ
Guideline π’È ”‡√Á®≈ÿ≈à«ß‰¥â¥’‚¥¬§«“¡√à«¡¡◊Õ¢Õß°√√¡°“√∑’Ë√–¥¡§«“¡§‘¥
∑—Èß„π°“√ª√–™ÿ¡§√—Èß·√° «—π∑’Ë 22 - 23 ¡°√“§¡ 2554 ·≈–§√—Èß∑’Ë Õß«—π∑’Ë 23 - 24
¡‘∂ÿπ“¬π 2555 ®÷ߢբÕ∫§ÿ≥‡ªìπÕ¬à“ß Ÿß ‰«â ≥ ∑’Ëπ’ȥ⫬
√».πæ.∫—≠™“ ‚Õ«“∑Ó√æ√
ª√–∏“π°“√®—¥∑” guideline
5§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
 “√∫—≠
§”π” 𓬰 ¡“§¡ª√– “∑∑“߇¥‘πÕ“À“√·≈–°“√‡§≈◊ËÕπ‰À« (‰∑¬) 3
§”π” ª√–∏“π°“√®—¥∑” Guideline for Management of Irritable Bowel Syndrome 4
§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 6
Definition 6
¢âÕ √ÿª∑’Ë 1. 6
¢âÕ √ÿª∑’Ë 2. 6
¢âÕ √ÿª∑’Ë 3. 7
Overlapping syndrome 8
¢âÕ √ÿª∑’Ë 4. 8
Pathophysiology 10
¢âÕ √ÿª∑’Ë 5. 10
¢âÕ √ÿª∑’Ë 6. 11
¢âÕ √ÿª∑’Ë 7. 11
Clinical evaluation 13
¢âÕ √ÿª∑’Ë 8. 13
¢âÕ √ÿª∑’Ë 9. 13
¢âÕ √ÿª∑’Ë 10. 14
¢âÕ √ÿª∑’Ë 11. 15
¢âÕ √ÿª∑’Ë 12. 15
¢âÕ √ÿª∑’Ë 13. 15
¢âÕ √ÿª∑’Ë 14. 16
¢âÕ √ÿª∑’Ë 15. 16
Non-pharmacological treatment 18
¢âÕ √ÿª∑’Ë 16. 18
¢âÕ √ÿª∑’Ë 17. 18
¢âÕ √ÿª∑’Ë 18. 19
¢âÕ √ÿª∑’Ë 19. 19
¢âÕ √ÿª∑’Ë 20. 20
Pharmacological treatment 24
¢âÕ √ÿª∑’Ë 21. 24
¢âÕ √ÿª∑’Ë 22. 26
Psychiatric problems „π IBS 29
¢âÕ √ÿª∑’Ë 23. 29
¢âÕ √ÿª∑’Ë 24. 30
IBS Guideline 31
√“¬π“¡ºŸâ‡¢â“√à«¡ª√–™ÿ¡ —¡¡π“æ‘®“√≥“ IBS Guideline 32
7§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
2.2 ¡’Õ“°“√ª«¥∑âÕßÀ√◊Õ‰¡à ∫“¬„π∑âÕß¡“°°«à“À√◊Õ‡∑à“°—∫ 3 «—πµàÕ‡¥◊Õπ„π
3 ‡¥◊Õπ∑’˺à“π¡“√à«¡°—∫≈—°…≥–Õ“°“√∑“ߧ≈‘π‘°Õ¬à“ßπâÕ¬ 2 „π 3 ≈—°…≥–µàÕ‰ªπ’È
2.2.1 Õ“°“√ª«¥∑âÕßÀ√◊Õ‰¡à ∫“¬„π∑âÕߥ’¢÷ÈπÀ≈—ß°“√∂à“¬Õÿ®®“√–
2.2.2 Õ“°“√ª«¥∑âÕßÀ√◊Õ‰¡à ∫“¬„π∑âÕ߇°‘¥√à«¡°—∫°“√‡ª≈’ˬπ·ª≈ߢÕß
§«“¡∂’Ë¢Õß°“√∂à“¬Õÿ®®“√–
2.2.3 Õ“°“√ª«¥∑âÕßÀ√◊Õ‰¡à ∫“¬„π∑âÕ߇°‘¥√à«¡°—∫°“√‡ª≈’ˬπ·ª≈ߢÕß
≈—°…≥–§«“¡·¢ÁßÀ√◊Õ‡À≈«¢ÕßÕÿ®®“√–
‡°≥±å°“√«‘π‘®©—¬RomeIII‡ªìπ∑’ˬա√—∫„πªí®®ÿ∫—π „™â‡ªìπ·π«∑“ßÀπ÷Ëß„π°“√
™à«¬«‘π‘®©—¬‚√§≈”‰ â·ª√ª√«π ·≈–„™â‡ªìπ·π«∑“ß„π°“√«‘®—¬
¢âÕ √ÿª∑’Ë 3.
ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«πÕ“®¡’Õ“°“√∑âÕ߇ ’¬‡ªìπÕ“°“√‡¥àπ ∑âÕߺŸ°‡ªìπ
Õ“°“√‡¥àπ∑âÕߺŸ° ≈—∫°—∫∑âÕ߇ ’¬À√◊Õ‰¡à “¡“√∂®–®—¥≈—°…≥–°“√¢—∫∂à“¬¢ÕߺŸâªÉ«¬
‰¥â‡≈¬°Á‰¥â
‚√§≈”‰ â·ª√ª√«π ·∫à߉¥â‡ªìπ 4 ™π‘¥ (subtype) ‰¥â·°à
1. ≈”‰ â·ª√ª√«π ™π‘¥∑âÕ߇ ’¬‡¥àπ (diarrhea predominate IBS or
IBS-D)ºŸâªÉ«¬µâÕß¡’Õ“°“√∑âÕ߇ ’¬‰¡àπâÕ¬°«à“√âÕ¬≈–25¢Õß°“√¢—∫∂à“¬·≈–µâÕß¡’
Õ“°“√∑âÕߺŸ°‰¡à‡°‘π√âÕ¬≈– 25 ¢Õß°“√¢—∫∂à“¬
2. ≈”‰ â·ª√ª√«π ™π‘¥∑âÕߺŸ°‡¥àπ (constipation predominate IBS or
IBS-C) ºŸâªÉ«¬µâÕß¡’Õ“°“√∑âÕߺŸ° ‰¡àπâÕ¬°«à“√âÕ¬≈– 25 ¢Õß°“√¢—∫∂à“¬ ·≈–µâÕß¡’
Õ“°“√∑âÕ߇ ’¬‰¡à‡°‘π√âÕ¬≈– 25 ¢Õß°“√¢—∫∂à“¬
3. ≈”‰ â·ª√ª√«π ™π‘¥∑âÕ߇ ’¬ ≈—∫∑âÕߺŸ° (mixed IBS À√◊Õ IBS-M)
ºŸâªÉ«¬µâÕß¡’Õ“°“√∑âÕ߇ ’¬ ≈—∫∑âÕߺŸ°Õ¬à“ß≈–‰¡àπâÕ¬°«à“√âÕ¬≈– 25 ¢Õß°“√¢—∫∂à“¬
4. ≈”‰ â·ª√ª√«π™π‘¥‰¡à™—¥‡®π (undetermined IBS À√◊Õ IBS-U) ºŸâªÉ«¬
µâÕß¡’Õ“°“√∑âÕ߇ ’¬ ≈—∫°—∫∑âÕߺŸ° Õ¬à“ß≈–‰¡à‡°‘π√âÕ¬≈– 25 ¢Õß°“√¢—∫∂à“¬
Reference:
1. Longstreth GF, Thompson W, Chey WD, Houghton LA, Mearin F, Spiller RC.
Functional Bowel Disorder p.487-556. In Rome III: The Functional Gastrointestinal Disorders.
Drossman DA, eds. Degnon Associates, Mclean, Virginia USA 2006.
8 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
Overlapping Syndrome
¢âÕ √ÿª∑’Ë 4.
‚√§≈”‰ â·ª√ª√«π “¡“√∂æ∫√à«¡°—∫‚√§°√¥‰À≈¬âÕπÀ√◊Õ°√–‡æ“–Õ“À“√
∑”ß“πº‘¥ª°µ‘ (dyspepsia) ‰¥â ·æ∑¬åºŸâ¥Ÿ·≈§«√„Àâ°“√√—°…“√à«¡µ“¡§«“¡
‡À¡“– ¡
‚√§≈”‰ â·ª√ª√«π “¡“√∂æ∫√à«¡°—∫‚√§°√¥‰À≈¬âÕπ °√–‡æ“–Õ“À“√∑”ß“π
º‘¥ª°µ‘ (dyspepsia) ·≈–‚√§∑âÕߺŸ°‰¥â∫àÕ¬ ®“°°“√»÷°…“¥â«¬·∫∫ Õ∫∂“¡Õ“°“√
°√¥‰À≈¬âÕπ dyspepsia ≈”‰ â·ª√ª√«π Õ“°“√∑âÕߺŸ° ·≈–Õ“°“√∑âÕ߇¥‘π „π
ª√–™“°√ 657 §π æ∫«à“¡’§«“¡™ÿ° (prevalence) „πª√–™“°√∑’Ë¡’Õ“°“√‡À≈à“π’È
Õ¬à“ßπâÕ¬ 2 Õ“°“√∑’Ë√âÕ¬≈– 4-9 ·≈–§«“¡™ÿ°„πª√–™“°√∑’Ë¡’Õ¬à“ßπâÕ¬ 3 °≈ÿà¡Õ“°“√
¢÷Èπ‰ª∑’Ë√âÕ¬≈– 1-41
‚¥¬Õ’°°“√»÷°…“ ºŸâªÉ«¬ 1290 √“¬ æ∫«à“¡’§«“¡™ÿ°¢Õß≈”‰ â
·ª√ª√«π √âÕ¬≈– 12.8 ·≈– dyspepsia √âÕ¬≈– 14 ‚¥¬√âÕ¬≈– 87 ¢ÕߺŸâªÉ«¬
≈”‰ â·ª√ª√«π ¡’Õ“°“√ dyspepsia √à«¡¥â«¬ æ∫«à“¡“°°«à“√âÕ¬≈– 50 ¢ÕߺŸâªÉ«¬
∑—ÈßÀ¡¥¡’Õ“°“√∑’ˇª≈’ˬπ·ª≈߉ª ¿“¬À≈—ß®“° 1 ªï æ∫«à“Õ“°“√≈”‰ â·ª√ª√«π
¬—ߧßÕ¬Ÿà√âÕ¬≈– 57-74 À√◊Õ  “¡“√∂À“¬‰ª À√◊ÕÕ“®¡’Õ“°“√Õ◊Ë𠇙àπ dyspepsia
¢÷Èπ¡“·∑π‰¥â2
„πÕ’°°“√»÷°…“ æ∫«à“ √âÕ¬≈– 23-87 ¢ÕߺŸâªÉ«¬≈”‰ â·ª√ª√«π ¡’
Õ“°“√ functional dyspepsia ¥â«¬ ·≈–√âÕ¬≈– 13-87 ¢ÕߺŸâªÉ«¬ dyspepsia ¡’
Õ“°“√≈”‰ â·ª√ª√«π™—¥‡®π3
 ”À√—∫Õ“°“√°√¥‰À≈¬âÕ𠇙àπ heartburn æ∫«à“
√âÕ¬≈– 47 ¢ÕߺŸâ¡’Õ“°“√π’È ¡’Õ“°“√≈”‰ â·ª√ª√«π√à«¡¥â«¬ ·≈–„π∑“ß°≈—∫°—π
ºŸâ∑’Ë¡’Õ“°“√≈”‰ â·ª√ª√«π°Áæ∫«à“¡’Õ“°“√°√¥‰À≈¬âÕπ‰¥â√âÕ¬≈– 46.54
πÕ°®“°Õ“°“√¥—ß°≈à“«¢â“ßµâπ∑’Ëæ∫√à«¡°—∫Õ“°“√≈”‰ â·ª√ª√«π‰¥â∫àÕ¬·≈â«
¬—ß¡’Õ“°“√À√◊Õ‚√§∑“߇¥‘πÕ“À“√Õ◊ËπÊ √«¡∑—ÈßÕ“°“√ functional disorders Õ◊ËπÊ
πÕ°√–∫∫∑“߇¥‘πÕ“À“√Õ’°À≈“¬™π‘¥ ∑’Ëæ∫√à«¡‰¥â∫àÕ¬„πºŸâªÉ«¬≈”‰ â·ª√ª√«πÕ’°
¥â«¬‡™àπ°—π5
‡π◊ËÕß®“° “¡“√∂æ∫Õ“°“√‡À≈à“π’ȉ¥âÀ≈“¬°≈ÿà¡Õ“°“√„πºŸâªÉ«¬√“¬‡¥’¬«°—π
·æ∑¬åºŸâ¥Ÿ·≈§«√„Àâ°“√√—°…“√à«¡µ“¡§«“¡‡À¡“– ¡„πºŸâªÉ«¬·µà≈–√“¬
9§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
References:
1. Locke GR, Zinsmeister AR, Fett SL, Melton LJ, Talley NJ. Overlap of gastrointestinal symp-
tom complexes in a US community. Neurogastroenterol Motil 2002;17:29-34.
2. Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the
general population: Overlap and lack of stability over time. Gastroenterology 1995;109:671-680.
3. Whitehead WE, Palsson OS, Levy RR, Feld AD, Turner M, Von Korff M . Comorbidity in
irritable bowel syndrome. Am J Gastroenterol 2007;102:2767-2776.
4. Kennedy TM, Jones RH, Hungin AP, Oûflanagan H, Kelly P. Irritabale Bowel Syndrome,
Gastro-oesophageal reflux, and bronchial responsiveness in the general population. Gut 1998;
43:770-774
5. Frissora CL and Koch KL. Symptom overlap and comorbidity of irritable bowel syndrome with
other conditions. Curr Gastroenterol Rep 2005;7:264-271.
6 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π
 ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘)
«—µ∂ÿª√– ß§å¢Õߧ”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π
1. ‡æ◊ËÕ‡ √‘¡ √â“ߧ«“¡√Ÿâ‡°’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π„Àâ°—∫·æ∑¬å∑—Ë«‰ª„Àâ
·æ√àÀ≈“¬¡“°¢÷Èπ
2. ‡æ◊ËÕ‡ªìπ·π«∑“ß„π°“√¥Ÿ·≈√—°…“ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π„Àâ‡À¡“– ¡
·≈–¡’ª√– ‘∑∏‘¿“æ
3. ‡æ◊ËÕ„Àâ°“√„™â∑√—欓°√∑“ß°“√·æ∑¬å·≈–§ÿ≥¿“æ™’«‘µ¥’¢÷Èπ ≈¥§à“„™â®à“¬
„π°“√¥Ÿ·≈ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π
§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª
Definition
¢âÕ √ÿª∑’Ë 1.
𑬓¡ ‚√§≈”‰ â·ª√ª√«π ‡ªìπ°≈ÿà¡Õ“°“√∑’ˇ°‘¥®“°°“√∑”ß“π¢Õß∑“ß
‡¥‘πÕ“À“√º‘¥ª°µ‘ ‚¥¬¡’Õ“°“√ª«¥∑âÕßÀ√◊Õ‰¡à ∫“¬„π∑âÕß∑’Ë —¡æ—π∏å°—∫°“√
∂à“¬Õÿ®®“√–‡ªìπÕ“°“√‡¥àπ‚¥¬‰¡àæ∫§«“¡º‘¥ª°µ‘∑“ß°“¬«‘¿“§À√◊Õ‚√§∑“ß°“¬
(organic disease) ∑’Ë “¡“√∂Õ∏‘∫“¬«à“‡ªì𠓇Àµÿ¢ÕßÕ“°“√‰¥â
ºŸâªÉ«¬≈”‰ â·ª√ª√«πµâÕß¡’Õ“°“√¢â“ßµâπ‰¡àπâÕ¬°«à“ 3 ‡¥◊Õπ
¢âÕ √ÿª∑’Ë 2.
‡°≥±å°“√«‘π‘®©—¬‚√§≈”‰ â·ª√ª√«πµ“¡ Rome III ºŸâªÉ«¬µâÕß¡’Õ“°“√µ“¡
¢âÕ 2.1 ·≈– 2.2 ¥—ßµàÕ‰ªπ’È
2.1 Õ“°“√ª«¥∑âÕßÀ√◊Õ‰¡à ∫“¬„π∑âÕ߇ªìπ‡«≈“¡“π“πÕ¬à“ßπâÕ¬ 6 ‡¥◊Õπ
π—∫µ—Èß·µà‡√‘Ë¡¡’Õ“°“√
10 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
Pathophysiology
¢âÕ √ÿª∑’Ë 5.
 “‡Àµÿ¢Õß‚√§≈”‰ â·ª√ª√«π¬—߉¡à‡ªìπ∑’Ë∑√“∫°—π™—¥‡®πæ∫«à“°≈‰°„π°“√
‡°‘¥‚√§≈”‰ â·ª√ª√«π¡’À≈“¬°≈‰° ‰¥â·°à °“√‡§≈◊ËÕπ‰À«¢Õß∑“߇¥‘πÕ“À“√
º‘¥ª°µ‘ (GI dysmotility) ª√– “∑√—∫√Ÿâ§«“¡√Ÿâ ÷°„π∑“߇¥‘πÕ“À“√‰«°«à“ª°µ‘
(visceralhypersensitivity)°“√Õ—°‡ ∫¢Õ߇¬◊ËÕ∫ÿº‘«≈”‰ â (gut inflammation)
§«“¡º‘¥ª°µ‘¢Õß·∫§∑’‡√’¬ª√–®”∂‘Ëπ„π≈”‰ â·≈–§«“¡º‘¥ª°µ‘¢Õß°“√µÕ∫ πÕß
√–À«à“ß ¡Õß·≈–≈”‰ â (brain-gut interaction)
°“√»÷°…“«‘®—¬æ∫«à“ §π∑’ˇªìπ‚√§≈”‰ â·ª√ª√«π¡’°“√‡§≈◊ËÕπ‰À«¢Õß
∑“߇¥‘πÕ“À“√º‘¥ª°µ‘ ‡™àπ ¡’°“√»÷°…“æ∫«à“°“√‡§≈◊ËÕπ‰À«¢Õß≈”‰ â‡≈Á°¡’≈—°…≥–
‡©æ“– ‡™à𠇪ìπ·∫∫ cluster À√◊Õ minute contraction ´÷Ëßæ∫‰¥â®“°°“√µ√«®¥Ÿ
°“√∫’∫µ—«¢Õß≈”‰ â‡≈Á° πÕ°®“°π—Èπ¬—ßæ∫«à“°“√∫’∫µ—«∑’˺‘¥ª°µ‘¢Õß≈”‰ â‡≈Á°
‚¥¬‡©æ“–°“√∫’∫µ—«∑’Ë·√ßÊ ∑’Ë∫√‘‡«≥≈”‰ â‡≈Á° à«πª≈“¬¡’§«“¡ —¡æ—π∏å°—∫Õ“°“√
ª«¥∑âÕß„πºŸâªÉ«¬≈”‰ â·ª√ª√«π ·≈–¬—ß¡’°“√»÷°…“æ∫«à“‡¡◊ËÕ°√–µÿâπ≈”‰ â„À≠à
„πºŸâªÉ«¬∑’ˇªìπ≈”‰ â·ª√ª√«π ºŸâªÉ«¬®–√—∫√Ÿâ§«“¡√Ÿâ ÷°‰¥â¡“°°«à“§πª°µ‘ √«¡∂÷ß
°“√°√–µÿâπ¥â«¬ “√‡§¡’ ‡™àπ °“√√—∫ª√–∑“πæ√‘° ∑’Ë¡’ à«πª√–°Õ∫¢Õß·§ª‰´´‘π
°Á¡’√“¬ß“π«à“®–∑”„À⇰‘¥Õ“°“√ª«¥∑âÕß · ∫∑âÕß„πºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π∑’Ë¡’
Õ“°“√∑âÕ߇ ’¬‡¥àπ¡“°°«à“§πª°µ‘ ¥—ßπ—ÈπºŸâªÉ«¬≈”‰ â·ª√ª√«π®÷ß¡’§«“¡‰«¢Õß
∑“߇¥‘πÕ“À“√∑’˵Õ∫ πÕßµàÕ∑—Èß°“√°√–µÿâπ∑“ß°≈(mechanicalstimulation)À√◊Õ
∑“߇§¡’ (chemical stimulation)
πÕ°®“°π—Èπ¬—ßæ∫«à“¿“«–≈”‰ â·ª√ª√«π¡’§«“¡ —¡æ—π∏å°—∫°“√¡’°“√Õ—°‡ ∫
‡≈Á°πâÕ¬∫√‘‡«≥≈”‰ â ´÷Ëß¡’√“¬ß“π„πºŸâªÉ«¬∑’ˇªìπ≈”‰ â·ª√ª√«πÀ≈—ß°“√µ‘¥‡™◊ÈÕ¢Õß
∑“߇¥‘πÕ“À“√ (post infectious IBS) ·≈–¬—ß¡’√“¬ß“π∂÷ߧ«“¡º‘¥ª°µ‘¢Õß°“√
µÕ∫ πÕߢÕß ¡Õß„πºŸâªÉ«¬≈”‰ â·ª√ª√«π´÷Ëßµà“߉ª®“°§πª°µ‘
11§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
¢âÕ √ÿª∑’Ë 6.
ªí®®—¬∑’Ë “¡“√∂°√–µÿâπ„À⺟âªÉ«¬‚√§≈”‰ â·ª√ª√«π¡’Õ“°“√°”‡√‘∫‰¥â·°à
Õ“À“√∫“ß™π‘¥ ¬“∫“ß™π‘¥ §«“¡‡§√’¬¥∑—Èß∑“ß°“¬·≈–®‘µ„® °“√µ‘¥‡™◊ÈÕ„π
∑“߇¥‘πÕ“À“√·≈–πÕ°∑“߇¥‘πÕ“À“√
ºŸâªÉ«¬∑’ˇªìπ‚√§≈”‰ â·ª√ª√«πÕ“®¡’Õ“°“√°”‡√‘∫¢÷Èπ®“°ªí®®—¬À≈“¬Õ¬à“߇™àπ
¡’°“√»÷°…“æ∫«à“Õ“À“√∫“ß™π‘¥ “¡“√∂°√–µÿâπ„À⺟âªÉ«¬‚√§≈”‰ â·ª√ª√«π¡’
Õ“°“√¡“°¢÷Èπ‰¥â ‡™àπ Õ“À“√¡—π Õ“À“√∑’˺≈‘µ·°ä „π≈”‰ â¡“°º‘¥ª°µ‘ ‡™àπ °≈ÿà¡
fructose ÀÕ¡ °√–‡∑’¬¡ ´÷Ëß “¡“√∂°√–µÿâπ„À⇰‘¥Õ“°“√¡“°¢÷Èπ¬“∫“ßÕ¬à“ß∑’Ë√–§“¬
‡§◊ÕßµàÕ∑“߇¥‘πÕ“À“√Õ“®®–∑”„À⇰‘¥Õ“°“√§≈⓬‚√§≈”‰ â·ª√ª√«π ‡™àπ Õ“°“√
ª«¥∑âÕß Õ◊¥·πàπ∑âÕß À√◊Õ§«“¡‡§√’¬¥∑“ߥâ“π√à“ß°“¬·≈–®‘µ„®°Á°√–µÿâπ„Àâ
∑“߇¥‘πÕ“À“√¡’§«“¡‰«µàÕ°“√√—∫√Ÿâ§«“¡√Ÿâ ÷°√«¡∂÷ß∫’∫µ—«º‘¥ª°µ‘‰¥â
πÕ°®“°π—Èπ°“√µ‘¥‡™◊ÈÕ∑—Èß„π∑“߇¥‘πÕ“À“√·≈–πÕ°∑“߇¥‘πÕ“À“√ “¡“√∂
°√–µÿâπ„À⇰‘¥°“√°”‡√‘∫¢Õß‚√§≈”‰ â·ª√ª√«π‰¥â ¥—ßπ—Èπ°“√À≈’°‡≈’Ë¬ßªí®®—¬µà“ßÊ
‡™àπ Õ“À“√ ¬“ ·≈–§«“¡‡§√’¬¥ Õ“® “¡“√∂∑”„À⺟âªÉ«¬‡°‘¥Õ“°“√°”‡√‘∫‰¥âπâÕ¬≈ß
®÷ߧ«√·π–π”„ÀâÀ≈’°‡≈’Ë¬ßªí®®—¬¥—ß°≈à“«„πºŸâªÉ«¬∑ÿ°√“¬
¢âÕ √ÿª∑’Ë 7.
‚√§∑“߇¥‘πÕ“À“√∑’Ë∑”„Àâ¡’Õ“°“√‡À¡◊Õπ‚√§≈”‰ â·ª√ª√«π∑’Ëæ∫‰¥â„π
ª√–‡∑»‰∑¬‰¥â·°à °“√µ‘¥‡™◊ÈÕ„π∑“߇¥‘πÕ“À“√ ¿“«–°“√¥Ÿ¥´÷¡πÈ”µ“≈·≈Á°‚∑ 
‰¡à ¡∫Ÿ√≥å (lactose malabsorption) °“√¥Ÿ¥´÷¡ “√Õ“À“√∫°æ√àÕß (malab-
sorption syndrome) ¡’·∫§∑’‡√’¬„π≈”‰ â‡≈Á°¡“°°«à“ª°µ‘ (small intestinal
bacterial overgrowth) °≈â“¡‡π◊ÈÕÀŸ√Ÿ¥∑«“√Àπ—°∑”ß“π‰¡àª√– “π°—∫°“√‡∫àß
(anismus) ≈”‰ âÕ—°‡ ∫‡√◊ÈÕ√—ß (inflammatory bowel disease) ·≈–¡–‡√Áß
¢Õß∑“߇¥‘πÕ“À“√ ‡ªìπµâπ
‚√§∑“߇¥‘πÕ“À“√∑’ËÕ“®∑”„À⇰‘¥Õ“°“√§≈⓬‚√§≈”‰ â·ª√ª√«π∑’Ëæ∫‰¥â
∫àÕ¬„πª√–‡∑»‰∑¬‰¥â·°à°“√µ‘¥‡™◊ÈÕ„π∑“߇¥‘πÕ“À“√‡™àπ°“√µ‘¥‡™◊ÈÕ Giardia lamblia
‡ªìπ«—≥‚√§„π≈”‰ â‡≈Á° à«πª≈“¬À√◊Õ≈”‰ â„À≠à À√◊Õ°“√¥Ÿ¥´÷¡πÈ”µ“≈·≈Á°‚∑ 
‰¡à ¡∫Ÿ√≥å ´÷ËßÕ“®∑”„À⇰‘¥Õ“°“√Õ◊¥·πàπ∑âÕß ª«¥∑âÕß À√◊Õ∑âÕ߇ ’¬ §≈⓬‚√§≈”‰ â
12 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
·ª√ª√«π‰¥â °“√¥Ÿ¥´÷¡ “√Õ“À“√∫°æ√àÕß ‡π◊ËÕß®“° “‡Àµÿ„¥Ê °Áµ“¡ ‡™àπ ®“°
µ—∫ÕàÕπ∑”ß“πº‘¥ª°µ‘∑”„À⇰‘¥°“√¥Ÿ¥´÷¡‰¢¡—π‰¡à ¡∫Ÿ√≥å (fat malabsorption)
°ÁÕ“®∑”„À⇰‘¥Õ“°“√∂à“¬º‘¥ª°µ‘ Õ◊¥·πàπ∑âÕß ‡À¡◊Õπ‚√§≈”‰ â·ª√ª√«π‰¥â ¿“«–
·∫§∑’‡√’¬„π≈”‰ â‡≈Á°¡“°°«à“ª°µ‘ ∑”„À⇰‘¥Õ“°“√∑âÕ߇ ’¬ Õ◊¥∑âÕß √à«¡°—∫
ª«¥∑âÕߧ≈⓬‚√§≈”‰ â·ª√ª√«π™π‘¥∑âÕ߇ ’¬ πÕ°®“°π—Èπ°“√¡’°≈â“¡‡π◊ÈÕÀŸ√Ÿ¥
∑«“√Àπ—°∑”ß“π‰¡à —¡æ—π∏å°—∫·√߇∫àß À√◊Õ anismus °Á “¡“√∂∑”„À⺟âªÉ«¬¡’
Õ“°“√ª«¥∂à“¬·µà∂à“¬‰¡à ÿ¥ À√◊Õ°√–µÿâπ„À⇰‘¥Õ“°“√Õ◊¥·πàπ∑âÕß ª«¥∑âÕß´÷Ë߇ªìπ
Õ“°“√¢Õß≈”‰ â·ª√ª√«π‡ªìπ¡“°¢÷Èπ‰¥â
‚√§≈”‰ âÕ—°‡ ∫ À√◊Õ inflammatory bowel disease  “¡“√∂∑”„À⇰‘¥
Õ“°“√ª«¥∑âÕß ∂à“¬‡À≈« §≈⓬‚√§≈”‰ â·ª√ª√«π‰¥â‡™àπ°—π  à«π¡–‡√ÁߢÕß∑“߇¥‘π
Õ“À“√√–¬–·√°¡—°‰¡à∑”„À⇰‘¥Õ“°“√ ·µà‡¡◊ËÕ¡’¢π“¥¢Õß¡–‡√Áß„À≠à¢÷ÈπÀ√◊Õ‡ªìπ∑’Ë
∫√‘‡«≥∑«“√Àπ—° Õ“®∑”„À⇰‘¥Õ“°“√∂à“¬º‘¥ª°µ‘ À√◊ÕÕ“°“√ª«¥∑âÕß ·πàπ∑âÕß
§≈⓬ÊÕ“°“√≈”‰ â·ª√ª√«π‰¥â¥—ßπ—ÈπºŸâªÉ«¬∑’Ë¡’Õ“°“√≈”‰ â·ª√ª√«π §«√´—°ª√–«—µ‘
µ√«®√à“ß°“¬À√◊Õ àßµ√«®∑“ßÀâÕߪؑ∫—µ‘°“√‡∫◊ÈÕßµâπ‡™àπstoolexamination,CBC,
ESR ‡æ◊ËÕª√–‡¡‘π«à“ºŸâªÉ«¬¡’‚Õ°“ ‡ªìπ‚√§∑’Ë°≈à“«¡“À√◊Õ‰¡à
13§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
Clinical evaluation
¢âÕ √ÿª∑’Ë 8.
°“√«‘π‘®©—¬‚√§≈”‰ â·ª√ª√«πÕ“»—¬≈—°…≥–Õ“°“√·≈–Õ“°“√· ¥ß¢Õß
ºŸâªÉ«¬∑“ߧ≈‘π‘°‡ªìπÀ≈—°  à«π°“√µ√«®∑“ßÀâÕߪؑ∫—µ‘°“√‡∫◊ÈÕßµâπ·≈–°“√µ√«®
摇»…Õ◊ËπÊ §«√æ‘®“√≥“µ“¡§«“¡‡À¡“– ¡¢ÕߺŸâªÉ«¬ ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π
Õ“®®–¡’Õ“°“√Õ◊ËπÊ πÕ°‡Àπ◊Õ®“°Õ“°“√¥â“π∑“߇¥‘πÕ“À“√‰¥â
‚√§≈”‰ â·ª√ª√«π‡ªìπ‚√§∑’Ë«‘π‘®©—¬‚¥¬Õ“»—¬ª√–«—µ‘ Õ“°“√ ·≈–Õ“°“√· ¥ß
‡ªìπÀ≈—° ‰¡à¡’§«“¡®”‡ªìπµâÕß∑”°“√ ◊∫§âπ‡æ‘Ë¡‡µ‘¡ ‡π◊ËÕß®“°º≈¢Õß°“√ ◊∫§âπ‡æ‘Ë¡
‡µ‘¡‰¡à‰¥âæ∫‚√§·µ°µà“ß°—∫°≈ÿࡪ√–™“°√ª°µ‘ ¡’‡æ’¬ß∫“ß·π«∑“ß°“√¥Ÿ·≈√—°…“
(guidelines)1
∑’Ë·π–π”°“√ ◊∫§âπ‡∫◊ÈÕßµâπ∫“ßÕ¬à“ß«à“Õ“®¡’§«“¡®”‡ªìπ ”À√—∫ºŸâªÉ«¬
‚√§π’È2-4
‚¥¬ºŸâªÉ«¬‰¡à§«√®–¡’Õ“°“√·≈–Õ“°“√· ¥ß‡µ◊Õπ (alarm features)3, 5
„πºŸâªÉ«¬∫“ß√“¬ °“√ ◊∫§âπ Õ“∑‘ complete blood count (CBC), stool
examination, ESR, C-reactive protein ‡ªìπµâπÕ“®¡’§«“¡®”‡ªìπ4
 ”À√—∫°“√
 ◊∫§âπ‡∫◊ÈÕßµâπ∑’Ë¡’‚√§∑’˧≈⓬§≈÷ß°—∫‚√§π’È Õ“∑‘ °“√µ√«®Õÿ®®“√–‡æ◊ËÕ«‘π‘®©—¬‚√§
欓∏‘≈”‰ â„πºŸâªÉ«¬∑’Ë¡’Õ“°“√‚√§≈”‰ â·ª√ª√«π™π‘¥∑’Ë¡’Õ“°“√∑âÕ߇ ’¬‡¥àπÀ√◊Õ
¡’Õ“°“√ ≈—∫∑—Èß∑âÕߺŸ°·≈–∑âÕ߇ ’¬·≈–·∫∫º ¡‡¥àπ3, 6
 ”À√—∫ºŸâªÉ«¬∑’Ë¡’Õ“°“√
‡∫◊ÈÕßµâπ∑’Ëπà“ ß —¬«à“®–‡ªìπ‚√§Õ◊Ëπ ·π–π”„Àâµ√«®‡æ‘Ë¡‡µ‘¡À√◊Õª√÷°…“·æ∑¬å
ºŸâ‡™’ˬ«™“≠‚√§≈”‰ â·ª√ª√«π  “¡“√∂∑’Ë®–æ∫Õ“°“√„π¥â“πÕ◊Ëπ Ê πÕ°‡Àπ◊Õ
Õ“°“√∑“߇¥‘πÕ“À“√√à«¡‰¥â ‡™àπ ÕàÕπ‡æ≈’¬, πÕπ‰¡àÀ≈—∫, fibromyalgia, ª«¥À≈—ß,
ªí  “«–∫àÕ¬ ·≈–¡’Õ“°“√‡®Á∫ª«¥¢≥–¡’‡æ» —¡æ—π∏å (dyspareunia), §«“¡‡§√’¬¥,
´÷¡‡»√â“ ·≈–¡’ somatization
¢âÕ √ÿª∑’Ë 9.
ºŸâªÉ«¬∑’Ë¡’Õ“°“√ª«¥∑âÕßÀ√◊Õ‰¡à ∫“¬„π∑âÕ߇√◊ÈÕ√—ß∑ÿ°√“¬·æ∑¬åºŸâ¥Ÿ·≈§«√
 Õ∫∂“¡§«“¡ —¡æ—π∏å¢ÕßÕ“°“√ª«¥∑âÕß/‰¡à ∫“¬„π∑âÕß°—∫°“√‡ª≈’ˬπ·ª≈ß
¢Õߧ«“¡∂’Ë¢Õß°“√∂à“¬Õÿ®®“√–·≈–≈—°…≥–¢ÕßÕÿ®®“√–
 ◊∫‡π◊ËÕß®“°‚√§≈”‰ â·ª√ª√«π‡ªìπ‚√§∑’Ë„Àâ°“√«‘π‘®©—¬‚¥¬Õ“»—¬Õ“°“√ª«¥∑âÕß
À√◊Õ‰¡à ∫“¬„π∑âÕ߇√◊ÈÕ√—ß√à«¡°—∫¡’°“√¢—∫∂à“¬∑’ˇª≈’ˬπ·ª≈߉ª À√◊ÕÕ“°“√ª«¥∑âÕß
14 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
À√◊Õ‰¡à ∫“¬„π∑âÕß∑’Ë¥’¢÷ÈπÀ≈—ß°“√∂à“¬Õÿ®®“√– ∂÷ß·¡âºŸâªÉ«¬®–¡’Õ“°“√‡©æ“–À√◊Õ®–
¡’Õ“°“√ª«¥∑âÕßÀ√◊Õ‰¡à ∫“¬„π∑âÕ߇©æ“–∫√‘‡«≥≈‘Èπªïò°Áµ“¡ ‚¥¬°“√«‘π‘®©—¬·≈–
·¬°™π‘¥¢Õß‚√§π’È¡’§«“¡®”‡ªìπµâÕß√Ÿâ§«“¡∂’Ë¢Õß°“√∂à“¬Õÿ®®“√–·≈–≈—°…≥–¢Õß
Õÿ®®“√–1
´÷Ëß®– “¡“√∂∑”„Àâ·¬°™π‘¥‡ªìπ 4 ™π‘¥ µ“¡¢âÕ √ÿª∑’Ë 3
¢âÕ √ÿª∑’Ë 10.
ºŸâªÉ«¬∑’˧«√‰¥â√—∫°“√µ√«®∑“ßÀâÕߪؑ∫—µ‘°“√À√◊Õ°“√µ√«®‡æ‘Ë¡‡µ‘¡‰¥â·°à
ºŸâªÉ«¬∑’Ë¡’≈—°…≥–‡µ◊Õπ¥—ßµàÕ‰ªπ’È
10.1ºŸâªÉ«¬∑’Ë¡’Õ“°“√√ÿπ·√ß
10.2ºŸâªÉ«¬∑’Ë¡’πÈ”Àπ—°≈¥≈ߺ‘¥ª°µ‘ (≈¥≈ß¡“°°«à“À√◊Õ‡∑à“°—∫√âÕ¬≈– 10
„π 3 ‡¥◊Õπ)
10.3ºŸâªÉ«¬∑’ˇ√‘Ë¡¡’Õ“°“√‡¡◊ËÕÕ“¬ÿ 50 ªï¢÷Èπ‰ª
10.4ºŸâªÉ«¬∑’Ë¡’Õ“°“√∂à“¬‡ªìπ‡≈◊Õ¥À√◊Õ¡Ÿ°‡≈◊Õ¥
10.5‚≈À‘µ®“ß®“°¢“¥∏“µÿ‡À≈Á° «‘µ“¡‘π∫’ 12 À√◊Õ‚ø‡≈µ∑’ˉ¡à “¡“√∂Õ∏‘∫“¬
‰¥â®“° “‡ÀµÿÕ◊ËππÕ°∑“߇¥‘πÕ“À“√
10.6ºŸâªÉ«¬∑’Ë¡’Õ“°“√ª«¥À√◊Õ·πàπ∑âÕß√∫°«π¢≥–πÕπÀ≈—∫
10.7µ√«®√à“ß°“¬æ∫≈—°…≥–º‘¥ª°µ‘ ‡™àπ µ—∫‚µ °âÕπ„π∑âÕß ´’¥ ‡À≈◊Õß
‡ªìπµâπ
10.8¡’‰¢â
10.9ª√–«—µ‘¡–‡√Áß≈”‰ â„À≠à„π§√Õ∫§√—«∑’ˇªìπ≠“µ‘ “¬µ√ß (first degree
relatives)
°“√Õ“»—¬≈—°…≥–¢ÕßÕ“°“√·≈–Õ“°“√· ¥ß‡µ◊Õπ„π·π«∑“ß°“√¥Ÿ·≈ºŸâªÉ«¬
‚√§≈”‰ â·ª√ª√«π¢Õߪ√–‡∑»‰∑¬‰¥â„™â·π«∑“ß°“√¥Ÿ·≈ºŸâªÉ«¬‚√§π’È¢Õ߇Շ™’¬¡“
ª√–°Õ∫5
„π°√≥’∑’˺ŸâªÉ«¬¡’≈—°…≥–‡µ◊Õπ·π–π”«à“§«√µ√«®‡æ‘Ë¡‡µ‘¡À√◊Õª√÷°…“·æ∑¬å
ºŸâ‡™’ˬ«™“≠
15§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
¢âÕ √ÿª∑’Ë 11.
ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π∑’ˉ¡à¡’≈—°…≥–‡µ◊Õπ¡’‚Õ°“ ‡°‘¥¡–‡√Áß≈”‰ â„À≠à
‰¡àµà“ß®“°ª√–™“°√∑—Ë«‰ª
°“√»÷°…“¢Õß Cash ·≈–§≥–7
æ∫«à“ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π¡’§«“¡™ÿ°¢Õß
‚√§¡–‡√Áß≈”‰ â„À≠à∑’Ë√âÕ¬≈– 0-0.51 ¢≥–∑’˧«“¡™ÿ°¢Õß‚√§π’È„πª√–™“°√∑—Ë«‰ªÕ¬Ÿà∑’Ë
√âÕ¬≈– 0-6 ´÷Ë߉¡à¡’§«“¡·µ°µà“ß°—π
¢âÕ √ÿª∑’Ë 12.
‚√§≈”‰ â·ª√ª√«π‡ªìπ‚√§‡√◊ÈÕ√—ß À√◊Õ‡ªìπÊÀ“¬Ê ºŸâªÉ«¬¡—°¡’Õ“¬ÿ¬◊𬓫
‰¡àµà“ß®“°ª√–™“°√∑—Ë«‰ª ·µà®–¡’§ÿ≥¿“æ™’«‘µ∑’Ë¥âÕ¬°«à“
°“√»÷°…“À≈“¬°“√»÷°…“8, 9
æ∫«à“ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π¡’§ÿ≥¿“æ™’«‘µ∑’Ë
¥âÕ¬°«à“ª√–™“°√∑—Ë«‰ª Õ“∑‘ °“√»÷°…“¢Õß Lu ·≈–§≥–8
„πºŸâªÉ«¬™“«®’π∑’ˇªìπ
‚√§≈”‰ â·ª√ª√«πæ∫«à“ºŸâªÉ«¬‡æ»À≠‘ß¡’·π«‚πâ¡À¬ÿ¥ß“π¡“°°«à“¡’ªí≠À“°“√πÕπ
(sleep disturbance) ¡“°°«à“ºŸâªÉ«¬™“¬  à«π°“√»÷°…“¢Õß Rey ·≈–§≥–9
°Áæ∫
«à“„πºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π∑’˪√÷°…“·æ∑¬å ·≈–∑’ˉ¡à‰¥âª√÷°…“·æ∑¬å≈â«π¡’
§ÿ≥¿“æ™’«‘µ∑’Ë¥âÕ¬°«à“°≈ÿà¡∑’ˉ¡à¡’‚√§
¢âÕ √ÿª∑’Ë 13.
≈—°…≥–°“√∂à“¬Õÿ®®“√–„πºŸâªÉ«¬≈”‰ â·ª√ª√«π¡’ª√–‚¬™πå„π°“√°”Àπ¥
·π«∑“ß°“√ ◊∫§âπÀ“ “‡Àµÿ¢ÕßÕ“°“√ („π°√≥’∑’Ë¡’¢âÕ∫àß™’È) ·≈–·π«∑“ß°“√
„À⬓√—°…“
·π–π”„Àâ ◊∫§âπ‡æ‘Ë¡‡µ‘¡„πºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«πµ“¡™π‘¥¢Õß‚√§π’È3, 10
‚¥¬
‡©æ“–™π‘¥∑’ˇªìπ·∫∫∑âÕ߇ ’¬‡¥àπ„Àâ√–«—ß‚√§°≈ÿà¡∑’ËÕ“®¡’Õ“°“√∑âÕ߇ ’¬‡√◊ÈÕ√—߉¥â ‡™àπ
giardiasis, tropical sprue, hyperthyroidism, inflammatory bowel disease
(IBD) ‡ªìπµâπ
‡ªÑ“À¡“¬¢Õß°“√√—°…“ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π§◊Õ ≈¥Õ“°“√·≈–‡æ‘Ë¡§ÿ≥¿“æ
™’«‘µ¢ÕߺŸâªÉ«¬3, 5
¥—ßπ—Èπ°“√®”·π°ºŸâªÉ«¬‚√§π’ȇªìπ 4 ™π‘¥§◊Õ ≈”‰ â·ª√ª√«π ™π‘¥
∑âÕ߇ ’¬‡¥àπ, ≈”‰ â·ª√ª√«π ™π‘¥∑âÕߺŸ°‡¥àπ, ≈”‰ â·ª√ª√«π ™π‘¥∑âÕ߇ ’¬ ≈—∫
∑âÕߺŸ° (IBS-M), ≈”‰ â·ª√ª√«π™π‘¥‰¡à™—¥‡®π (IBS-U) ®–∑”„Àâ°“√√—°…“´÷Ëß
16 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
¡ÿà߇πâπ∑’˵âÕß°“√≈¥Õ“°“√¢ÕߺŸâªÉ«¬‡ªìπÀ≈—° ∑”‰¥â –¥«°·≈–ßà“¬µàÕ°“√®—¥¬“Õ’°
√«¡‰ª∂÷ß∑”„Àâ°“√»÷°…“«‘®—¬‚√§π’ȇªìπ‰ª„π·π«∑“߇¥’¬«°—πÕ’°¥â«¬‡™àπ ºŸâªÉ«¬∑’Ë¡’
Õ“°“√∑âÕ߇ ’¬‡¥àπÕ“®„™â¬“´÷Ëߪ√–°Õ∫‰ª¥â«¬¬“ antispasmodics, loperamide ·≈–
alosetron ‡ªìπµâπ
¢âÕ √ÿª∑’Ë 14.
°“√µ√«®∑“ßÀâÕߪؑ∫—µ‘°“√·≈–°“√µ√«®æ‘‡»…∑’Ë¡’ª√–‚¬™πå„π°“√·¬°‚√§
Õ◊Ëπ∑’Ë∑”„À⇰‘¥Õ“°“√§≈⓬Փ°“√¢Õß‚√§≈”‰ â·ª√ª√«π ‰¥â·°à
14.1 °“√µ√«®æ◊Èπ∞“π CBC, ESR, stool exam
14.2 °“√µ√«®æ‘‡»…√–∫∫∑“߇¥‘πÕ“À“√ ‰¥â·°à barium enema, upper GI
study with small bowel follow through, gastroscopy, sigmoidoscopy,
colonoscopy, ultrasono-graphy À√◊Õ CT scan ¢Õß™àÕß∑âÕß, πà“®–∑” H2-breath
test  ”À√—∫ small bowel bacterial overgrowth, lactose malabsorption, gastro-
intestinal transit study ·≈– anorectal function tests
14.3 °“√µ√«®Õ◊ËπÊ ‡™àπ thyroid function tests, serum cortisol, serum
calcium, electrolytes ‡ªìπµâπ
°“√µ√«®‡æ‘Ë¡‡µ‘¡∑“ßÀâÕߪؑ∫—µ‘°“√π—Èπ®–¡’ª√–‚¬™πå„πºŸâªÉ«¬‚√§≈”‰ â
·ª√ª√«π‚¥¬‡©æ“–∂â“¡’≈—°…≥–‡µ◊Õπ ‚¥¬®–¡’·π«∑“ß°“√ ◊∫§âπµ“¡≈—°…≥–¢Õß
™π‘¥¢Õß‚√§≈”‰ â·ª√ª√«π∑’˺ŸâªÉ«¬π—Èπ¡’ªí≠À“3
 ”À√—∫ Asian guideline ·π–π”«à“
∂â“√—°…“ºŸâªÉ«¬‰ª 12  —ª¥“Àå·≈â« ºŸâªÉ«¬¬—ߧߡ’Õ“°“√‰¡à¥’¢÷Èπ·π–π”«à“ §«√ àßµàÕ
ºŸâªÉ«¬ª√÷°…“·æ∑¬å‡©æ“–∑“ß‚√§√–∫∫∑“߇¥‘πÕ“À“√
¢âÕ √ÿª∑’Ë 15.
ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π∑’˧«√ àßµàÕ‰ªæ∫·æ∑¬å‡©æ“–∑“ß‚√§√–∫∫
∑“߇¥‘πÕ“À“√ ‰¥â·°à ºŸâªÉ«¬∑’Ë¡’¢âÕ∫àß™’È„π°“√µ√«®æ‘‡»…‡æ‘Ë¡‡µ‘¡À√◊ÕºŸâªÉ«¬∑’Ë¡’
Õ“°“√√ÿπ·√ß√—°…“·≈⫉¡à “¡“√∂§«∫§ÿ¡Õ“°“√‰¥â
°“√√—°…“ºŸâªÉ«¬‚√§ IBS3, 11
π’È·∫àß°“√¥Ÿ·≈‡ªìπ 3 √–¥—∫§◊Õ „π°“√¥Ÿ·≈ºŸâªÉ«¬
∑’Ë¡’Õ“°“√‰¡à¡“° „ÀℙⰓ√ª√—∫‡ª≈’ˬπ惵‘°√√¡ (life style modifications)
°“√À≈’°‡≈’ˬßÕ“À“√À√◊Õ°“√‡ª≈’ˬπ™π‘¥¢ÕßÕ“À“√ Õ∏‘∫“¬°“√«‘π‘®©—¬·≈–°“√¥”‡π‘π
17§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
¢Õß‚√§ ∑”„À⺟âªÉ«¬¡—Ëπ„®„πµ—«‚√§«à“‚√§π’ȉ¡à√⓬·√ß·µà‡√◊ÈÕ√—ß´÷ËßÕ“®¡’º≈„Àâ§ÿ≥¿“æ
™’«‘µ≈¥≈߉¥â ∂⓺ŸâªÉ«¬‡√‘Ë¡¡’Õ“°“√¡“°¢÷Èπ·π–π”„Àℙ⬓√—°…“µ“¡Õ“°“√·≈–™π‘¥
¢Õß≈”‰ â·ª√ª√«π∑’˺ŸâªÉ«¬‡ªìπ √à«¡°—∫°“√√—°…“§«“¡‡§√’¬¥ µ≈Õ¥®π°“√µ‘¥µ“¡
ºŸâªÉ«¬Õ¬à“ßµàÕ‡π◊ËÕß  ”À√—∫√“¬∑’Ë¡’§«“¡√ÿπ·√ß¡“°·π–π”„Àâ¡’°“√¥Ÿ·≈√—°…“Õ¬à“ß
µàÕ‡π◊ËÕßµ≈Õ¥®πæ‘®“√≥“ª√÷°…“∑“ß®‘µ‡«™∑—Èß°“√„™â¬“·≈–®‘µ∫”∫—¥‡æ‘Ë¡
 ”À√—∫·æ∑¬å∑—Ë«‰ª°“√√—°…“„πºŸâªÉ«¬∑’Ë¡’Õ“°“√‡≈Á°πâÕ¬®π∂÷ߪ“π°≈“ß
 “¡“√∂∑”‰¥â  à«π„π√“¬∑’Ë¡’Õ“°“√¡“° °“√√—°…“‚¥¬·æ∑¬å‡©æ“–∑“ß‚√§√–∫∫
∑“߇¥‘πÕ“À“√·≈–®‘µ‡«™¡’§«“¡®”‡ªìπ ‡π◊ËÕß®“°Õ“®µâÕß¡’°“√ ◊∫§âπ‡æ‘Ë¡‡µ‘¡·≈–
‡ªìπ°“√∑”„À⺟âªÉ«¬¡’§«“¡¡—Ëπ„®„π·π«∑“ß°“√√—°…“¡“°¢÷Èπ «à“‰¥â√—∫°“√¥Ÿ·≈®“°
·æ∑¬åºŸâ¡’§«“¡‡™’ˬ«™“≠„π‚√§∑’ˇªìπ „π¢≥–∑’ËÕ“°“√¬—߉¡à¥’¢÷Èπ‡∑à“∑’˧«√
References
1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC.
Functional bowel disorders. Gastroenterology 2006;130:1480-91.
2. Svendsen JH, Munck LK, Andersen JR. Irritable bowel syndrome: prognosis and
diagnostic safety. A 5-year follow-up study. Scand J Gastroenterol 1985;20:415-8.
3. Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, et al.
An evidence-based position statement on the management of irritable bowel syndrome. Am J
Gastroenterol 2009;104 Suppl 1:S1-35.
4. Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and
practical management. Gut 2007;56:1770-98.
5. Gwee KA, Bak YT, Ghoshal UC, et al. Asian consensus on irritable bowel syndrome.
J Gastroenterol Hepatol 2010;25:1189-205.
6. Tungtrongchitr A, Manatsathit S, Kositchaiwat C, et al. Blastocystis hominis infection in
irritable bowel syndrome patients. Southeast Asian J Trop Med Public Health 2004;35:
705-10.
7. Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome
patients: a systematic review. Am J Gastroenterol 2002;97:2812-9.
8. Lu CL, Chang FY, Lang HC, Chen CY, Luo JC, Lee SD. Gender difference on the symptoms,
health-seeking behaviour, social impact and sleep quality in irritable bowel syndrome: a Rome
II-based survey in an apparent healthy adult Chinese population in Taiwan. Aliment Pharmacol
Ther 2005;21:1497-505.
9. Rey E, Garcia-Alonso MO, Moreno-Ortega M, Alvarez-Sanchez A, Diaz-Rubio M.
Determinants of quality of life in irritable bowel syndrome. J Clin Gastroenterol 2008;42:
1003-9.
10. Mayer EA. Clinical practice. Irritable bowel syndrome. N Engl J Med 2008;358:1692-9.
11. Drossman DA, Camilleri M, Mayer EA, Whitehead WE.. AGA technical review on irritable
bowel syndrome. Gastroentero-logy 2002;123:2108-31.
18 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
Non-pharmacological Treatment
¢âÕ √ÿª∑’Ë 16.
ºŸâªÉ«¬≈”‰ â·ª√ª√«π∑’Ë¡’Õ“°“√‰¡à√∫°«π§ÿ≥¿“æ™’«‘µ °“√¥Ÿ·≈√—°…“¡’
‡ªÑ“À¡“¬‡æ◊ËÕ √â“ߧ«“¡¡—Ëπ„®·≈–§≈“¬§«“¡«‘µ°°—ß«≈¢ÕߺŸâªÉ«¬
°“√¥Ÿ·≈√—°…“ºŸâªÉ«¬≈”‰ â·ª√ª√«π∑’Ë¡’Õ“°“√‰¡à√∫°«π§ÿ≥¿“æ™’«‘µ¡’‡ªÑ“À¡“¬
∑’Ë ”§—≠§◊Õ √â“ߧ«“¡¡—Ëπ„®·≈–§≈“¬§«“¡«‘µ°°—ß«≈¢ÕߺŸâªÉ«¬  ‘Ëß·√°µâÕßÕ∏‘∫“¬
„À⺟âªÉ«¬∑√“∫∂÷ß natural history ¢Õß‚√§«à“‚√§≈”‰ â·ª√ª√«π ‡ªìπ‚√§∑’ˉ¡à√⓬·√ß
‰¡à¡’¿“«–·∑√°´âÕπ∑’Ë®–∑”„À⇠’¬™’«‘µ ·µà¡’°“√¥”‡π‘π‚√§∑’ˇ√◊ÈÕ√—ß ¡—°‡ªìπÊ À“¬Ê
·¡â‰¥â√—∫°“√√—°…“À≈—ß°“√√—°…“∂⓺ŸâªÉ«¬Õ“°“√‰¡à¥’¢÷Èπ®–¬‘Ëß∑”„À⺟âªÉ«¬«‘µ°°—ß«≈¡“°
§◊Õ°≈—«‡ªìπ¡–‡√Áß≈”‰ â ·æ∑¬åµâÕßÕ∏‘∫“¬‡æ◊ËÕ √â“ߧ«“¡¡—Ëπ„®„À⺟âªÉ«¬«à“‚√§≈”‰ â
·ª√ª√«π‰¡à„™à‚√§¡–‡√Áß·≈–®–‰¡à°≈“¬‡ªìπ¡–‡√Áß·¡â®–¡’Õ“°“√∑’Ëπ”ºŸâªÉ«¬¡“æ∫·æ∑¬å
‡À¡◊Õπ°—π·æ∑¬åµâÕß´—°ª√–«—µ‘·≈–µ√«®√à“ß°“¬Õ¬à“ß≈–‡Õ’¬¥·≈–∑”°“√ ◊∫§âπÕ¬à“ß
‡À¡“– ¡°àÕπ∑’Ë®–„Àâ°“√«‘π‘®©—¬«à“‡ªìπ‚√§≈”‰ â·ª√ª√«π √«¡∑—Èß®–µâÕߧâπÀ“Õ¬à“ß
‡µÁ¡∑’Ë«à“‰¡àæ∫¡’≈—°…≥–‡µ◊Õπ (alarm symptoms) ´÷Ëß∫àß™’È«à“Õ“®®–¡’‚√§√⓬·√ß
‡™àπ¡–‡√Áß≈”‰ â√à«¡¥â«¬ ‡æ◊ËÕ¬◊π¬—π„À⺟âªÉ«¬¡—Ëπ„®«à“‰¡à¡’‚√§√⓬·√ß1-5
¢âÕ √ÿª∑’Ë 17.
ºŸâªÉ«¬≈”‰ â·ª√ª√«π∑’Ë¡’Õ“°“√√∫°«π§ÿ≥¿“æ™’«‘µ «—µ∂ÿª√– ß§å¢Õß°“√
√—°…“πÕ°®“° √â“ߧ«“¡¡—Ëπ„®·≈–§≈“¬§«“¡«‘µ°°—ß«≈„À⺟âªÉ«¬·≈â« §«√„Àâ
°“√√—°…“‡æ◊ËÕ∫√√‡∑“Õ“°“√¢ÕߺŸâªÉ«¬§«√‡√‘Ë¡µâπ¥â«¬°“√·π–π”„Àâª√—∫‡ª≈’ˬπ
°“√ªØ‘∫—µ‘µ—«„π°“√¥”‡π‘π™’«‘µª√–®”«—π (life style modifications)
°“√√—°…“‡æ◊ËÕ∫√√‡∑“Õ“°“√¢ÕߺŸâªÉ«¬§«√‡√‘Ë¡µâπ¥â«¬°“√·π–π”„Àâª√—∫‡ª≈’ˬπ
°“√ªØ‘∫—µ‘µ—«„π°“√¥”‡π‘π™’«‘µª√–®”«—π (life style modifications) ‡™àπ
°“√√—∫ª√–∑“πÕ“À“√ ™π‘¥¢ÕßÕ“À“√ ¬“ §«“¡‡§√’¬¥ À≈’°‡≈’ˬߠ‘Ëß∑’Ë∑”„À⺟âªÉ«¬¡’
Õ“°“√¡“°¢÷Èπ‡ªìπµâπ ·¡â‰¡à¡’À≈—°∞“π∑“ß«‘∑¬“»“ µ√å∑’Ë π—∫ πÿπ«à“°“√ª√—∫
‡ª≈’ˬπ°“√ªØ‘∫—µ‘µ—«¡’ª√–‚¬™πå„π°“√√—°…“ ·µà°“√·π–π”„Àâª√—∫‡ª≈’ˬπ°“√ªØ‘∫—µ‘
µ—«Õ“®∑”„ÀâÕ“°“√¥’¢÷Èπ„πºŸâªÉ«¬∫“ß√“¬·≈–™à«¬≈¥§«“¡∂’Ë„π°“√°≈—∫‡ªìπ´È”
‰¥â¥â«¬6
19§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
¢âÕ √ÿª∑’Ë 18.
°“√„Àâ°“√«‘π‘®©—¬‚√§‡™‘ß∫«°·≈–°“√¡’§«“¡ —¡æ—π∏å∑’Ë¥’√–À«à“ß·æ∑¬å
·≈–ºŸâªÉ«¬¡’§«“¡ ”§—≠µàÕº≈ ”‡√Á®¢Õß°“√√—°…“ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π
°“√µ√–Àπ—°∂÷ß·≈–«‘π‘®©—¬‚√§≈”‰ â·ª√ª√«π¥â«¬§«“¡¡—Ëπ„®‡ªìπ ‘Ëß ”§—≠∑’Ë
·æ∑¬å®– √â“ߧ«“¡¡—Ëπ„®·°àºŸâªÉ«¬·≈– ”§—≠µàÕº≈ ”‡√Á®¢Õß°“√√—°…“ºŸâªÉ«¬‚√§≈”‰ â
·ª√ª√«π ‡¡◊ËÕºŸâªÉ«¬¡’§«“¡¡—Ëπ„®„π°“√¥Ÿ·≈√—°…“¢Õß·æ∑¬å®– àߺ≈„À⇰‘¥§«“¡
 —¡æ—π∏å∑’Ë¥’√–À«à“ß·æ∑¬å·≈–ºŸâªÉ«¬ ´÷Ëß®–¡’§«“¡ ”§—≠µàÕº≈ ”‡√Á®¢Õß°“√√—°…“
‡π◊ËÕß®“°‚√§≈”‰ â·ª√ª√«π¡’°“√¥”‡π‘π‚√§∑’ˇ√◊ÈÕ√—ß ¡—°‡ªìπÊÀ“¬Ê ºŸâªÉ«¬®”‡ªìπµâÕß
‰¥â√—∫°“√¥Ÿ·≈√—°…“µ‘¥µàÕ°—π√–¬–¬“«·≈–µâÕ߉¥â√—∫§«“¡√à«¡¡◊ÕÕ¬à“ߥ’®“°ºŸâªÉ«¬
Õ’°¥â«¬¥—ßπ—Èπ‡¡◊ËÕºŸâªÉ«¬¡’§«“¡‡™◊ËÕ∂◊Õ·≈–§«“¡¡—Ëπ„®„πµ—«·æ∑¬å·≈⫺ŸâªÉ«¬®–√Ÿâ ÷°«à“
·æ∑¬å‡ªìπ∑’Ëæ÷Ë߉¥âµ≈Õ¥‡«≈“∑”„À⺟âªÉ«¬§≈“¬§«“¡«‘µ°°—ß«≈≈ßÕ“®™à«¬∑”„ÀâÕ“°“√
¥’¢÷Èπ·¡âºŸâªÉ«¬®–¬—ߧߡ’Õ“°“√Õ¬Ÿà∫â“߉¡àÀ“¬¢“¥·µàºŸâªÉ«¬®–¡’§«“¡∑ÿ°¢å∑√¡“π‡°’Ë¬«°—∫
‚√§≈¥πâÕ¬≈ß6-9
¢âÕ √ÿª∑’Ë 19.
°“√´—°ª√–«—µ‘惵‘°√√¡°“√√—∫ª√–∑“πÕ“À“√·≈–‡§√◊ËÕߥ◊Ë¡√«¡∂÷ߧ”·π–π”
‡°’ˬ«°—∫°“√√—∫ª√–∑“πÕ“À“√·≈–‡§√◊ËÕߥ◊Ë¡ ¡’ª√–‚¬™πå„π°“√¥Ÿ·≈√—°…“ºŸâªÉ«¬
≈”‰ â·ª√ª√«π
ºŸâªÉ«¬ à«π„À≠à√Ÿâ ÷°«à“Õ“À“√∫“ßÕ¬à“ß∑”„ÀâÕ“°“√¢Õß‚√§≈”‰ â·ª√ª√«π
‡ªìπ¡“°¢÷Èπ10
¡’°“√»÷°…“∑’ˇªìπ systematic review ´÷Ëß à«π„À≠à‡ªìπ°“√»÷°…“·∫∫
uncontrolled æ∫«à“ °“√À≈’°‡≈’ˬßÕ“À“√∑’Ë®–∑”„Àâ¡’Õ“°“√‡æ‘Ë¡¢÷Èπ‡¡◊ËÕ‡ª√’¬∫‡∑’¬∫
°—∫ placebo ºŸâªÉ«¬®–¡’Õ“°“√¥’¢÷Èπ√âÕ¬≈– 12.5-67 ´÷Ë߉¡à “¡“√∂ √ÿª‰¥â«à“‡ªìπ
placebo effect À√◊Õ‰¡à11
¡’°“√»÷°…“∑’ˇªìπrandomized control trial (RCT) æ∫«à“
°“√À≈’°‡≈’ˬßÕ“À“√∑’Ë®–∑”„Àâ¡’Õ“°“√‡æ‘Ë¡¢÷Èπ´÷Ë߬◊π¬—π‚¥¬°“√µ√«®æ∫ IgG antibody
µàÕÕ“À“√™π‘¥π—Èπ ∑”„À⺟âªÉ«¬¡’Õ“°“√¥’¢÷ÈπÕ¬à“ß¡’π—¬ ”§—≠∑“ß ∂‘µ‘‡¡◊ËÕ‡ª√’¬∫‡∑’¬∫
°—∫ sham diet ‚¥¬¡’ number needed to treat (NNT) ‡∑à“°—∫ 2.512
„πªí®®ÿ∫—π
¬—߉¡à¡’À≈—°∞“π∑’Ë¥’‡æ’¬ßæÕ∑’Ë®–· ¥ß∂÷ߪ√– ‘∑∏‘¿“æ¢Õß°“√À≈’°‡≈’ˬßÕ“À“√∑’Ë®–
∑”„À⺟âªÉ«¬¡’Õ“°“√‡æ‘Ë¡¢÷Èπ13
®÷߬—߉¡à·π–π”„Àâµ√«®À“ IgG antibody ‡ªìπ routine
„π‡«™ªØ‘∫—µ‘∑—Ë«‰ª Õ¬à“߉√°Áµ“¡°“√·π–π”„ÀâÀ≈’°‡≈’ˬßÕ“À“√∑’Ë®–∑”„Àâ¡’Õ“°“√‡æ‘Ë¡¢÷Èπ
‡™àπÕ“À“√√ ®—¥ Õ“À“√¡—π ¢ÕߥÕß ·Õ≈°ÕŒÕ≈å∑ÿ°™π‘¥ °“·ø πȔ՗¥≈¡ ‡ªìπµâπ
20 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
∂◊Õ«à“¡’ª√–‚¬™πå‚¥¬Õ“®∑”„ÀâÕ“°“√¢ÕߺŸâªÉ«¬¥’¢÷Èπ‰¥âπÕ°®“°π’È°“√°‘πÕ“À“√§«√°‘π
∑’≈–πâÕ¬·µà°‘π„Àâ∫àÕ¬¢÷Èπ‰¡à§«√°‘π®πÕ‘Ë¡¡“°‡æ√“–«à“®–°√–µÿâπ„Àâ¡’Õ“°“√ª«¥∑âÕß
·≈–∑âÕ߇ ’¬‰¥âßà“¬
¢âÕ √ÿª∑’Ë 20.
°“√√—°…“‚¥¬‰¡à„™â¬“∑’ËÕ“®¡’ª√–‚¬™πå„πºŸâªÉ«¬≈”‰ â·ª√ª√«π‰¥â·°à
°“√„™â educational self-help guidebook, psychological therapy, °“√√—°…“
¥â«¬ “√ ¡ÿπ‰æ√ °“√Ωí߇¢Á¡ ·≈– biofeedback therapy
°“√√—°…“‚¥¬‰¡à„™â¬“ (non-drug therapy) ∑’ËÕ“®¡’ª√–‚¬™πå„πºŸâªÉ«¬
‚√§≈”‰ â·ª√ª√«π‰¥â·°à
20.1 °“√„™â educational self-help guidebook ‡ªìπ°“√„Àâ°“√»÷°…“·°à
ºŸâªÉ«¬„Àâ¡’§«“¡√Ÿâ‡°’ˬ«°—∫‚√§∑—Èß„π¥â“π欓∏‘°”‡π‘¥ °“√«‘π‘®©—¬·≈–°“√√—°…“
µ≈Õ¥®π‡¢â“„®≈—°…≥–°“√¥”‡π‘π‚√§·≈–·π«∑“ß„π°“√ª√—∫‡ª≈’ˬπ°“√ªØ‘∫—µ‘µ—«∑’Ë
‡À¡“– ¡‡æ◊ËÕ≈¥Õ“°“√∑’Ë∑”„À⺟âªÉ«¬∑ÿ°¢å∑√¡“π ¡’°“√»÷°…“∑’ˇªìπ RCT ‚¥¬
ª√–‡¡‘πº≈≈—æ∏å§◊Õ symptom score, perception of improvement ·≈– primary
care consultation rates º≈°“√»÷°…“∑’ËÀπ÷Ëߪïæ∫«à“„π°≈ÿà¡ self-help guidebook
¡’ºŸâªÉ«¬¡“æ∫·æ∑¬å≈¥≈ßπâÕ¬°«à“ control group 1.56 §√—ÈßµàÕªïÕ¬à“ß¡’π—¬ ”§—≠
(95% CI, 1.15-1.98) À√◊Õ≈¥≈ß√âÕ¬≈– 60 πÕ°®“°π’Èæ∫«à“„π°≈ÿà¡ self-help
guidebook ºŸâªÉ«¬√“¬ß“π perceived improvement ¡“°°«à“‚¥¬¡’ mean effect
෈ҡѺ 0.51 (95% CI, 0.23-0.79)14
20.2 Psychological therapy ‡π◊ËÕß®“°ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π¡—°¡’¿“«–
anxiety, depression ·≈– somatization √à«¡¥â«¬15,16
¡’°“√»÷°…“∑’ˇªìπ systematic
review ·≈– meta-analysis ∑’Ë· ¥ß«à“ psychological therapy ´÷Ëߪ√–°Õ∫¥â«¬
cognitive behavioral therapy (CBT), dynamic psychotherapy ·≈– hypno-
therapy ∑”„Àâ global IBS symptoms ¥’¢÷ÈπÕ¬à“ß¡’π—¬ ”§—≠‡¡◊ËÕ‡ª√’¬∫‡∑’¬∫
°—∫°“√√—°…“µ“¡ª°µ‘17-19
‚¥¬ CBT ‡ªìπ·π«∑“ß°“√√—°…“∑’Ë¡’°“√»÷°…“¡“°∑’Ë ÿ¥
‚¥¬‡©æ“–¡’°“√»÷°…“∑’Ë„À≠à·≈–¡’§ÿ≥¿“æ ŸßÀπ÷Ëß°“√»÷°…“∑’Ë· ¥ß«à“ CBT ‰¥â
ª√–‚¬™πå∑”„À⺟âªÉ«¬Õ“°“√¥’¢÷ÈπÕ¬à“ß™—¥‡®π ¡’°“√»÷°…“∑’ˇªìπsingle-blindedstudy
‡ª√’¬∫‡∑’¬∫ CBT °—∫ patient education alone æ∫«à“ CBT ∑”„À⺟âªÉ«¬Õ“°“√
¥’¢÷Èπ√âÕ¬≈–73´÷Ë߉¥âº≈¥’°«à“educationgroup´÷Ë߉¥âº≈√âÕ¬≈–41.3Õ¬à“ß¡’π—¬ ”§—≠
21§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
∑“ß ∂‘µ‘ (NNT= 3.2)20
 ”À√—∫ hypnotherapy ¡’°“√»÷°…“∑’ˇªìπ systematic
review ª√–°Õ∫¥â«¬ 6 °“√»÷°…“∑’Ë¡’ control ·≈– 8 °“√»÷°…“∑’ˉ¡à¡’ control ¡’
ºŸâªÉ«¬√«¡ 644 √“¬ æ∫«à“√âÕ¬≈– 80 ¡’ global IBS symptoms ¥’¢÷Èπ ‚¥¬‡©æ“–
ºŸâªÉ«¬ typical IBS ®–µÕ∫ πÕ߉¥â¥’  à«πºŸâªÉ«¬™“¬∑’Ë¡’∑âÕ߇ ’¬‡ªìπÕ“°“√‡¥àπ
·≈–ºŸâªÉ«¬ IBS ∑’Ë¡’ atypical symptoms À√◊Õ¡’ comorbid psychopathology
¡—°‰¡à§àÕ¬µÕ∫ πÕßµàÕ°“√√—°…“21
20.3 Probiotics22-25
°≈‰°Àπ÷ËߢÕß欓∏‘ √’√–«‘∑¬“¢ÕßIBS§◊Õ¡’°“√‡ª≈’ˬπ
·ª≈ߢÕß intestinal microbiota º‘¥ª°µ‘‰ª®“°‡¥‘¡ ‚¥¬‡°‘¥§«“¡‰¡à ¡¥ÿ≈¬å¢Õß
intestinal microbiota ‡™àπ ¡’°“√≈¥≈ߢÕß Lactobacilli ·≈– Bifidobacteria ´÷Ëß
‡ªìπ·∫§∑’‡√’¬∑’Ë¥’‡°‘¥ª√–‚¬™πåµàÕ√à“ß°“¬¢≥–‡¥’¬«°—π¡’·∫§∑’‡√’¬∑’ˉ¡à¥’‡æ‘Ë¡¢÷Èπ‡™àπ
Clostridia ·≈– Enterobacteriaceae ‡ªìπµâπ 𔉪 Ÿà¿“«– dysbiosis, elevated
luminal gas production ·≈– immune activation ¥—ßπ—Èπ‡ªÑ“À¡“¬Àπ÷ËߢÕß°“√
√—°…“ IBS ®÷ß¡ÿà߉ª∑’Ë°“√·°â‰¢§«“¡º‘¥ª°µ‘¢Õß intestinal microbiota ¡’°“√»÷°…“
∑’ˇªìπ systematic review 3 °“√»÷°…“ (2 °“√»÷°…“‡ªìπºŸâªÉ«¬ºŸâ„À≠àÕ¬à“߇¥’¬«,
1 °“√»÷°…“‡ªìπºŸâ„À≠à·≈–‡¥Á°)2-4
æ∫«à“ probiotics ∑”„À⺟âªÉ«¬¡’ global IBS
symptoms, abdominal pain ·≈– flatulence ¥’¢÷ÈπÕ¬à“ß¡’π—¬ ”§—≠·≈–ª√–‚¬™πå
∑’ˉ¥â‡ªìπ strain-specific ·≈– symptom-specific  ”À√—∫ probiotic ∑’ˇªìπ
 “¬æ—π∏ÿ凥’ˬ« À≈—°∞“π∑’Ë¥’∑’Ë ÿ¥§◊Õ Bifidobacteria infantis √Õß≈߉ª§◊Õ Lacto-
bacillus planetarium  à«π probiotic ∑’ˇªì𠓬æ—π∏ÿ庠¡‡™àπ E.coli-Nisle +
Streptococcusfaecalis ‡π◊ËÕß®“°¡’ªí®®—¬À≈“¬Õ¬à“߇™àπ strain selection, optimum
dosage, mode of action,† safety ·≈– long-term tolerability ´÷Ëß¡’º≈µàÕ
º≈¢Õß°“√√—°…“®÷߬—߉¡à “¡“√∂°”Àπ¥„Àâ probiotics ‡ªìπ general recommenda-
tion „π°“√√—°…“ºŸâªÉ«¬ IBS ‰¥â
20.4  “√ ¡ÿπ‰æ√ ®“°°“√»÷°…“‚¥¬ Cochrane systematic review 75
RCTs ¡’ºŸâªÉ«¬√«¡ 7,957 √“¬ æ∫«à“¡’ “√ ¡ÿπ‰æ√∫“ßÕ¬à“ßÕ“®∑”„ÀâÕ“°“√¢Õß
ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π¥’¢÷Èπ‰¥â26
¡’°“√»÷°…“∑’ˇªìπ RCT ·∫∫ multicenter ‚¥¬
»÷°…“µ”√—∫ ¡ÿπ‰æ√™◊ËÕ Iberogast ´÷Ëߪ√–°Õ∫¥â«¬ ¡ÿπ‰æ√À≈“¬™π‘¥ æ∫«à“∑”„Àâ
Õ“°“√¢ÕߺŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π¥’¢÷ÈπÕ¬à“ß¡’π—¬ ”§—≠‡¡◊ËÕ‡ª√’¬∫‡∑’¬∫°—∫¬“À≈Õ°
‚¥¬ºŸâªÉ«¬∑𬓉¥â¥’·≈–‰¥âº≈¥’‰¡à«à“®–¡’ predominant symptom ·∫∫„¥27
Õ¬à“߉√
°Áµ“¡°“√ª√–‡¡‘πª√–‚¬™πå∑’Ë·∑â®√‘ߢÕß ¡ÿπ‰æ√Õ“®‰¥âº≈‰¡à·πàπÕπ ‡π◊ËÕß®“°
22 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
°“√»÷°…“µà“ßÊ ¡’§«“¡À≈“°À≈“¬¢Õß®”π«π·≈–™π‘¥ ¡ÿπ‰æ√∑’Ë„™â·≈–µâÕߧ”π÷ß
∂÷ßæ‘…®“°§«“¡‰¡à∫√‘ ÿ∑∏‘Ï„π ¡ÿπ‰æ√π—ÈπÊ ¥â«¬´÷Ëß∑”„À⇪ìπ¢âÕ®”°—¥¢Õß ¡ÿπ‰æ√
∑’Ë®–π”¡“„™â„À⇰‘¥ª√–‚¬™πå„π°“√√—°…“13
20.5 °“√Ωí߇¢Á¡ ®“°°“√»÷°…“∑’ˇªìπ systematic review æ∫«à“‰¡à “¡“√∂
 √ÿª‰¥â«à“°“√Ωí߇¢Á¡‰¥âª√–‚¬™πå„π°“√√—°…“‚√§≈”‰ â·ª√ª√«π ‡π◊ËÕß®“°º≈°“√√—°…“
¡’∑—Èß∑’Ë∑”„ÀâÕ“°“√¥’¢÷Èπ·≈–‰¡à¥’¢÷Èπ ®÷ßµâÕß°“√°“√»÷°…“‡æ‘Ë¡‡µ‘¡Õ’°¡“°°àÕπ∑’Ë®–
·π–π”°“√Ωí߇¢Á¡„À⇪ìπÀπ÷Ëß„π·π«∑“ß°“√√—°…“13
20.6 Biofeedback therapy
Biofeedback therapy28
À√◊Õ°“√Ωñ°‡∫àßÕÿ®®“√– ¡’√“¬ß“π«à“¡’ª√–‚¬™πå„π
ºŸâªÉ«¬≈”‰ â·ª√ª√«π™π‘¥∑âÕߺŸ°‡¥àπ∑’Ë¡’ªí≠À“‡∫à߉¡à∂Ÿ°«‘∏’ (anismus) √à«¡¥â«¬
‚¥¬æ∫«à“∂⓺ŸâªÉ«¬ “¡“√∂Ωñ°‡∫àß®π “¡“√∂‡∫àßÕÿ®®“√–‰¥â∂Ÿ°«‘∏’ Õ“°“√ª«¥·πàπ
∑âÕß®“°≈”‰ â·ª√ª√«π®–¥’¢÷Èπ  —¡æ—π∏å°—∫°“√§≈“¬µ—«¢ÕßÀŸ√Ÿ¥∑«“√Àπ—°¢≥–‡∫àß
∑’Ë¥’¢÷Èπ ¥—ßπ—ÈπºŸâªÉ«¬≈”‰ â·ª√ª√«π™π‘¥∑âÕߺŸ°‡¥àπ∑’Ë¡’Õ“°“√√∫°«π¡“°À√◊Õ¥◊ÈÕµàÕ
°“√√—°…“ °“√µ√«®°“√∑”ß“π¢Õß∑«“√Àπ—° ‡™àπ anorectal manometry, balloon
expulsion test À√◊Õ defecogram ‡æ◊ËÕ§âπÀ“¿“«–‡∫à߉¡à∂Ÿ°«‘∏’ (anismus) ·≈–
„Àâ°“√√—°…“‚¥¬«‘∏’ biofeedback ®÷ßπà“®–¡’ª√–‚¬™πåµàÕºŸâªÉ«¬
References :
1. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable
bowel syndrome in North America. Am J Gastroenterol 2002;97 (Suppl 11):S7- 26.
2. Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treat-
ments for irritable bowel syndrome: a European perspective. Aliment Pharmacol Ther 2006;24:183
- 205.
3. Hammer J, Eslick GD, Howell SC, Altiparmak E, Talley NJ. Diagnostic yield of alarm features
in irritable bowel syndrome and functional dyspepsia. Gut 2004;53:666-72.
4. Ford AC, Talley NJ, Veldhuyzen van Zanten SJ, Vakil NB, Simel DL, Moayyedi P. Will the
history and physical examination help establish that irritable bowel syndrome is causing my
patientûs lower gastrointestinal symptoms? JAMA 2008;300:1793-805.
5. Cash BD, Schemed P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome
patients: a systematic review. Am J Gastroenterol 2002;97:2812-9.
6. American Gastroenterological Association. AGA medical position statement: Irritable bowel
syndrome. Gastroenterology 2002;123:2105-7.
7. Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. Br
Med J 1978;277:653-4.
8. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the
physician-patient interaction. Ann Intern Med 1995;122:107-12.
9. Spiegel BMR, Nalibo7 B, Mayer E, et al. The effectiveness of a model physician-patient
relationship versus usual care in irritable bowel syndrome: a andomized controlled trial. Gastro-
enterology 2006;130:A773.
10. Simren M, Mansson A, Langkilde AM, et al. Food-related gastrointestinal symptoms in the
irritable bowel syndrome. Digestion 2001;63:108-15.
23§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
11. Park MI, Camilleri M. Is there a role of food allergy in irritable bowel syndrome and functional
dyspepsia? A systematic review. NeurogastroenterolMotil 2006;18:595-607.
12. Atkinson W, Sheldon T, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in
irritable bowel syndrome: a randomized controlled trial. Gut 2004;53:1459-64.
13. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. American College of Gastroenterology Task
Force on Irritable Bowel Syndrome. An evidence-based position statement on the management
of irritable bowel syndrome. Am J Gastroenterol. 2009;104 Suppl 1:S1-35.
14. Robinson A , Lee V, Kennedy A , et al. A randomized controlled trial of self-help interventions
in patients with a primary care diagnosis of irritable bowel syndrome. Gut 2006;55:643-648.
15. Whitehead WE, Palsson O, Jones KR.. Systematic review of the comorbidity of irritable bowel
syndrome with other disorders: what are the causes and implications? Gastroenterology
2002;122:1140-56.
16. Miller AR, North CS, Clouse RE, Wetzel RD, Spitznagel EL, Alpers DH. The association of
irritable bowel syndrome and somatization disorder. Ann Clin Psychiatry 2001;13:25-30.
17. Lackner JM, Mesmer C, Morley S, Dowzer C, Hamilton S. Psychological treatments for irritable
bowel syndrome: a systematic review and meta-analysis .J Consult Clin Psychol 2004;72:
1100-13.
18. Ford A, Talley N, Schoenfeld P, et al. Efficacy of psychological therapies in irritable bowel
syndrome: systematic and meta-analysis. Am J Gastroenterol 2008;103 (Suppl 1):S477.
19. Webb AN, Kukuruzovic RH, Catto-Smith AG, Sawyer SM. Hypnotherapy for treatment of
irritable bowel syndrome. Cochrane Database Syst Rev 2007 (4) CD005110.
20. Drossman D, Toner B, Whitehead W, et al. Cognitive-behavioral therapy vs. education and
desipramine vs. placebo for moderate to severe functional bowel disorders. Gastroenterology
2003; 125:19-31.
21. Tan G, Hammond D, Gurrala J. Hypnosis and irritable bowel syndrome: a review of efficacy and
mechanism of action. Am J Clin Hypnosis 2005;47:161-178.
22. Whelan K. Probiotics and prebiotics in the management of IBS: a review of recent clinical trials
and systematic reviews. Curr Opin Clin Nutr Care 2011;14:531-7.
23. McFarland LV, Dubin S. Meta-analysis of probiotics for the treatment of IBS. World J Gastroenterol
2008;14:2650-61.
24. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of
IBS; a systematic review. Am J Gastroenterol 2009;104:1033-49.
25. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of IBS: a
systematic review. Gut 2010;59:325-32.
26. Liu J, Yang M, Liu Y, Wei M, Grimsgaard S. Herbal medicines for treatment of irritable bowel
syndrome. Cochrane Database Syst Rev 2006 ;(1):CD004116.
27. Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal
preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Ali-
ment Pharmacol Ther 2004;19:271-279.
28. Patcharatrakul T, Gonlachanvit S. Outcome of biofeedback therapy in dyssynergic defecation
patients with and without irritable bowel syndrome. J Clin Gastroenterol 2011; 45(7):593-598.
24 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
Pharmacological Treatment
¢âÕ √ÿª∑’Ë 21.
¬“∑’Ë¡’ª√–‚¬™πå„π°“√√—°…“ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π‰¥â·°à antispasmodics,
fiber, anti-diarrheal, laxatives, antibiotics, probiotics, lubiprostone,
linaclotide,anti-depressants(TCAandSSRI)·≈–¬“∑’ËÕÕ°ƒ∑∏‘Ϻà“π√–∫∫
serotonin À√◊Õ 5-HT receptor
°“√√—°…“≈”‰ â·ª√ª√«πªí®®ÿ∫—π¬—߇πâπ∑’Ë°“√√—°…“µ“¡Õ“°“√‡ªìπÀ≈—° à«π¬“
∑’ËÕÕ°ƒ∑∏‘Ϻà“π serotonin receptors π—Èπ°Á “¡“√∂„™â‰¥âµ“¡¢âÕ∫àß™’È
21.1. °“√√—°…“Õ“°“√ª«¥∑âÕß  “¡“√∂„™â¬“∑’Ë≈¥Õ“°“√ª«¥‡°√Áß
(antispasmodics) ‰¥â ‰¡à«à“®–‡ªìπ hyoscine, mebeverine ·µà‡π◊ËÕß®“°¬“‡À≈à“π’È
¡’®”Àπà“¬¡“π“π·≈â« °“√»÷°…“∑’ˇ§¬∑”‡¡◊ËÕπ“π·≈â«π—Èπ ¡—°¡’¢π“¥‡≈Á° ‰¡à ¡∫Ÿ√≥å
„π‡™‘ß RCT ·≈–Õ“®¡’ publication bias ·¡â¡’ºŸâ∑” meta-analysis · ¥ß„Àâ‡ÀÁπ
ª√–‚¬™πå·≈â«°Áµ“¡1
πÕ°®“°π—Èπ¡’¬“∑’Ë¢÷Èπ∑–‡∫’¬π„πª√–‡∑»Õ’° ‡™àπ Trimebutine (´÷Ë߇ªìπ opioid
antagononist), pinaverium (Dicetel
) ·≈– dicyclomine (dicycloverine)
·µà°Á‰¡à¡’À≈—°∞“π«à“¡’ª√–‚¬™πåÕ¬à“ß™—¥‡®π Õ¬à“߉√°Áµ“¡¡’ºŸâªÉ«¬∫“ß√“¬∑’˵Õ∫ πÕß
µàÕ°“√√—°…“‡™àπ°—π
 à«π¬“ ‡™àπ alverine (Spasmonal
), fenoverine (Spasmopriv
) ‡§¬¡’
®”Àπà“¬„πª√–‡∑» ·µàªí®®ÿ∫—π‰¥â∂Õπ∑–‡∫’¬π‰ª·≈â«
¬“∑’Ë¡’º≈µàÕ pain modulation °Á‡≈◊Õ°„™â‰¥â ‡™àπ tricyclic antidepressant
·≈– SSRI2
·µà¬“°≈ÿà¡ GABA analogue ‡™àπ gabapentin ·≈– pregabalin ¬—ß
‰¡à¡’°“√»÷°…“„π IBS
21.2. °“√√—°…“Õ“°“√∑âÕ߇ ’¬ ‡≈◊Õ°„™â¬“µàÕ‰ªπ’ȉ¥â
● Antidiarrheal drugs ‡™à𠬓º ¡ diphenoxylate À√◊Õ loperamide
‚¥¬¬“ “¡“√∂≈¥§«“¡∂’Ë ∑”„Àâª√‘¡“≥Õÿ®®“√–, ≈—°…≥–Õÿ®®“√–¥’¢÷Èπ‰¥â ·µà‰¡à¡’º≈
µàÕÕ“°“√ª«¥∑âÕß ·≈– global assessment ¥’¢÷ÈππâÕ¬3,4
●  à«π codeine ‰¡à·π–π”„Àâ„™â‡æ√“–𔉪 Ÿà abuse ‰¥â
● 5-HT3
antagonists ‡™àπ alosetron, ramosetron
25§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
Alosetron ¬“¬—߉¡à‰¥â¢÷Èπ∑–‡∫’¬π„πª√–‡∑»‰∑¬ ·¡âæ∫«à“‰¥âº≈¥’¡“°
·µà‡π◊ËÕß®“°æ∫º≈¢â“߇§’¬ß§◊Õ ischemic colitis ·≈–¡’∫“ß√“¬‡ ’¬™’«‘µ ºŸâº≈‘µ®÷ß
®”°—¥„Àâ·æ∑¬å —Ëß„™â‡©æ“–°√≥’¡’¢âÕ∫àß™’È·≈–ºŸâªÉ«¬∑√“∫º≈¢â“߇§’¬ß·≈–¬‘π¬Õ¡„™â
‡∑à“π—Èπ·≈–‡©æ“–„π À√—∞Õ‡¡√‘°“ª√–‡∑»‡¥’¬«≈à“ ÿ¥æ∫«à“ºŸâªÉ«¬°≈ÿà¡π’È “¡“√∂„™â¬“
„π√–¬–¬“«‰¥âÕ¬à“߉¥âº≈·≈–ª≈Õ¥¿—¬5
Ramosetron ¢÷Èπ∑–‡∫’¬π„πª√–‡∑»·≈â« æ∫«à“‰¥âº≈¥’¡“°„πºŸâªÉ«¬™“¬ ·≈–
°”≈—ß¡’°“√»÷°…“„π«ß°«â“ßµàÕ‰ª6
°“√„™â¬“ªØ‘™’«π–Õ“®¡’ª√–‚¬™πå„π°“√√—°…“ IBS-D ‰¥â ‚¥¬¡’ ¡¡µ‘∞“π«à“
ºŸâªÉ«¬Õ“®¡’°“√µ‘¥‡™◊ÈÕ·ΩßÀ√◊Õ‡ªìπ°“√ª√—∫ ‘Ëß·«¥≈âÕ¡®ÿ≈™’æ„π≈”‰ âÀ√◊ÕºŸâªÉ«¬Õ“®¡’
small intestinal bacterial overgrowth À√◊Õ tropical sprue Õ¬Ÿà
¬“ªØ‘™’«π–∑’Ë¡’°“√»÷°…“ªí®®ÿ∫—π¡’‡æ’¬ß¢π“π‡¥’¬«§◊ÕRifaximin ‡¡◊ËÕªï2011
¡’°“√»÷°…“ phase III ∑’Ë· ¥ß„Àâ‡ÀÁπ«à“ Rifaximin ‰¥âº≈¥’„πºŸâªÉ«¬ non IBS-C
‚¥¬∑”„ÀâÕ“°“√√«¡¥’¢÷È𠪫¥∑âÕß ∑âÕßÕ◊¥¥’¢÷Èπ µ≈Õ¥®π≈—°…≥–Õÿ®®“√–∑’ˇÀ≈«
‡ªìππÈ”°Á¥’¢÷Èπ¥â«¬7
21.3. °“√√—°…“Õ“°“√∑âÕߺŸ° ‡≈◊Õ°„™â¬“µàÕ‰ªπ’ȉ¥â
● Fiber „¬Õ“À“√„Àâº≈¥’„π√“¬∑’ˉ¥â√—∫„¬Õ“À“√µàÕ«—ππâÕ¬°«à“‡°≥±å
À√◊Õ°≈ÿà¡∑’˵âÕß°“√„¬Õ“À“√¡“°°«à“Õ—µ√“‡©≈’ˬ À√◊ÕºŸâ∑’Ë√—∫ª√–∑“π„¬Õ“À“√‰¡à
 ¡Ë”‡ ¡Õ8-10
Õ¬à“߉√°Áµ“¡À“°ºŸâªÉ«¬‰¡à‰¥âµâÕß°“√„¬Õ“À“√‡æ‘Ë¡¢÷Èπ°«à“∑’˧«√‰¥â°Á¡—°¡’
Õ“°“√¢â“߇§’¬ß‡™àπ ∑âÕßÕ◊¥ ¡’≈¡„π∑âÕß À“°‡ªìπ‰ª‰¥â§«√‰¥â√—∫„¬Õ“À“√„π√Ÿª·∫∫
∏√√¡™“µ‘ ‡™àπ®“°º—° º≈‰¡â ¡“°°«à“„π√Ÿª∑’Ë¢÷Èπ∑–‡∫’¬π‡ªìπ¬“À√◊Õº≈‘µ¿—≥±å‡ √‘¡
Õ“À“√
● Laxatives‰¡à¡’À≈—°∞“π‡™‘ßª√–®—°…å„π°“√„™â¬“ conventional laxatives
(‡™àπ magnesium salt, lactulose, bisacodyl, senna) „πºŸâªÉ«¬ IBS ·µàæ∫«à“
¡’°“√„™â¬“°≈ÿà¡π’ÈÕ¬à“ß°«â“ߢ«“ß ·≈–‡ªìπ∑’ˬա√—∫∑—Èß„πºŸâªÉ«¬·≈–·æ∑¬å
 à«πpolyethyleneglycol¡’°“√»÷°…“¢π“¥‡≈Á°·µà°Áæ∫«à“‰¥âº≈¥’°«à“Õ“°“√
¢â“߇§’¬ßπâÕ¬°«à“ lactulose11
● Lubiprostone´÷Ëßæ∫«à“°“√„™â·¡â„π√–¬–¬“«°Á‰¥âº≈¥’ª≈Õ¥¿—¬·≈–ºŸâªÉ«¬
∑π°“√√—°…“‰¥â¥’ ¬“ºà“π°“√√—∫√Õß®“° US FDA ·≈â«·≈–‡ªìπ‡æ’¬ß¢π“π‡¥’¬«∑’Ë
26 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
√—∫√Õß„Àâ„™â„π IBS-C ‰¥â∑—Ë«‰ª‰¡à¡’¢âÕ®”°—¥À√◊Õ¢âÕ∫àß™’ȇ©æ“– ¢≥–π’È√Õ¢÷Èπ∑–‡∫’¬π
„πª√–‡∑»‰∑¬12
● 5-HT4 agonist
Tegaserod ‡ªì𬓰≈ÿà¡π’È∑’ˇ§¬¢÷Èπ∑–‡∫’¬π„πª√–‡∑» ·≈–æ‘ Ÿ®πå«à“‰¥âº≈¥’
ª≈Õ¥¿—¬ ·µàµàÕ¡“ºŸâº≈‘µ·≈–®”Àπà“¬¢Õ¬°‡≈‘°‰¡à®”Àπà“¬ ®“°∑’Ë¡’°“√»÷°…“
∑∫∑«πºŸâªÉ«¬∑’ˇ¢â“√à«¡°“√∑¥ Õ∫∑“ߧ≈‘π‘°®”π«π¡“°æ∫«à“ºŸâ∑’ˉ¥â√—∫¬“¡’Õ—µ√“
‡°‘¥¿“«–·∑√°´âÕπ·≈–Õ—µ√“µ“¬®“°‚√§À—«„®·≈– stroke ¡“°°«à“13
● Prucalopride ¬“π’È¢÷Èπ∑–‡∫’¬π·≈â«∑—Èß„π·≈–µà“ߪ√–‡∑»‡æ◊ËÕ„™â√—°…“
chronicconstipation´÷Ëß„Àâº≈¥’·≈–ª≈Õ¥¿—¬¢≥–π’È¡’¢âÕ¡Ÿ≈«à“‰¥âº≈¥’„πºŸâªÉ«¬IBS-
C ·µà¬—߉¡à‰¥â¢÷Èπ∑–‡∫’¬π°“√√—°…“„π¢âÕ∫àß™’Èπ’È
● Linaclotide ªí®®ÿ∫—π¢÷Èπ∑–‡∫’¬π„π À√—∞Õ‡¡√‘°“‡æ◊ËÕ√—°…“ IBS-C
·≈â«14
·µà¬—߉¡à¡’„™â„πª√–‡∑»‰∑¬
● Cisapride ªí®®ÿ∫—πºŸâº≈‘µ¬“µâπµ”√—∫∂Õπ∑–‡∫’¬π‰ªπ“π·≈â« „πª√–‡∑»
¡’®”Àπà“¬‡ªì𬓠generic ‡∑à“π—Èπ °“√»÷°…“º≈¢Õß cisapride „π IBS-C ¡’‰¡à¡“°
¡’‡æ’¬ß°“√»÷°…“‡¥’¬«∑’Ëæ∫«à“¥’°«à“ placebo17
·µàÀ≈—ß®“°π—Èπ·≈–®“° systematic
review18
æ∫«à“‰¡à‰¥âº≈¥’°«à“ placebo
● Mosapride ‡∑à“∑’Ë ◊∫§âπ‰¥â¡’‡æ’¬ß°“√»÷°…“‡¥’¬«19
‡ªìπ°“√»÷°…“·∫∫‡ªî¥
„πºŸâªÉ«¬ 10 √“¬ æ∫«à“™à«¬„ÀâÕ“°“√‚¥¬√«¡¥’¢÷Èπ‰¥â
¢âÕ √ÿª∑’Ë 22.
‰¡à¡’¢âÕ∫àß™’È„π°“√„™â¬“≈¥°√¥„πºŸâªÉ«¬≈”‰ â·ª√ª√«π∑’ˉ¡à¡’Õ“°“√¢Õß
°√¥‰À≈¬âÕπÀ√◊Õ°√–‡æ“–Õ“À“√∑”ß“πº‘¥ª°µ‘ (ª«¥· ∫∑âÕß∫√‘‡«≥≈‘Èπªïò)
ºŸâªÉ«¬≈”‰ â·ª√ª√«π∑’ˉ¡à¡’Õ“°“√¢Õß°√¥‰À≈¬âÕπÀ√◊Õ°√–‡æ“–Õ“À“√
∑”ß“πº‘¥ª°µ‘ (ª«¥· ∫∑âÕß∫√‘‡«≥≈‘Èπªïò) °“√„™â¬“√–ß—∫°“√À≈—Ëß°√¥¡’∫∑∫“∑πâÕ¬
®“°°“√ ◊∫§âπ æ∫«à“
22.1. ‰¡à¡’°“√»÷°…“∂÷ß∫∑∫“∑¢Õ߬“√–ß—∫°“√À≈—Ëß°√¥ ‰¡à«à“®–‡ªìπ H2-
receptor antagonist À√◊Õ PPI „πºŸâªÉ«¬≈”‰ â·ª√ª√«π‡≈¬
22.2. Õ¬à“߉√°Áµ“¡ æ∫«à“ºŸâªÉ«¬Õ“®¡’Õ“°“√¢Õß∑—Èß≈”‰ â·ª√ª√«π·≈–
27§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
‚√§°√¥‰À≈¬âÕπÀ√◊Õ functional dyspepsia ‡À≈◊ËÕ¡´âÕπ‰¥â„π¢≥–‡¥’¬«°—π ‚¥¬
¡’§«“¡™ÿ°Õ¬Ÿà√“« 11-27 %15
ºŸâªÉ«¬¡—°¡’Õ“°“√¡“°°«à“ºŸâ∑’Ë¡’¿“«–Àπ÷Ëß¿“«–„¥
‡æ’¬ßÕ¬à“߇¥’¬« ®÷ßæ∫‰¥â¡“°„π ∂“π欓∫“≈√–¥—∫µµ‘¬¿Ÿ¡‘ ·≈–¡—°¡’ psychiatric
comorbidity16
Õ—πÕ“®‰¥â√—∫ª√–‚¬™π宓°°“√ª√–‡¡‘π·≈–√—°…“∑“ß®‘µ‡«™ à«πÕ“°“√
¢Õß·µà≈–¿“«–·π–π”„Àâ√—°…“·¬°®“°°—π
Reference
1. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth musclerelaxants in the
treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15:355-61.
2. Jackson JL, OûMalley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional
gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;
108:65-72.
3. Lavo B, Stenstam M, Nielsen A-L. Loperamide in treatment of irritable bowel syndrome - A
double-blind placebo controlled study. Scand J Gastroenterol Suppl 1987;22:77-80.
4. Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide,
codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology 1980;79:1272-
5.
5. Nicandro JP, Shin P, Chuang E. Evaluation of treatment continuation with alosetron by IBS-D
severity criteria. Curr Med Res Opin 2012;28:449-56.
6. Lee KJ, Kim NY , Kwon JK , et al. Efficacy of ramosetron in the treatment of male patients with
irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with
mebeverine. Neurogastroenterol Motil 2011;23:1098-104.
7. PimentelM, Lembo A, Chey WD, et al. Rifaximin Therapy for Patients with Irritable Bowel
Syndrome without Constipation. New Engl J Med 2011;364:22-32.
8. Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet
1994;344:39-40.
9. Prior A, Whorwell PJ. Double blind study of ispaghula in irritable bowel syndrome. Gut
1987;28:1510-13.
10. Bijkerk CJ, Muris JWM, Knottnerus JA, Hoes AW, De Wit NJ. Systematic review: the role of
different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther
2004;19:245-51.
11. Attar A, Lemann M, Ferguson A, et al. Comparison of a low dose polyethylene glycol electro-
lyte solution with lactulose for treatment of chronic constipation. Gut 1999;44:226-30.
12. Chey WD, Drossman DA, Johanson JF, Scott C, Panas RM, Ueno R. Safety and patient out-
comes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with
constipation. Aliment Pharmacol Ther 2012;35:587-99.
13. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel
syndrome and chronic constipation. Cochrane Database Syst Rev 2007:CD003960.
14. Wensel TM, Luthin DR. Linaclotide: a novel approach to the treatment of irritable bowel syn-
drome. Ann Pharmacother 2011;45:1535-43.
15. Suzuki H, Hibi T. Overlap syndrome of functional dyspepsia and irritable bowel syndrome - are
both diseases mutually exclusive? J Neurogastroenterol Motil 2011;17:360-5.
28 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
16. Piacentino D, Cantarini R, Alfonsi M, et al. Psychopathological features of irritable bowel
syndrome patients with and without functional dyspepsia: a cross sectional study. BMC
Gastroenterol 2011;11:94.
17. Van Outryve M, Milo R, Toussaint J, Van Eeghem P. çProkinetic-treatment of constipation-
predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol
1991;13:49-57.
18. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3
antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analy-
sis. Am J Gastroenterol 2009;104:1831-43.
19. Nakamura M, Ohmiya N, Miyahara R, et al. Are symptomatic changes in irritable bowel syn-
drome correlated with the capsule endoscopy transit time? A pilot study using the 5-HT4 recep-
tor agonist mosapride. Hepatogastroenterology 2011;58:453-8.
29§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
Psychiatric problems „π IBS
¢âÕ √ÿª∑’Ë 23.
¿“«–§«“¡º‘¥ª°µ‘∑“ß®‘µ‡«™‡™àπ‡§√’¬¥«‘µ°°—ß«≈À√◊Õ´÷¡‡»√Ⓡªìπ¿“«–
∑’Ëæ∫∫àÕ¬„πºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π ·≈–§«√‰¥â√—∫°“√√—°…“Õ¬à“߇À¡“– ¡
§«“¡º‘¥ª°µ‘∑“ß®‘µ‡«™ ‡™àπ anxiety, depression ·≈– somatization
„πºŸâªÉ«¬ Irritable Bowel Syndrome (IBS) ¢âÕ¡Ÿ≈¢Õß Lee ·≈–§≥–1
´÷Ëß»÷°…“„πª√–™“°√∑—Ë«‰ª∑’ËŒàÕß°ß®”π«π2,005√“¬æ∫«à“ºŸâªÉ«¬∑’Ë¡’generalanxiety
disorder (GAD) ¡’Õ—µ√“°“√æ∫ IBS ‰¥â¡“°°«à“ºŸâ∑’ˉ¡à¡’ GAD 4.7 ‡∑à“
·≈–ºŸâªÉ«¬ IBS ¡’Õ—µ√“°“√æ∫ GAD ‰¥â¡“°°«à“ºŸâ∑’ˉ¡à¡’Õ“°“√ IBS ‰¥â∂÷ß 5 ‡∑à“
¢âÕ¡Ÿ≈°“√»÷°…“¢Õß Choung PS ·≈–§≥–2
æ∫«à“ºŸâªÉ«¬∑’Ë¡’ somatic symptom score
 Ÿß ¡’Õ—µ√“°“√‡°‘¥‚√§ IBS ‰¥â Ÿß°«à“ºŸâ∑’Ë¡’ somatic symptom score µË” ‰¥â∂÷ß 4
‡∑à“ º≈°“√»÷°…“¢Õß Henningsen ·≈–§≥–3
‚¥¬∑” meta-analysis æ∫«à“
ºŸâªÉ«¬∑’Ë¡’Õ“°“√¢Õß IBS ¡’Õ—µ√“°“√æ∫ anxiety ·≈– depression ‰¥â¡“°°«à“
∑’Ëæ∫„π§πª°µ‘ À√◊ÕºŸâªÉ«¬∑’Ë¡’Õ“°“√‡π◊ËÕß®“°¡’ organic cause „πºŸâªÉ«¬ IBS
∑’Ë¡“ª√÷°…“·æ∑¬å®–¡’Õ—µ√“°“√æ∫anxiety‰¥â Ÿß°«à“ºŸâªÉ«¬IBS∑’ˉ¡à‰¥â¡“æ∫·æ∑¬å
„π√“¬ß“π¢Õß Gros ·≈–§≥–4
æ∫«à“ºŸâªÉ«¬ panic disorders, GAD ·≈–ºŸâªÉ«¬
∑’Ë¡’ major depression ¡’Õ—µ√“°“√‡°‘¥Õ“°“√¢Õß IBS ‰¥â¡“°°«à“ ‚¥¬∑’˺ŸâªÉ«¬
∑’ˇªìπ social anxiety disorder, specific phobia ·≈– obsessive-compulsive
disorder ¡’Õ“°“√¢Õß IBS ‰¡àµà“ß®“°§πª°µ‘ §«“¡√ÿπ·√ß·≈–§«“¡∂’Ë¢ÕßÕ“°“√
IBS „πºŸâªÉ«¬ GAD ®–¡“°°«à“„π°≈ÿࡺŸâªÉ«¬Õ◊ËπÊ √“¬ß“π¢Õß Creed ·≈–§≥–5
æ∫«à“ºŸâªÉ«¬ IBS ∑’Ë¡’ marked somatization Õ“°“√¢Õß IBS ®–¥’¢÷Èπ‚¥¬°“√√—°…“
¥â«¬ psychotherapy À√◊Õ antidepressant ¡“°°«à“°“√√—°…“‚¥¬«‘∏’ª°µ‘
°“√»÷°…“‚¥¬ Friedrich ·≈–§≥–6
´÷Ë߇ªìπ°“√∑” meta-analysis æ∫«à“°“√„™â¬“
antidepressant (TCA ·≈– SSRI) „π°“√√—°…“ IBS ∑’Ë¡’ depression √à«¡¥â«¬
æ∫«à“¬“ antidepressant ∫“ߢπ“πÕ“®®–∑”„ÀâÕ“°“√¢Õß IBS ¥’¢÷Èπ ‚¥¬‰¡à¡’
§«“¡ —¡æ—π∏å°—∫º≈¢Õ߬“µàÕÕ“°“√ depression ∑’ˇ°‘¥√à«¡
‚√§ IBS ‰¡à‰¥â‡ªìπ‚√§∑“ß®‘µ‡«™·µàºŸâªÉ«¬IBS¡’‚Õ°“ ∑’Ë®–æ∫§«“¡º‘¥ª°µ‘
30 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
∑“ß®‘µ‡«™‰¥â¡“°°«à“ª√–™“°√∑—Ë«‰ª¥—ß°≈à“«¡“¢â“ßµâπ ºŸâªÉ«¬ IBS ∑’Ë¡’ªí≠À“
∑“ß®‘µ‡«™§«√‰¥â√—∫°“√¥Ÿ·≈√—°…“√à«¡‰ª¥â«¬°—π∑—Èß Õߪí≠À“
References
1. Lee S, Wu J, Ma YL, Tsang A, Guo WJ, Sung J. Irritable bowel syndrome is strongly associated
with generalized anxiety disorder: a community study. Aliment Pharmacol Ther 2009;30:643-
51.
2. Choung RS, Locke R, Zinsmeistr AR, Schleck CD, Talley NJ. Psychosocial distress and somatic
symptoms in community subjects with irritable bowel syndrome: a psychological component is
the rule. Am J Gastroenterol 2009;104:1772-9.
3. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety,
and depression: a meta-analytic review. Psychosomatic Medicine 2003;65:528-33.
4. Gros DF, Antony MM, McCabe RE, Swinson RP. Frequency and severity of the symptoms of
irritable bowel syndrome across the anxiety disorders and depression. J Anxiety Disorders
2009;23:290-6.
5. Creed F, Tomenson B, Guthrie E, et al. The relationship between somatization and outcome in
patients with severe irritable bowel syndrome. J of Psychosomatic Res 2008;64:613-20.
6. Friedrich M, Grady SE, Wall GC. Effects of antidepressants in patients with irritable bowel
syndrome and comorbid depression. Clin Ther 2010;32:1221-33.
¢âÕ √ÿª∑’Ë 24.
°“√ «π≈â“ß≈”‰ âÕ“®∑”„ÀâÕ“°“√≈”‰ â·ª√ª√«π¥’¢÷Èπ™—Ë«§√“«·µàº≈¥’À√◊Õ
º≈‡ ’¬√–¬–¬“«¬—߉¡à¡’¢âÕ¡Ÿ≈∑“ß°“√·æ∑¬å™—¥‡®π
„πºŸâªÉ«¬≈”‰ â·ª√ª√«π∑’Ë¡’Õ“°“√∑âÕߺŸ°‡ªìπª√–®”°“√ «π≈â“ß≈”‰ â
Õ“®∑”„ÀâÕ“°“√¥’¢÷Èπ™—Ë«§√“«·µà‰¡à§«√∑”‡ªìπª√–®”‡π◊ËÕß®“°‰¡à¡’¢âÕ¡Ÿ≈∑“ß°“√
·æ∑¬å∑’Ë∫àß∫Õ°∂÷ߺ≈¥’À√◊Õº≈‡ ’¬√–¬–¬“«
„πºŸâªÉ«¬≈”‰ â·ª√ª√«π∑’Ë¡’Õ“°“√§àÕπ‰ª∑“ß∑âÕ߇ ’¬°“√ «π≈â“ß≈”‰ â‰¡àπà“
®–‰¥âª√–‚¬™πå„¥ Ê
31§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
No alarm features
32 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
𓬷æ∑¬å°‘µµ‘ ®—π∑√å‡≈‘»ƒ∑∏‘Ï ‚√ß欓∫“≈»√’π§√‘π∑√å ¢Õπ·°àπ
·æ∑¬åÀ≠‘ß®‘π¥“√—µπå ‡®’¬‡®…Ø“°ÿ≈ ‚√ß欓∫“≈æ√–¡ß°ÿƇ°≈â“ °√ÿ߇∑æ¡À“π§√
·æ∑¬åÀ≠‘ß‚©¡»√’ ‚¶…‘µ™—¬«—≤πå ‚√ß欓∫“≈√“¡“∏‘∫¥’ °√ÿ߇∑æ¡À“π§√
·æ∑¬åÀ≠‘ß∞π‘ “ æ—™√µ√–°Ÿ≈ ‚√ß欓∫“≈®ÿÓ≈ß°√≥å °√ÿ߇∑æ¡À“π§√
𓬷æ∑¬å∏‡π» ®—¥«—≤π°ÿ≈ ‚√ß欓∫“≈ ¡‡¥Á®æ√–∫√¡√“™‡∑«’ ≥ »√’√“™“ ™≈∫ÿ√’
𓬷æ∑¬å∏‡π» ™‘µ“æπ“√—°…å ‚√ß欓∫“≈¡À“√“™π§√‡™’¬ß„À¡à ‡™’¬ß„À¡à
𓬷æ∑¬åπæ«ÿ≤‘ °’√µ‘°√≥å ÿ¿—§ ‚√ß欓∫“≈ ¡‡¥Á®æ√–∫√¡√“™‡∑«’ ≥ »√’√“™“ ™≈∫ÿ√’
·æ∑¬åÀ≠‘ßπ‘»“ ‡πµ‘π“∂ ÿπ∑√ ‚√ß欓∫“≈ ß¢≈“π§√‘π∑√å  ß¢≈“
𓬷æ∑¬å∫—≠™“ ‚Õ«“∑Ó√æ√ ‚√ß欓∫“≈ ß¢≈“π§√‘π∑√å  ß¢≈“
·æ∑¬åÀ≠‘ß∫ÿ…∫“ «‘«—≤π凫§‘π ‚√ß欓∫“≈®ÿÓ≈ß°√≥å °√ÿ߇∑æ¡À“π§√
·æ∑¬åÀ≠‘ß¡≥±‘√“ ¡≥’√—µπ–æ√ ‚√ß欓∫“≈»‘√‘√“™ °√ÿ߇∑æ¡À“π§√
𓬷æ∑¬å√—∞°√ «‘‰≈™π¡å ‚√ß欓∫“≈∏√√¡»“ µ√å °√ÿ߇∑æ¡À“π§√
·æ∑¬åÀ≠‘ß«√πÿ™ ®ß»√’ «— ¥‘Ï ‚√ß欓∫“≈®ÿÓ≈ß°√≥å °√ÿ߇∑æ¡À“π§√
·æ∑¬åÀ≠‘ß«√¡π ‡®’¬¡»√’æß…å ‚√ß欓∫“≈æÿ∑∏™‘π√“™ æ‘…≥ÿ‚≈°
𓬷æ∑¬å«“π‘™ ªî¬π‘√—π¥√å ‚√ß欓∫“≈æ√–¡ß°ÿƇ°≈â“ °√ÿ߇∑æ¡À“π§√
·æ∑¬åÀ≠‘ß«‚√™“ ¡À“™—¬ ‚√ß欓∫“≈®ÿÓ≈ß°√≥å °√ÿ߇∑æ¡À“π§√
𓬷æ∑¬å»µ«√√… ∑Õß «— ¥‘Ï ‚√ß欓∫“≈¡À“√“™π§√‡™’¬ß„À¡à ‡™’¬ß„À¡à
𓬷æ∑¬å»√—≥¬å «√√≥¿“ π’ ‚√ß欓∫“≈ √√æ ‘∑∏‘ª√– ß§å Õÿ∫≈√“™∏“π’
𓬷æ∑¬å»ÿ¿™—¬ »√’»‘√‘√ÿàß ‚√ß欓∫“≈æ≠“‰∑ »√’√“™“ ™≈∫ÿ√’
𓬷æ∑¬å ¡™“¬ ≈’≈“°ÿ»≈«ß»å ‚√ß欓∫“≈»‘√‘√“™ °√ÿ߇∑æ¡À“π§√
𓬷æ∑¬å ¬“¡ »‘√‘π∏√ªí≠≠“ ‚√ß欓∫“≈√“™«‘∂’ °√ÿ߇∑æ¡À“π§√
𓬷æ∑¬å ‘π Õπÿ√“…Æ√å ‚√ß欓∫“≈∫”√ÿß√“…Æ√å °√ÿ߇∑æ¡À“π§√
·æ∑¬åÀ≠‘ß ÿæ√ µ√’æß…å°√ÿ≥“ ‚√ß欓∫“≈√“¡“∏‘∫¥’ °√ÿ߇∑æ¡À“π§√
𓬷æ∑¬å ÿ√‘¬– ®—°°–æ“° ‚√ß欓∫“≈√“¡“∏‘∫¥’ °√ÿ߇∑æ¡À“π§√
𓬷æ∑¬å ÿ‡∑æ °≈™“≠«‘∑¬å ‚√ß欓∫“≈®ÿÓ≈ß°√≥å °√ÿ߇∑æ¡À“π§√
𓬷æ∑¬åÕÿ¥¡ §™‘π∑√ ‚√ß欓∫“≈»‘√‘√“™ °√ÿ߇∑æ¡À“π§√
√“¬π“¡ºŸâ‡¢â“√à«¡ª√–™ÿ¡ —¡¡π“æ‘®“√≥“
Guideline for Management of Irritable bowel syndrome
§√—Èß∑’Ë 1 «—π∑’Ë 22-23 ¡°√“§¡ 2554
≥ ‚√ß·√¡¥ÿ ‘µ ∏“π’ æ—∑¬“ ®—ßÀ«—¥™≈∫ÿ√’
§√—Èß∑’Ë 2 «—π∑’Ë 23-24 ¡‘∂ÿπ“¬π 2555
≥ ‚√ß·√¡‡™Õ√“µ—π À—«À‘π √’ Õ√å∑·Õπ¥å ª“ ®—ßÀ«—¥ª√–®«∫§’√’¢—π∏å
Guideline irritable bowel syndrome 2012

Contenu connexe

Tendances

QNBFS Daily Technical Trader Qatar - January 17, 2021 التحليل الفني اليومي لب...
QNBFS Daily Technical Trader Qatar - January 17, 2021 التحليل الفني اليومي لب...QNBFS Daily Technical Trader Qatar - January 17, 2021 التحليل الفني اليومي لب...
QNBFS Daily Technical Trader Qatar - January 17, 2021 التحليل الفني اليومي لب...QNB Group
 
IE-027 動作與時間研究建立精實生產環境
IE-027 動作與時間研究建立精實生產環境IE-027 動作與時間研究建立精實生產環境
IE-027 動作與時間研究建立精實生產環境handbook
 
QNBFS Daily Technical Trader Qatar - December 28, 2020 التحليل الفني اليومي ل...
QNBFS Daily Technical Trader Qatar - December 28, 2020 التحليل الفني اليومي ل...QNBFS Daily Technical Trader Qatar - December 28, 2020 التحليل الفني اليومي ل...
QNBFS Daily Technical Trader Qatar - December 28, 2020 التحليل الفني اليومي ل...QNB Group
 
Gram Eng Easy:9789740326366
Gram Eng Easy:9789740326366Gram Eng Easy:9789740326366
Gram Eng Easy:9789740326366CUPress
 
Product Catalog 2009
Product Catalog 2009Product Catalog 2009
Product Catalog 2009Peter Chan
 
宋代《演雅》诗研究
宋代《演雅》诗研究宋代《演雅》诗研究
宋代《演雅》诗研究sugeladi
 
Chandrayaanam
ChandrayaanamChandrayaanam
ChandrayaanamBalu Bold
 
Qawaa Id Al Mouslaa
Qawaa Id Al MouslaaQawaa Id Al Mouslaa
Qawaa Id Al MouslaaAbousalimata
 
Color Book
Color BookColor Book
Color Bookmfadel69
 
Vaakkiyam amaittal 2012
Vaakkiyam amaittal 2012Vaakkiyam amaittal 2012
Vaakkiyam amaittal 2012Raja Segaran
 

Tendances (16)

Cough guideline 2016
Cough guideline 2016Cough guideline 2016
Cough guideline 2016
 
QNBFS Daily Technical Trader Qatar - January 17, 2021 التحليل الفني اليومي لب...
QNBFS Daily Technical Trader Qatar - January 17, 2021 التحليل الفني اليومي لب...QNBFS Daily Technical Trader Qatar - January 17, 2021 التحليل الفني اليومي لب...
QNBFS Daily Technical Trader Qatar - January 17, 2021 التحليل الفني اليومي لب...
 
Ph10 pa-004
Ph10 pa-004Ph10 pa-004
Ph10 pa-004
 
IE-027 動作與時間研究建立精實生產環境
IE-027 動作與時間研究建立精實生產環境IE-027 動作與時間研究建立精實生產環境
IE-027 動作與時間研究建立精實生產環境
 
QNBFS Daily Technical Trader Qatar - December 28, 2020 التحليل الفني اليومي ل...
QNBFS Daily Technical Trader Qatar - December 28, 2020 التحليل الفني اليومي ل...QNBFS Daily Technical Trader Qatar - December 28, 2020 التحليل الفني اليومي ل...
QNBFS Daily Technical Trader Qatar - December 28, 2020 التحليل الفني اليومي ل...
 
Gram Eng Easy:9789740326366
Gram Eng Easy:9789740326366Gram Eng Easy:9789740326366
Gram Eng Easy:9789740326366
 
Product Catalog 2009
Product Catalog 2009Product Catalog 2009
Product Catalog 2009
 
宋代《演雅》诗研究
宋代《演雅》诗研究宋代《演雅》诗研究
宋代《演雅》诗研究
 
Scientific Journals
Scientific JournalsScientific Journals
Scientific Journals
 
Chandrayaanam
ChandrayaanamChandrayaanam
Chandrayaanam
 
Qawaa Id Al Mouslaa
Qawaa Id Al MouslaaQawaa Id Al Mouslaa
Qawaa Id Al Mouslaa
 
Khutbah Jumuah, Eid and Nikah (خطبہ جمعہ،عید و نکاح )
Khutbah Jumuah, Eid and Nikah (خطبہ جمعہ،عید و نکاح )Khutbah Jumuah, Eid and Nikah (خطبہ جمعہ،عید و نکاح )
Khutbah Jumuah, Eid and Nikah (خطبہ جمعہ،عید و نکاح )
 
Color Book
Color BookColor Book
Color Book
 
Vaakkiyam amaittal 2012
Vaakkiyam amaittal 2012Vaakkiyam amaittal 2012
Vaakkiyam amaittal 2012
 
Rbi banking
Rbi bankingRbi banking
Rbi banking
 
2020 summary
2020 summary2020 summary
2020 summary
 

En vedette (9)

Presentación1 de accesss
Presentación1 de accesssPresentación1 de accesss
Presentación1 de accesss
 
Practica 1
Practica 1Practica 1
Practica 1
 
Religion sister
Religion sisterReligion sister
Religion sister
 
1 puntaje adicional
1 puntaje adicional1 puntaje adicional
1 puntaje adicional
 
Proyectodere estructuracióndelosperitajesenimel
Proyectodere estructuracióndelosperitajesenimelProyectodere estructuracióndelosperitajesenimel
Proyectodere estructuracióndelosperitajesenimel
 
Recursos Naturales
Recursos  NaturalesRecursos  Naturales
Recursos Naturales
 
La felicitat
La felicitatLa felicitat
La felicitat
 
Economia 2
Economia 2Economia 2
Economia 2
 
Proyectodere estructuracióndelosperitajesenimel
Proyectodere estructuracióndelosperitajesenimelProyectodere estructuracióndelosperitajesenimel
Proyectodere estructuracióndelosperitajesenimel
 

Similaire à Guideline irritable bowel syndrome 2012

2012 sirisamut j health sc_evaluation of outcomes and determinants of cervica...
2012 sirisamut j health sc_evaluation of outcomes and determinants of cervica...2012 sirisamut j health sc_evaluation of outcomes and determinants of cervica...
2012 sirisamut j health sc_evaluation of outcomes and determinants of cervica...Chuchai Sornchumni
 
แนวทางการวินิจฉัยและรักษาโรคหืดในประเทศไทย สำหรับผู้ใหญ่ 2559
แนวทางการวินิจฉัยและรักษาโรคหืดในประเทศไทย สำหรับผู้ใหญ่ 2559แนวทางการวินิจฉัยและรักษาโรคหืดในประเทศไทย สำหรับผู้ใหญ่ 2559
แนวทางการวินิจฉัยและรักษาโรคหืดในประเทศไทย สำหรับผู้ใหญ่ 2559Utai Sukviwatsirikul
 
แนวทางรักษา stroke-fast-track 2007
แนวทางรักษา stroke-fast-track 2007แนวทางรักษา stroke-fast-track 2007
แนวทางรักษา stroke-fast-track 2007Utai Sukviwatsirikul
 
แนวทางการวินิจฉัยและรักษาโรคหืดในประเทศไทย สำหรับผู้ใหญ่ พ.ศ. 2560
แนวทางการวินิจฉัยและรักษาโรคหืดในประเทศไทย สำหรับผู้ใหญ่ พ.ศ. 2560แนวทางการวินิจฉัยและรักษาโรคหืดในประเทศไทย สำหรับผู้ใหญ่ พ.ศ. 2560
แนวทางการวินิจฉัยและรักษาโรคหืดในประเทศไทย สำหรับผู้ใหญ่ พ.ศ. 2560Utai Sukviwatsirikul
 
اینفوگرافی:‌ بیشترین‌های جام‌جهانی ۲۰۱۸ در کافه‌بازار
اینفوگرافی:‌ بیشترین‌های جام‌جهانی ۲۰۱۸ در کافه‌بازاراینفوگرافی:‌ بیشترین‌های جام‌جهانی ۲۰۱۸ در کافه‌بازار
اینفوگرافی:‌ بیشترین‌های جام‌جهانی ۲۰۱۸ در کافه‌بازارBazaar Insight
 
創業家研習營-7分鐘創意簡報技巧,Mr.6劉威麟
創業家研習營-7分鐘創意簡報技巧,Mr.6劉威麟創業家研習營-7分鐘創意簡報技巧,Mr.6劉威麟
創業家研習營-7分鐘創意簡報技巧,Mr.6劉威麟taiwanweb20
 
معرفی محصول تبلیغات در جستجوی بازار
معرفی محصول تبلیغات در جستجوی بازارمعرفی محصول تبلیغات در جستجوی بازار
معرفی محصول تبلیغات در جستجوی بازارBazaar Insight
 
2021 _01 _ اجتماع مجموعة صغيرة
2021 _01 _ اجتماع مجموعة صغيرة2021 _01 _ اجتماع مجموعة صغيرة
2021 _01 _ اجتماع مجموعة صغيرةelhayalaka
 
سيكولوجيه اللغه والمرض العقلى
سيكولوجيه اللغه والمرض العقلىسيكولوجيه اللغه والمرض العقلى
سيكولوجيه اللغه والمرض العقلىmshary mshary
 
[Nahu] - 'Alamat Irab (arabic)
[Nahu] - 'Alamat Irab (arabic)[Nahu] - 'Alamat Irab (arabic)
[Nahu] - 'Alamat Irab (arabic)Syukran
 
تحصیل دبیرستان در کانادا
تحصیل دبیرستان در کاناداتحصیل دبیرستان در کانادا
تحصیل دبیرستان در کاناداhamidrezagh
 
Correct English:9789740326281
Correct English:9789740326281Correct English:9789740326281
Correct English:9789740326281CUPress
 
گزارش توسعه‌دهندگان بازار در فصل بهار ۱۳۹۸
گزارش توسعه‌دهندگان بازار در فصل بهار ۱۳۹۸گزارش توسعه‌دهندگان بازار در فصل بهار ۱۳۹۸
گزارش توسعه‌دهندگان بازار در فصل بهار ۱۳۹۸Bazaar Insight
 
چرخه حسابداری
چرخه حسابداریچرخه حسابداری
چرخه حسابداریMobina Dorri
 
د. ماجدة الجارودي - ملتقى سيدات الأعمال الثقافي الثالث
د. ماجدة الجارودي - ملتقى سيدات الأعمال الثقافي الثالثد. ماجدة الجارودي - ملتقى سيدات الأعمال الثقافي الثالث
د. ماجدة الجارودي - ملتقى سيدات الأعمال الثقافي الثالثRiyadhBWF
 
[Nahu] - 'ilm Kalam (arabic)
[Nahu] - 'ilm Kalam (arabic)[Nahu] - 'ilm Kalam (arabic)
[Nahu] - 'ilm Kalam (arabic)Syukran
 
Arabic bible book of life old testament psalms
Arabic bible book of life old testament psalmsArabic bible book of life old testament psalms
Arabic bible book of life old testament psalmsArabBibles
 

Similaire à Guideline irritable bowel syndrome 2012 (20)

2012 sirisamut j health sc_evaluation of outcomes and determinants of cervica...
2012 sirisamut j health sc_evaluation of outcomes and determinants of cervica...2012 sirisamut j health sc_evaluation of outcomes and determinants of cervica...
2012 sirisamut j health sc_evaluation of outcomes and determinants of cervica...
 
แนวทางการวินิจฉัยและรักษาโรคหืดในประเทศไทย สำหรับผู้ใหญ่ 2559
แนวทางการวินิจฉัยและรักษาโรคหืดในประเทศไทย สำหรับผู้ใหญ่ 2559แนวทางการวินิจฉัยและรักษาโรคหืดในประเทศไทย สำหรับผู้ใหญ่ 2559
แนวทางการวินิจฉัยและรักษาโรคหืดในประเทศไทย สำหรับผู้ใหญ่ 2559
 
แนวทางรักษา stroke-fast-track 2007
แนวทางรักษา stroke-fast-track 2007แนวทางรักษา stroke-fast-track 2007
แนวทางรักษา stroke-fast-track 2007
 
แนวทางการวินิจฉัยและรักษาโรคหืดในประเทศไทย สำหรับผู้ใหญ่ พ.ศ. 2560
แนวทางการวินิจฉัยและรักษาโรคหืดในประเทศไทย สำหรับผู้ใหญ่ พ.ศ. 2560แนวทางการวินิจฉัยและรักษาโรคหืดในประเทศไทย สำหรับผู้ใหญ่ พ.ศ. 2560
แนวทางการวินิจฉัยและรักษาโรคหืดในประเทศไทย สำหรับผู้ใหญ่ พ.ศ. 2560
 
Cough guideline 2016
Cough guideline 2016Cough guideline 2016
Cough guideline 2016
 
Guideline%20 upper%20gi%20bleeding
Guideline%20 upper%20gi%20bleedingGuideline%20 upper%20gi%20bleeding
Guideline%20 upper%20gi%20bleeding
 
اینفوگرافی:‌ بیشترین‌های جام‌جهانی ۲۰۱۸ در کافه‌بازار
اینفوگرافی:‌ بیشترین‌های جام‌جهانی ۲۰۱۸ در کافه‌بازاراینفوگرافی:‌ بیشترین‌های جام‌جهانی ۲۰۱۸ در کافه‌بازار
اینفوگرافی:‌ بیشترین‌های جام‌جهانی ۲۰۱۸ در کافه‌بازار
 
創業家研習營-7分鐘創意簡報技巧,Mr.6劉威麟
創業家研習營-7分鐘創意簡報技巧,Mr.6劉威麟創業家研習營-7分鐘創意簡報技巧,Mr.6劉威麟
創業家研習營-7分鐘創意簡報技巧,Mr.6劉威麟
 
معرفی محصول تبلیغات در جستجوی بازار
معرفی محصول تبلیغات در جستجوی بازارمعرفی محصول تبلیغات در جستجوی بازار
معرفی محصول تبلیغات در جستجوی بازار
 
5s
5s5s
5s
 
2021 _01 _ اجتماع مجموعة صغيرة
2021 _01 _ اجتماع مجموعة صغيرة2021 _01 _ اجتماع مجموعة صغيرة
2021 _01 _ اجتماع مجموعة صغيرة
 
سيكولوجيه اللغه والمرض العقلى
سيكولوجيه اللغه والمرض العقلىسيكولوجيه اللغه والمرض العقلى
سيكولوجيه اللغه والمرض العقلى
 
[Nahu] - 'Alamat Irab (arabic)
[Nahu] - 'Alamat Irab (arabic)[Nahu] - 'Alamat Irab (arabic)
[Nahu] - 'Alamat Irab (arabic)
 
تحصیل دبیرستان در کانادا
تحصیل دبیرستان در کاناداتحصیل دبیرستان در کانادا
تحصیل دبیرستان در کانادا
 
Correct English:9789740326281
Correct English:9789740326281Correct English:9789740326281
Correct English:9789740326281
 
گزارش توسعه‌دهندگان بازار در فصل بهار ۱۳۹۸
گزارش توسعه‌دهندگان بازار در فصل بهار ۱۳۹۸گزارش توسعه‌دهندگان بازار در فصل بهار ۱۳۹۸
گزارش توسعه‌دهندگان بازار در فصل بهار ۱۳۹۸
 
چرخه حسابداری
چرخه حسابداریچرخه حسابداری
چرخه حسابداری
 
د. ماجدة الجارودي - ملتقى سيدات الأعمال الثقافي الثالث
د. ماجدة الجارودي - ملتقى سيدات الأعمال الثقافي الثالثد. ماجدة الجارودي - ملتقى سيدات الأعمال الثقافي الثالث
د. ماجدة الجارودي - ملتقى سيدات الأعمال الثقافي الثالث
 
[Nahu] - 'ilm Kalam (arabic)
[Nahu] - 'ilm Kalam (arabic)[Nahu] - 'ilm Kalam (arabic)
[Nahu] - 'ilm Kalam (arabic)
 
Arabic bible book of life old testament psalms
Arabic bible book of life old testament psalmsArabic bible book of life old testament psalms
Arabic bible book of life old testament psalms
 

Plus de Utai Sukviwatsirikul

Nanoxร้านยาใช้สื่อ Social อย่างไร ให้ได้ยอดขาย…อย่างยั่งยืน
Nanoxร้านยาใช้สื่อ Social อย่างไร ให้ได้ยอดขาย…อย่างยั่งยืนNanoxร้านยาใช้สื่อ Social อย่างไร ให้ได้ยอดขาย…อย่างยั่งยืน
Nanoxร้านยาใช้สื่อ Social อย่างไร ให้ได้ยอดขาย…อย่างยั่งยืนUtai Sukviwatsirikul
 
Clinical Guidance for Acute Pain Management เเนวทางพัฒนาการระงับปวดเฉียบพลัน
Clinical Guidance for Acute Pain Management เเนวทางพัฒนาการระงับปวดเฉียบพลันClinical Guidance for Acute Pain Management เเนวทางพัฒนาการระงับปวดเฉียบพลัน
Clinical Guidance for Acute Pain Management เเนวทางพัฒนาการระงับปวดเฉียบพลันUtai Sukviwatsirikul
 
แนวทางการจัดการความเสี่ยงที่ส่งผลต่อต้นทุนการจัดการสินค้าคงคลัง ของร้านขายยา ...
แนวทางการจัดการความเสี่ยงที่ส่งผลต่อต้นทุนการจัดการสินค้าคงคลัง ของร้านขายยา ...แนวทางการจัดการความเสี่ยงที่ส่งผลต่อต้นทุนการจัดการสินค้าคงคลัง ของร้านขายยา ...
แนวทางการจัดการความเสี่ยงที่ส่งผลต่อต้นทุนการจัดการสินค้าคงคลัง ของร้านขายยา ...Utai Sukviwatsirikul
 
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoeaSaccharomyces boulardii in the prevention of antibiotic-associated diarrhoea
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoeaUtai Sukviwatsirikul
 
การใช้โพรไบโอติกทางการแพทย์ (Medical Uses of Probiotic)
การใช้โพรไบโอติกทางการแพทย์ (Medical Uses of Probiotic)การใช้โพรไบโอติกทางการแพทย์ (Medical Uses of Probiotic)
การใช้โพรไบโอติกทางการแพทย์ (Medical Uses of Probiotic)Utai Sukviwatsirikul
 
Drugs Used in Acute Diarrhea Wandee Varavithya
Drugs Used in Acute Diarrhea Wandee VaravithyaDrugs Used in Acute Diarrhea Wandee Varavithya
Drugs Used in Acute Diarrhea Wandee VaravithyaUtai Sukviwatsirikul
 
Systematic review with meta-analysis: Saccharomyces boulardii in the preventi...
Systematic review with meta-analysis: Saccharomyces boulardii in the preventi...Systematic review with meta-analysis: Saccharomyces boulardii in the preventi...
Systematic review with meta-analysis: Saccharomyces boulardii in the preventi...Utai Sukviwatsirikul
 
Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarr...
Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarr...Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarr...
Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarr...Utai Sukviwatsirikul
 
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea ...
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea ...Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea ...
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea ...Utai Sukviwatsirikul
 
แนวทางการตรวจคัดกรองและดูแลรักษาภาวะแทรกซ้อนทางไต
แนวทางการตรวจคัดกรองและดูแลรักษาภาวะแทรกซ้อนทางไตแนวทางการตรวจคัดกรองและดูแลรักษาภาวะแทรกซ้อนทางไต
แนวทางการตรวจคัดกรองและดูแลรักษาภาวะแทรกซ้อนทางไตUtai Sukviwatsirikul
 
การประเมินโอกาสเสี่ยงต่อโรคหัวใจและหลอดเลือดในผู้ป่วยเบาหวานและความดันโลหิตสูง
การประเมินโอกาสเสี่ยงต่อโรคหัวใจและหลอดเลือดในผู้ป่วยเบาหวานและความดันโลหิตสูงการประเมินโอกาสเสี่ยงต่อโรคหัวใจและหลอดเลือดในผู้ป่วยเบาหวานและความดันโลหิตสูง
การประเมินโอกาสเสี่ยงต่อโรคหัวใจและหลอดเลือดในผู้ป่วยเบาหวานและความดันโลหิตสูงUtai Sukviwatsirikul
 
ความรู้เรื่องโรคไต
ความรู้เรื่องโรคไตความรู้เรื่องโรคไต
ความรู้เรื่องโรคไตUtai Sukviwatsirikul
 
แนวทางการพัฒนาการตรวจรักษาโรคจมูกอักเสบภูมิแพ้ในคนไทย (ฉบับปรับปรุง พ.ศ. ๒๕๕๔)
แนวทางการพัฒนาการตรวจรักษาโรคจมูกอักเสบภูมิแพ้ในคนไทย (ฉบับปรับปรุง พ.ศ. ๒๕๕๔)แนวทางการพัฒนาการตรวจรักษาโรคจมูกอักเสบภูมิแพ้ในคนไทย (ฉบับปรับปรุง พ.ศ. ๒๕๕๔)
แนวทางการพัฒนาการตรวจรักษาโรคจมูกอักเสบภูมิแพ้ในคนไทย (ฉบับปรับปรุง พ.ศ. ๒๕๕๔)Utai Sukviwatsirikul
 
พระราชบัญญัติว่าด้วยราคาสินค้าและบริการ
พระราชบัญญัติว่าด้วยราคาสินค้าและบริการพระราชบัญญัติว่าด้วยราคาสินค้าและบริการ
พระราชบัญญัติว่าด้วยราคาสินค้าและบริการUtai Sukviwatsirikul
 
ข้อเท็จจริงเรื่องยาคุมฉุกเฉิน
ข้อเท็จจริงเรื่องยาคุมฉุกเฉินข้อเท็จจริงเรื่องยาคุมฉุกเฉิน
ข้อเท็จจริงเรื่องยาคุมฉุกเฉินUtai Sukviwatsirikul
 

Plus de Utai Sukviwatsirikul (20)

Nanoxร้านยาใช้สื่อ Social อย่างไร ให้ได้ยอดขาย…อย่างยั่งยืน
Nanoxร้านยาใช้สื่อ Social อย่างไร ให้ได้ยอดขาย…อย่างยั่งยืนNanoxร้านยาใช้สื่อ Social อย่างไร ให้ได้ยอดขาย…อย่างยั่งยืน
Nanoxร้านยาใช้สื่อ Social อย่างไร ให้ได้ยอดขาย…อย่างยั่งยืน
 
Clinical Guidance for Acute Pain Management เเนวทางพัฒนาการระงับปวดเฉียบพลัน
Clinical Guidance for Acute Pain Management เเนวทางพัฒนาการระงับปวดเฉียบพลันClinical Guidance for Acute Pain Management เเนวทางพัฒนาการระงับปวดเฉียบพลัน
Clinical Guidance for Acute Pain Management เเนวทางพัฒนาการระงับปวดเฉียบพลัน
 
แนวทางการจัดการความเสี่ยงที่ส่งผลต่อต้นทุนการจัดการสินค้าคงคลัง ของร้านขายยา ...
แนวทางการจัดการความเสี่ยงที่ส่งผลต่อต้นทุนการจัดการสินค้าคงคลัง ของร้านขายยา ...แนวทางการจัดการความเสี่ยงที่ส่งผลต่อต้นทุนการจัดการสินค้าคงคลัง ของร้านขายยา ...
แนวทางการจัดการความเสี่ยงที่ส่งผลต่อต้นทุนการจัดการสินค้าคงคลัง ของร้านขายยา ...
 
Supply chain management
Supply chain managementSupply chain management
Supply chain management
 
Best practice in communication
Best practice in communicationBest practice in communication
Best practice in communication
 
Basic communication skills 2554
Basic communication skills 2554Basic communication skills 2554
Basic communication skills 2554
 
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoeaSaccharomyces boulardii in the prevention of antibiotic-associated diarrhoea
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea
 
SME Handbook
SME HandbookSME Handbook
SME Handbook
 
การใช้โพรไบโอติกทางการแพทย์ (Medical Uses of Probiotic)
การใช้โพรไบโอติกทางการแพทย์ (Medical Uses of Probiotic)การใช้โพรไบโอติกทางการแพทย์ (Medical Uses of Probiotic)
การใช้โพรไบโอติกทางการแพทย์ (Medical Uses of Probiotic)
 
Scientific evidence of BIOFLOR
Scientific evidence of BIOFLORScientific evidence of BIOFLOR
Scientific evidence of BIOFLOR
 
Drugs Used in Acute Diarrhea Wandee Varavithya
Drugs Used in Acute Diarrhea Wandee VaravithyaDrugs Used in Acute Diarrhea Wandee Varavithya
Drugs Used in Acute Diarrhea Wandee Varavithya
 
Systematic review with meta-analysis: Saccharomyces boulardii in the preventi...
Systematic review with meta-analysis: Saccharomyces boulardii in the preventi...Systematic review with meta-analysis: Saccharomyces boulardii in the preventi...
Systematic review with meta-analysis: Saccharomyces boulardii in the preventi...
 
Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarr...
Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarr...Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarr...
Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarr...
 
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea ...
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea ...Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea ...
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea ...
 
แนวทางการตรวจคัดกรองและดูแลรักษาภาวะแทรกซ้อนทางไต
แนวทางการตรวจคัดกรองและดูแลรักษาภาวะแทรกซ้อนทางไตแนวทางการตรวจคัดกรองและดูแลรักษาภาวะแทรกซ้อนทางไต
แนวทางการตรวจคัดกรองและดูแลรักษาภาวะแทรกซ้อนทางไต
 
การประเมินโอกาสเสี่ยงต่อโรคหัวใจและหลอดเลือดในผู้ป่วยเบาหวานและความดันโลหิตสูง
การประเมินโอกาสเสี่ยงต่อโรคหัวใจและหลอดเลือดในผู้ป่วยเบาหวานและความดันโลหิตสูงการประเมินโอกาสเสี่ยงต่อโรคหัวใจและหลอดเลือดในผู้ป่วยเบาหวานและความดันโลหิตสูง
การประเมินโอกาสเสี่ยงต่อโรคหัวใจและหลอดเลือดในผู้ป่วยเบาหวานและความดันโลหิตสูง
 
ความรู้เรื่องโรคไต
ความรู้เรื่องโรคไตความรู้เรื่องโรคไต
ความรู้เรื่องโรคไต
 
แนวทางการพัฒนาการตรวจรักษาโรคจมูกอักเสบภูมิแพ้ในคนไทย (ฉบับปรับปรุง พ.ศ. ๒๕๕๔)
แนวทางการพัฒนาการตรวจรักษาโรคจมูกอักเสบภูมิแพ้ในคนไทย (ฉบับปรับปรุง พ.ศ. ๒๕๕๔)แนวทางการพัฒนาการตรวจรักษาโรคจมูกอักเสบภูมิแพ้ในคนไทย (ฉบับปรับปรุง พ.ศ. ๒๕๕๔)
แนวทางการพัฒนาการตรวจรักษาโรคจมูกอักเสบภูมิแพ้ในคนไทย (ฉบับปรับปรุง พ.ศ. ๒๕๕๔)
 
พระราชบัญญัติว่าด้วยราคาสินค้าและบริการ
พระราชบัญญัติว่าด้วยราคาสินค้าและบริการพระราชบัญญัติว่าด้วยราคาสินค้าและบริการ
พระราชบัญญัติว่าด้วยราคาสินค้าและบริการ
 
ข้อเท็จจริงเรื่องยาคุมฉุกเฉิน
ข้อเท็จจริงเรื่องยาคุมฉุกเฉินข้อเท็จจริงเรื่องยาคุมฉุกเฉิน
ข้อเท็จจริงเรื่องยาคุมฉุกเฉิน
 

Dernier

"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 

Dernier (20)

"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 

Guideline irritable bowel syndrome 2012

  • 3. 2 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π  ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 ‚¥¬  ¡“§¡ª√– “∑∑“߇¥‘πÕ“À“√·≈–°“√‡§≈◊ËÕπ‰À« (‰∑¬) æ‘¡æ§√—Èß∑’Ë 1 ‡¡…“¬π 2556 ®”π«π 5,000 ‡≈à¡ 32 Àπâ“  ß«π≈‘¢ ‘∑∏‘Ï æ‘¡æå∑’Ë PENTAGON ADVERTISING LTD., PART. 566/124 ´Õ¬°‘®æ“π‘™ ∂ππæ√–√“¡ 4 ·¢«ß¡À“æƒ≤“√“¡ ‡¢µ∫“ß√—° °√ÿ߇∑æœ 10500 566/124 Soi Kijpanich, Rama 4 Rd., Bangrak, Bangkok 10500 Tel : 235-6038, 633-3762 Fax 633-0334 Email: toon47@asianet.co.th
  • 4. 3§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 Irritable Bowel Syndrome (IBS) ‡ªìπªí≠À“∑’Ëæ∫∫àÕ¬„πª√–‡∑»‰∑¬·≈– post infectious diarrhea Õ“®®–‡ªì𠓇ÀµÿÀπ÷ËߢÕß IBS ‰¥â ∑”„Àâ incidence ‡æ‘Ë¡¢÷Èπ„π∫â“π‡√“ Guideline π’È ™à«¬„Àâ·æ∑¬å∑’Ëæ∫ºŸâªÉ«¬¥â«¬ªí≠À“π’ȇ¢â“„®·≈– approach §π‰¢â ‰¥â‡À¡“– ¡¢÷Èπ ¢Õ¢Õ∫§ÿ≥Õ“®“√¬å∑ÿ°∑à“π∑’Ë ≈–‡«≈“ ·≈–µ—Èß„®∑”„À≥â guideline ¥’·≈– practical ∑’Ë ÿ¥ ”À√—∫ª√–‡∑»‰∑¬ ».πæ. ‘π Õπÿ√“…Æ√å 𓬰 ¡“§¡ª√– “∑∑“߇¥‘πÕ“À“√·≈–°“√‡§≈◊ËÕπ‰À« (‰∑¬) §”π”
  • 5. 4 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 §”π” IrritableBowelSyndrome(IBS)‡ªìπ°≈ÿà¡Õ“°“√∑’Ëæ∫∫àÕ¬„π∑“߇«™ªØ‘∫—µ‘ ºŸâªÉ«¬ IBS ¡’Õ“°“√§≈⓬°—∫‚√§Õ◊Ë𠇙àπ dyspepsia ∑âÕ߇ ’¬ ·≈–∑âÕߺŸ° À√◊Õ IBS Õ“®‡°‘¥√à«¡°—π°—∫‚√§Õ◊Ë𠧫“¡√Ÿâ·≈–§«“¡‡¢â“„®‡°’ˬ«°—∫‚√§ IBS „πÀ¡Ÿà·æ∑¬å ‡«™ªØ‘∫—µ‘∑—Ë«‰ª¬—ß¡’πâÕ¬Õ¬Ÿà‚¥¬∑’˺ŸâªÉ«¬ IBS ¡—°®–‰¥â√—∫°“√«‘π‘®©—¬‡ªìπ‚√§Õ◊Ë𠇙àπ dyspepsia ®ÿ¥¡ÿàßÀ¡“¬¢Õß guideline π’È §◊Õ ‡ªìπ°“√„ÀâÕߧ姫“¡√Ÿâ‡°’ˬ«°—∫ IBS ·π«∑“ß„π°“√µ√«®§âπ·≈–°“√√—°…“∑’ˇÀ¡“– ¡µ“¡ ¿“«–·≈–¢âÕ¡Ÿ≈∑’Ë¡’Õ¬Ÿà„πªí®®ÿ∫—𠧔·π–π”„π guideline π’È ‡ªìπ‡æ’¬ß·π«∑“ß„π°“√¥Ÿ·≈ºŸâªÉ«¬ IBS Õ¬à“߉√ °Áµ“¡·æ∑¬å∑’Ë¥Ÿ·≈ºŸâªÉ«¬Õ“®®–∑”°“√¥Ÿ·≈√—°…“ºŸâªÉ«¬·µ°µà“߉ª®“°§Ÿà¡◊Õπ’ȉ¥âµ“¡ §«“¡‡À¡“– ¡ ”À√—∫ºŸâªÉ«¬·µà≈–√“¬ ∫∑ √ÿªµà“ßÊ ∑’ˇ°’ˬ«°—∫ IBS „π§Ÿà¡◊Õ©∫—∫π’ȉ¥â√«∫√«¡·≈–‡¢’¬π¢÷Èπ¡“ ‚¥¬Õâ“ßÕ‘ß∂÷ߢâÕ¡Ÿ≈®“°µà“ߪ√–‡∑»‡ªìπ à«π„À≠à·≈–‡ªì𧫓¡‡ÀÁπ¢ÕߺŸâ‡™’ˬ«™“≠ „π°√≥’∑’Ë¢âÕ¡Ÿ≈‰¡à‡æ’¬ßæÕÀ√◊Õ‰¡à¡’ ‚¥¬‡©æ“–Õ¬à“߬‘ËߢâÕ¡Ÿ≈∑’ˇ°’ˬ«¢âÕß°—∫ IBS „πª√–‡∑»‰∑¬ ´÷Ëß¡’§”∂“¡À≈“¬ª√–°“√∑’ˬ—߉¡à¡’§”µÕ∫∑’Ë™—¥‡®π ·≈–§ßµâÕß ∑”°“√»÷°…“‡æ‘Ë¡‡µ‘¡‡æ◊ËÕπ”¡“„™â„π°“√®—¥∑” guideline §√—ÈßµàÕ‰ª„Àâ ¡∫Ÿ√≥嬑Ëߢ÷Èπ Guideline π’È ”‡√Á®≈ÿ≈à«ß‰¥â¥’‚¥¬§«“¡√à«¡¡◊Õ¢Õß°√√¡°“√∑’Ë√–¥¡§«“¡§‘¥ ∑—Èß„π°“√ª√–™ÿ¡§√—Èß·√° «—π∑’Ë 22 - 23 ¡°√“§¡ 2554 ·≈–§√—Èß∑’Ë Õß«—π∑’Ë 23 - 24 ¡‘∂ÿπ“¬π 2555 ®÷ߢբÕ∫§ÿ≥‡ªìπÕ¬à“ß Ÿß ‰«â ≥ ∑’Ëπ’ȥ⫬ √».πæ.∫—≠™“ ‚Õ«“∑Ó√æ√ ª√–∏“π°“√®—¥∑” guideline
  • 6. 5§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012  “√∫—≠ §”π” 𓬰 ¡“§¡ª√– “∑∑“߇¥‘πÕ“À“√·≈–°“√‡§≈◊ËÕπ‰À« (‰∑¬) 3 §”π” ª√–∏“π°“√®—¥∑” Guideline for Management of Irritable Bowel Syndrome 4 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 6 Definition 6 ¢âÕ √ÿª∑’Ë 1. 6 ¢âÕ √ÿª∑’Ë 2. 6 ¢âÕ √ÿª∑’Ë 3. 7 Overlapping syndrome 8 ¢âÕ √ÿª∑’Ë 4. 8 Pathophysiology 10 ¢âÕ √ÿª∑’Ë 5. 10 ¢âÕ √ÿª∑’Ë 6. 11 ¢âÕ √ÿª∑’Ë 7. 11 Clinical evaluation 13 ¢âÕ √ÿª∑’Ë 8. 13 ¢âÕ √ÿª∑’Ë 9. 13 ¢âÕ √ÿª∑’Ë 10. 14 ¢âÕ √ÿª∑’Ë 11. 15 ¢âÕ √ÿª∑’Ë 12. 15 ¢âÕ √ÿª∑’Ë 13. 15 ¢âÕ √ÿª∑’Ë 14. 16 ¢âÕ √ÿª∑’Ë 15. 16 Non-pharmacological treatment 18 ¢âÕ √ÿª∑’Ë 16. 18 ¢âÕ √ÿª∑’Ë 17. 18 ¢âÕ √ÿª∑’Ë 18. 19 ¢âÕ √ÿª∑’Ë 19. 19 ¢âÕ √ÿª∑’Ë 20. 20 Pharmacological treatment 24 ¢âÕ √ÿª∑’Ë 21. 24 ¢âÕ √ÿª∑’Ë 22. 26 Psychiatric problems „π IBS 29 ¢âÕ √ÿª∑’Ë 23. 29 ¢âÕ √ÿª∑’Ë 24. 30 IBS Guideline 31 √“¬π“¡ºŸâ‡¢â“√à«¡ª√–™ÿ¡ —¡¡π“æ‘®“√≥“ IBS Guideline 32
  • 7. 7§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 2.2 ¡’Õ“°“√ª«¥∑âÕßÀ√◊Õ‰¡à ∫“¬„π∑âÕß¡“°°«à“À√◊Õ‡∑à“°—∫ 3 «—πµàÕ‡¥◊Õπ„π 3 ‡¥◊Õπ∑’˺à“π¡“√à«¡°—∫≈—°…≥–Õ“°“√∑“ߧ≈‘π‘°Õ¬à“ßπâÕ¬ 2 „π 3 ≈—°…≥–µàÕ‰ªπ’È 2.2.1 Õ“°“√ª«¥∑âÕßÀ√◊Õ‰¡à ∫“¬„π∑âÕߥ’¢÷ÈπÀ≈—ß°“√∂à“¬Õÿ®®“√– 2.2.2 Õ“°“√ª«¥∑âÕßÀ√◊Õ‰¡à ∫“¬„π∑âÕ߇°‘¥√à«¡°—∫°“√‡ª≈’ˬπ·ª≈ߢÕß §«“¡∂’Ë¢Õß°“√∂à“¬Õÿ®®“√– 2.2.3 Õ“°“√ª«¥∑âÕßÀ√◊Õ‰¡à ∫“¬„π∑âÕ߇°‘¥√à«¡°—∫°“√‡ª≈’ˬπ·ª≈ߢÕß ≈—°…≥–§«“¡·¢ÁßÀ√◊Õ‡À≈«¢ÕßÕÿ®®“√– ‡°≥±å°“√«‘π‘®©—¬RomeIII‡ªìπ∑’ˬա√—∫„πªí®®ÿ∫—π „™â‡ªìπ·π«∑“ßÀπ÷Ëß„π°“√ ™à«¬«‘π‘®©—¬‚√§≈”‰ â·ª√ª√«π ·≈–„™â‡ªìπ·π«∑“ß„π°“√«‘®—¬ ¢âÕ √ÿª∑’Ë 3. ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«πÕ“®¡’Õ“°“√∑âÕ߇ ’¬‡ªìπÕ“°“√‡¥àπ ∑âÕߺŸ°‡ªìπ Õ“°“√‡¥àπ∑âÕߺŸ° ≈—∫°—∫∑âÕ߇ ’¬À√◊Õ‰¡à “¡“√∂®–®—¥≈—°…≥–°“√¢—∫∂à“¬¢ÕߺŸâªÉ«¬ ‰¥â‡≈¬°Á‰¥â ‚√§≈”‰ â·ª√ª√«π ·∫à߉¥â‡ªìπ 4 ™π‘¥ (subtype) ‰¥â·°à 1. ≈”‰ â·ª√ª√«π ™π‘¥∑âÕ߇ ’¬‡¥àπ (diarrhea predominate IBS or IBS-D)ºŸâªÉ«¬µâÕß¡’Õ“°“√∑âÕ߇ ’¬‰¡àπâÕ¬°«à“√âÕ¬≈–25¢Õß°“√¢—∫∂à“¬·≈–µâÕß¡’ Õ“°“√∑âÕߺŸ°‰¡à‡°‘π√âÕ¬≈– 25 ¢Õß°“√¢—∫∂à“¬ 2. ≈”‰ â·ª√ª√«π ™π‘¥∑âÕߺŸ°‡¥àπ (constipation predominate IBS or IBS-C) ºŸâªÉ«¬µâÕß¡’Õ“°“√∑âÕߺŸ° ‰¡àπâÕ¬°«à“√âÕ¬≈– 25 ¢Õß°“√¢—∫∂à“¬ ·≈–µâÕß¡’ Õ“°“√∑âÕ߇ ’¬‰¡à‡°‘π√âÕ¬≈– 25 ¢Õß°“√¢—∫∂à“¬ 3. ≈”‰ â·ª√ª√«π ™π‘¥∑âÕ߇ ’¬ ≈—∫∑âÕߺŸ° (mixed IBS À√◊Õ IBS-M) ºŸâªÉ«¬µâÕß¡’Õ“°“√∑âÕ߇ ’¬ ≈—∫∑âÕߺŸ°Õ¬à“ß≈–‰¡àπâÕ¬°«à“√âÕ¬≈– 25 ¢Õß°“√¢—∫∂à“¬ 4. ≈”‰ â·ª√ª√«π™π‘¥‰¡à™—¥‡®π (undetermined IBS À√◊Õ IBS-U) ºŸâªÉ«¬ µâÕß¡’Õ“°“√∑âÕ߇ ’¬ ≈—∫°—∫∑âÕߺŸ° Õ¬à“ß≈–‰¡à‡°‘π√âÕ¬≈– 25 ¢Õß°“√¢—∫∂à“¬ Reference: 1. Longstreth GF, Thompson W, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional Bowel Disorder p.487-556. In Rome III: The Functional Gastrointestinal Disorders. Drossman DA, eds. Degnon Associates, Mclean, Virginia USA 2006.
  • 8. 8 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 Overlapping Syndrome ¢âÕ √ÿª∑’Ë 4. ‚√§≈”‰ â·ª√ª√«π “¡“√∂æ∫√à«¡°—∫‚√§°√¥‰À≈¬âÕπÀ√◊Õ°√–‡æ“–Õ“À“√ ∑”ß“πº‘¥ª°µ‘ (dyspepsia) ‰¥â ·æ∑¬åºŸâ¥Ÿ·≈§«√„Àâ°“√√—°…“√à«¡µ“¡§«“¡ ‡À¡“– ¡ ‚√§≈”‰ â·ª√ª√«π “¡“√∂æ∫√à«¡°—∫‚√§°√¥‰À≈¬âÕπ °√–‡æ“–Õ“À“√∑”ß“π º‘¥ª°µ‘ (dyspepsia) ·≈–‚√§∑âÕߺŸ°‰¥â∫àÕ¬ ®“°°“√»÷°…“¥â«¬·∫∫ Õ∫∂“¡Õ“°“√ °√¥‰À≈¬âÕπ dyspepsia ≈”‰ â·ª√ª√«π Õ“°“√∑âÕߺŸ° ·≈–Õ“°“√∑âÕ߇¥‘π „π ª√–™“°√ 657 §π æ∫«à“¡’§«“¡™ÿ° (prevalence) „πª√–™“°√∑’Ë¡’Õ“°“√‡À≈à“π’È Õ¬à“ßπâÕ¬ 2 Õ“°“√∑’Ë√âÕ¬≈– 4-9 ·≈–§«“¡™ÿ°„πª√–™“°√∑’Ë¡’Õ¬à“ßπâÕ¬ 3 °≈ÿà¡Õ“°“√ ¢÷Èπ‰ª∑’Ë√âÕ¬≈– 1-41 ‚¥¬Õ’°°“√»÷°…“ ºŸâªÉ«¬ 1290 √“¬ æ∫«à“¡’§«“¡™ÿ°¢Õß≈”‰ â ·ª√ª√«π √âÕ¬≈– 12.8 ·≈– dyspepsia √âÕ¬≈– 14 ‚¥¬√âÕ¬≈– 87 ¢ÕߺŸâªÉ«¬ ≈”‰ â·ª√ª√«π ¡’Õ“°“√ dyspepsia √à«¡¥â«¬ æ∫«à“¡“°°«à“√âÕ¬≈– 50 ¢ÕߺŸâªÉ«¬ ∑—ÈßÀ¡¥¡’Õ“°“√∑’ˇª≈’ˬπ·ª≈߉ª ¿“¬À≈—ß®“° 1 ªï æ∫«à“Õ“°“√≈”‰ â·ª√ª√«π ¬—ߧßÕ¬Ÿà√âÕ¬≈– 57-74 À√◊Õ  “¡“√∂À“¬‰ª À√◊ÕÕ“®¡’Õ“°“√Õ◊Ë𠇙àπ dyspepsia ¢÷Èπ¡“·∑π‰¥â2 „πÕ’°°“√»÷°…“ æ∫«à“ √âÕ¬≈– 23-87 ¢ÕߺŸâªÉ«¬≈”‰ â·ª√ª√«π ¡’ Õ“°“√ functional dyspepsia ¥â«¬ ·≈–√âÕ¬≈– 13-87 ¢ÕߺŸâªÉ«¬ dyspepsia ¡’ Õ“°“√≈”‰ â·ª√ª√«π™—¥‡®π3  ”À√—∫Õ“°“√°√¥‰À≈¬âÕ𠇙àπ heartburn æ∫«à“ √âÕ¬≈– 47 ¢ÕߺŸâ¡’Õ“°“√π’È ¡’Õ“°“√≈”‰ â·ª√ª√«π√à«¡¥â«¬ ·≈–„π∑“ß°≈—∫°—π ºŸâ∑’Ë¡’Õ“°“√≈”‰ â·ª√ª√«π°Áæ∫«à“¡’Õ“°“√°√¥‰À≈¬âÕπ‰¥â√âÕ¬≈– 46.54 πÕ°®“°Õ“°“√¥—ß°≈à“«¢â“ßµâπ∑’Ëæ∫√à«¡°—∫Õ“°“√≈”‰ â·ª√ª√«π‰¥â∫àÕ¬·≈â« ¬—ß¡’Õ“°“√À√◊Õ‚√§∑“߇¥‘πÕ“À“√Õ◊ËπÊ √«¡∑—ÈßÕ“°“√ functional disorders Õ◊ËπÊ πÕ°√–∫∫∑“߇¥‘πÕ“À“√Õ’°À≈“¬™π‘¥ ∑’Ëæ∫√à«¡‰¥â∫àÕ¬„πºŸâªÉ«¬≈”‰ â·ª√ª√«πÕ’° ¥â«¬‡™àπ°—π5 ‡π◊ËÕß®“° “¡“√∂æ∫Õ“°“√‡À≈à“π’ȉ¥âÀ≈“¬°≈ÿà¡Õ“°“√„πºŸâªÉ«¬√“¬‡¥’¬«°—π ·æ∑¬åºŸâ¥Ÿ·≈§«√„Àâ°“√√—°…“√à«¡µ“¡§«“¡‡À¡“– ¡„πºŸâªÉ«¬·µà≈–√“¬
  • 9. 9§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 References: 1. Locke GR, Zinsmeister AR, Fett SL, Melton LJ, Talley NJ. Overlap of gastrointestinal symp- tom complexes in a US community. Neurogastroenterol Motil 2002;17:29-34. 2. Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time. Gastroenterology 1995;109:671-680. 3. Whitehead WE, Palsson OS, Levy RR, Feld AD, Turner M, Von Korff M . Comorbidity in irritable bowel syndrome. Am J Gastroenterol 2007;102:2767-2776. 4. Kennedy TM, Jones RH, Hungin AP, Oûflanagan H, Kelly P. Irritabale Bowel Syndrome, Gastro-oesophageal reflux, and bronchial responsiveness in the general population. Gut 1998; 43:770-774 5. Frissora CL and Koch KL. Symptom overlap and comorbidity of irritable bowel syndrome with other conditions. Curr Gastroenterol Rep 2005;7:264-271.
  • 10. 6 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π  ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) «—µ∂ÿª√– ß§å¢Õߧ”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π 1. ‡æ◊ËÕ‡ √‘¡ √â“ߧ«“¡√Ÿâ‡°’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π„Àâ°—∫·æ∑¬å∑—Ë«‰ª„Àâ ·æ√àÀ≈“¬¡“°¢÷Èπ 2. ‡æ◊ËÕ‡ªìπ·π«∑“ß„π°“√¥Ÿ·≈√—°…“ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π„Àâ‡À¡“– ¡ ·≈–¡’ª√– ‘∑∏‘¿“æ 3. ‡æ◊ËÕ„Àâ°“√„™â∑√—欓°√∑“ß°“√·æ∑¬å·≈–§ÿ≥¿“æ™’«‘µ¥’¢÷Èπ ≈¥§à“„™â®à“¬ „π°“√¥Ÿ·≈ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª Definition ¢âÕ √ÿª∑’Ë 1. 𑬓¡ ‚√§≈”‰ â·ª√ª√«π ‡ªìπ°≈ÿà¡Õ“°“√∑’ˇ°‘¥®“°°“√∑”ß“π¢Õß∑“ß ‡¥‘πÕ“À“√º‘¥ª°µ‘ ‚¥¬¡’Õ“°“√ª«¥∑âÕßÀ√◊Õ‰¡à ∫“¬„π∑âÕß∑’Ë —¡æ—π∏å°—∫°“√ ∂à“¬Õÿ®®“√–‡ªìπÕ“°“√‡¥àπ‚¥¬‰¡àæ∫§«“¡º‘¥ª°µ‘∑“ß°“¬«‘¿“§À√◊Õ‚√§∑“ß°“¬ (organic disease) ∑’Ë “¡“√∂Õ∏‘∫“¬«à“‡ªì𠓇Àµÿ¢ÕßÕ“°“√‰¥â ºŸâªÉ«¬≈”‰ â·ª√ª√«πµâÕß¡’Õ“°“√¢â“ßµâπ‰¡àπâÕ¬°«à“ 3 ‡¥◊Õπ ¢âÕ √ÿª∑’Ë 2. ‡°≥±å°“√«‘π‘®©—¬‚√§≈”‰ â·ª√ª√«πµ“¡ Rome III ºŸâªÉ«¬µâÕß¡’Õ“°“√µ“¡ ¢âÕ 2.1 ·≈– 2.2 ¥—ßµàÕ‰ªπ’È 2.1 Õ“°“√ª«¥∑âÕßÀ√◊Õ‰¡à ∫“¬„π∑âÕ߇ªìπ‡«≈“¡“π“πÕ¬à“ßπâÕ¬ 6 ‡¥◊Õπ π—∫µ—Èß·µà‡√‘Ë¡¡’Õ“°“√
  • 11. 10 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 Pathophysiology ¢âÕ √ÿª∑’Ë 5.  “‡Àµÿ¢Õß‚√§≈”‰ â·ª√ª√«π¬—߉¡à‡ªìπ∑’Ë∑√“∫°—π™—¥‡®πæ∫«à“°≈‰°„π°“√ ‡°‘¥‚√§≈”‰ â·ª√ª√«π¡’À≈“¬°≈‰° ‰¥â·°à °“√‡§≈◊ËÕπ‰À«¢Õß∑“߇¥‘πÕ“À“√ º‘¥ª°µ‘ (GI dysmotility) ª√– “∑√—∫√Ÿâ§«“¡√Ÿâ ÷°„π∑“߇¥‘πÕ“À“√‰«°«à“ª°µ‘ (visceralhypersensitivity)°“√Õ—°‡ ∫¢Õ߇¬◊ËÕ∫ÿº‘«≈”‰ â (gut inflammation) §«“¡º‘¥ª°µ‘¢Õß·∫§∑’‡√’¬ª√–®”∂‘Ëπ„π≈”‰ â·≈–§«“¡º‘¥ª°µ‘¢Õß°“√µÕ∫ πÕß √–À«à“ß ¡Õß·≈–≈”‰ â (brain-gut interaction) °“√»÷°…“«‘®—¬æ∫«à“ §π∑’ˇªìπ‚√§≈”‰ â·ª√ª√«π¡’°“√‡§≈◊ËÕπ‰À«¢Õß ∑“߇¥‘πÕ“À“√º‘¥ª°µ‘ ‡™àπ ¡’°“√»÷°…“æ∫«à“°“√‡§≈◊ËÕπ‰À«¢Õß≈”‰ â‡≈Á°¡’≈—°…≥– ‡©æ“– ‡™à𠇪ìπ·∫∫ cluster À√◊Õ minute contraction ´÷Ëßæ∫‰¥â®“°°“√µ√«®¥Ÿ °“√∫’∫µ—«¢Õß≈”‰ â‡≈Á° πÕ°®“°π—Èπ¬—ßæ∫«à“°“√∫’∫µ—«∑’˺‘¥ª°µ‘¢Õß≈”‰ â‡≈Á° ‚¥¬‡©æ“–°“√∫’∫µ—«∑’Ë·√ßÊ ∑’Ë∫√‘‡«≥≈”‰ â‡≈Á° à«πª≈“¬¡’§«“¡ —¡æ—π∏å°—∫Õ“°“√ ª«¥∑âÕß„πºŸâªÉ«¬≈”‰ â·ª√ª√«π ·≈–¬—ß¡’°“√»÷°…“æ∫«à“‡¡◊ËÕ°√–µÿâπ≈”‰ â„À≠à „πºŸâªÉ«¬∑’ˇªìπ≈”‰ â·ª√ª√«π ºŸâªÉ«¬®–√—∫√Ÿâ§«“¡√Ÿâ ÷°‰¥â¡“°°«à“§πª°µ‘ √«¡∂÷ß °“√°√–µÿâπ¥â«¬ “√‡§¡’ ‡™àπ °“√√—∫ª√–∑“πæ√‘° ∑’Ë¡’ à«πª√–°Õ∫¢Õß·§ª‰´´‘π °Á¡’√“¬ß“π«à“®–∑”„À⇰‘¥Õ“°“√ª«¥∑âÕß · ∫∑âÕß„πºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π∑’Ë¡’ Õ“°“√∑âÕ߇ ’¬‡¥àπ¡“°°«à“§πª°µ‘ ¥—ßπ—ÈπºŸâªÉ«¬≈”‰ â·ª√ª√«π®÷ß¡’§«“¡‰«¢Õß ∑“߇¥‘πÕ“À“√∑’˵Õ∫ πÕßµàÕ∑—Èß°“√°√–µÿâπ∑“ß°≈(mechanicalstimulation)À√◊Õ ∑“߇§¡’ (chemical stimulation) πÕ°®“°π—Èπ¬—ßæ∫«à“¿“«–≈”‰ â·ª√ª√«π¡’§«“¡ —¡æ—π∏å°—∫°“√¡’°“√Õ—°‡ ∫ ‡≈Á°πâÕ¬∫√‘‡«≥≈”‰ â ´÷Ëß¡’√“¬ß“π„πºŸâªÉ«¬∑’ˇªìπ≈”‰ â·ª√ª√«πÀ≈—ß°“√µ‘¥‡™◊ÈÕ¢Õß ∑“߇¥‘πÕ“À“√ (post infectious IBS) ·≈–¬—ß¡’√“¬ß“π∂÷ߧ«“¡º‘¥ª°µ‘¢Õß°“√ µÕ∫ πÕߢÕß ¡Õß„πºŸâªÉ«¬≈”‰ â·ª√ª√«π´÷Ëßµà“߉ª®“°§πª°µ‘
  • 12. 11§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 ¢âÕ √ÿª∑’Ë 6. ªí®®—¬∑’Ë “¡“√∂°√–µÿâπ„À⺟âªÉ«¬‚√§≈”‰ â·ª√ª√«π¡’Õ“°“√°”‡√‘∫‰¥â·°à Õ“À“√∫“ß™π‘¥ ¬“∫“ß™π‘¥ §«“¡‡§√’¬¥∑—Èß∑“ß°“¬·≈–®‘µ„® °“√µ‘¥‡™◊ÈÕ„π ∑“߇¥‘πÕ“À“√·≈–πÕ°∑“߇¥‘πÕ“À“√ ºŸâªÉ«¬∑’ˇªìπ‚√§≈”‰ â·ª√ª√«πÕ“®¡’Õ“°“√°”‡√‘∫¢÷Èπ®“°ªí®®—¬À≈“¬Õ¬à“߇™àπ ¡’°“√»÷°…“æ∫«à“Õ“À“√∫“ß™π‘¥ “¡“√∂°√–µÿâπ„À⺟âªÉ«¬‚√§≈”‰ â·ª√ª√«π¡’ Õ“°“√¡“°¢÷Èπ‰¥â ‡™àπ Õ“À“√¡—π Õ“À“√∑’˺≈‘µ·°ä „π≈”‰ â¡“°º‘¥ª°µ‘ ‡™àπ °≈ÿà¡ fructose ÀÕ¡ °√–‡∑’¬¡ ´÷Ëß “¡“√∂°√–µÿâπ„À⇰‘¥Õ“°“√¡“°¢÷Èπ¬“∫“ßÕ¬à“ß∑’Ë√–§“¬ ‡§◊ÕßµàÕ∑“߇¥‘πÕ“À“√Õ“®®–∑”„À⇰‘¥Õ“°“√§≈⓬‚√§≈”‰ â·ª√ª√«π ‡™àπ Õ“°“√ ª«¥∑âÕß Õ◊¥·πàπ∑âÕß À√◊Õ§«“¡‡§√’¬¥∑“ߥâ“π√à“ß°“¬·≈–®‘µ„®°Á°√–µÿâπ„Àâ ∑“߇¥‘πÕ“À“√¡’§«“¡‰«µàÕ°“√√—∫√Ÿâ§«“¡√Ÿâ ÷°√«¡∂÷ß∫’∫µ—«º‘¥ª°µ‘‰¥â πÕ°®“°π—Èπ°“√µ‘¥‡™◊ÈÕ∑—Èß„π∑“߇¥‘πÕ“À“√·≈–πÕ°∑“߇¥‘πÕ“À“√ “¡“√∂ °√–µÿâπ„À⇰‘¥°“√°”‡√‘∫¢Õß‚√§≈”‰ â·ª√ª√«π‰¥â ¥—ßπ—Èπ°“√À≈’°‡≈’Ë¬ßªí®®—¬µà“ßÊ ‡™àπ Õ“À“√ ¬“ ·≈–§«“¡‡§√’¬¥ Õ“® “¡“√∂∑”„À⺟âªÉ«¬‡°‘¥Õ“°“√°”‡√‘∫‰¥âπâÕ¬≈ß ®÷ߧ«√·π–π”„ÀâÀ≈’°‡≈’Ë¬ßªí®®—¬¥—ß°≈à“«„πºŸâªÉ«¬∑ÿ°√“¬ ¢âÕ √ÿª∑’Ë 7. ‚√§∑“߇¥‘πÕ“À“√∑’Ë∑”„Àâ¡’Õ“°“√‡À¡◊Õπ‚√§≈”‰ â·ª√ª√«π∑’Ëæ∫‰¥â„π ª√–‡∑»‰∑¬‰¥â·°à °“√µ‘¥‡™◊ÈÕ„π∑“߇¥‘πÕ“À“√ ¿“«–°“√¥Ÿ¥´÷¡πÈ”µ“≈·≈Á°‚∑  ‰¡à ¡∫Ÿ√≥å (lactose malabsorption) °“√¥Ÿ¥´÷¡ “√Õ“À“√∫°æ√àÕß (malab- sorption syndrome) ¡’·∫§∑’‡√’¬„π≈”‰ â‡≈Á°¡“°°«à“ª°µ‘ (small intestinal bacterial overgrowth) °≈â“¡‡π◊ÈÕÀŸ√Ÿ¥∑«“√Àπ—°∑”ß“π‰¡àª√– “π°—∫°“√‡∫àß (anismus) ≈”‰ âÕ—°‡ ∫‡√◊ÈÕ√—ß (inflammatory bowel disease) ·≈–¡–‡√Áß ¢Õß∑“߇¥‘πÕ“À“√ ‡ªìπµâπ ‚√§∑“߇¥‘πÕ“À“√∑’ËÕ“®∑”„À⇰‘¥Õ“°“√§≈⓬‚√§≈”‰ â·ª√ª√«π∑’Ëæ∫‰¥â ∫àÕ¬„πª√–‡∑»‰∑¬‰¥â·°à°“√µ‘¥‡™◊ÈÕ„π∑“߇¥‘πÕ“À“√‡™àπ°“√µ‘¥‡™◊ÈÕ Giardia lamblia ‡ªìπ«—≥‚√§„π≈”‰ â‡≈Á° à«πª≈“¬À√◊Õ≈”‰ â„À≠à À√◊Õ°“√¥Ÿ¥´÷¡πÈ”µ“≈·≈Á°‚∑  ‰¡à ¡∫Ÿ√≥å ´÷ËßÕ“®∑”„À⇰‘¥Õ“°“√Õ◊¥·πàπ∑âÕß ª«¥∑âÕß À√◊Õ∑âÕ߇ ’¬ §≈⓬‚√§≈”‰ â
  • 13. 12 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 ·ª√ª√«π‰¥â °“√¥Ÿ¥´÷¡ “√Õ“À“√∫°æ√àÕß ‡π◊ËÕß®“° “‡Àµÿ„¥Ê °Áµ“¡ ‡™àπ ®“° µ—∫ÕàÕπ∑”ß“πº‘¥ª°µ‘∑”„À⇰‘¥°“√¥Ÿ¥´÷¡‰¢¡—π‰¡à ¡∫Ÿ√≥å (fat malabsorption) °ÁÕ“®∑”„À⇰‘¥Õ“°“√∂à“¬º‘¥ª°µ‘ Õ◊¥·πàπ∑âÕß ‡À¡◊Õπ‚√§≈”‰ â·ª√ª√«π‰¥â ¿“«– ·∫§∑’‡√’¬„π≈”‰ â‡≈Á°¡“°°«à“ª°µ‘ ∑”„À⇰‘¥Õ“°“√∑âÕ߇ ’¬ Õ◊¥∑âÕß √à«¡°—∫ ª«¥∑âÕߧ≈⓬‚√§≈”‰ â·ª√ª√«π™π‘¥∑âÕ߇ ’¬ πÕ°®“°π—Èπ°“√¡’°≈â“¡‡π◊ÈÕÀŸ√Ÿ¥ ∑«“√Àπ—°∑”ß“π‰¡à —¡æ—π∏å°—∫·√߇∫àß À√◊Õ anismus °Á “¡“√∂∑”„À⺟âªÉ«¬¡’ Õ“°“√ª«¥∂à“¬·µà∂à“¬‰¡à ÿ¥ À√◊Õ°√–µÿâπ„À⇰‘¥Õ“°“√Õ◊¥·πàπ∑âÕß ª«¥∑âÕß´÷Ë߇ªìπ Õ“°“√¢Õß≈”‰ â·ª√ª√«π‡ªìπ¡“°¢÷Èπ‰¥â ‚√§≈”‰ âÕ—°‡ ∫ À√◊Õ inflammatory bowel disease  “¡“√∂∑”„À⇰‘¥ Õ“°“√ª«¥∑âÕß ∂à“¬‡À≈« §≈⓬‚√§≈”‰ â·ª√ª√«π‰¥â‡™àπ°—π  à«π¡–‡√ÁߢÕß∑“߇¥‘π Õ“À“√√–¬–·√°¡—°‰¡à∑”„À⇰‘¥Õ“°“√ ·µà‡¡◊ËÕ¡’¢π“¥¢Õß¡–‡√Áß„À≠à¢÷ÈπÀ√◊Õ‡ªìπ∑’Ë ∫√‘‡«≥∑«“√Àπ—° Õ“®∑”„À⇰‘¥Õ“°“√∂à“¬º‘¥ª°µ‘ À√◊ÕÕ“°“√ª«¥∑âÕß ·πàπ∑âÕß §≈⓬ÊÕ“°“√≈”‰ â·ª√ª√«π‰¥â¥—ßπ—ÈπºŸâªÉ«¬∑’Ë¡’Õ“°“√≈”‰ â·ª√ª√«π §«√´—°ª√–«—µ‘ µ√«®√à“ß°“¬À√◊Õ àßµ√«®∑“ßÀâÕߪؑ∫—µ‘°“√‡∫◊ÈÕßµâπ‡™àπstoolexamination,CBC, ESR ‡æ◊ËÕª√–‡¡‘π«à“ºŸâªÉ«¬¡’‚Õ°“ ‡ªìπ‚√§∑’Ë°≈à“«¡“À√◊Õ‰¡à
  • 14. 13§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 Clinical evaluation ¢âÕ √ÿª∑’Ë 8. °“√«‘π‘®©—¬‚√§≈”‰ â·ª√ª√«πÕ“»—¬≈—°…≥–Õ“°“√·≈–Õ“°“√· ¥ß¢Õß ºŸâªÉ«¬∑“ߧ≈‘π‘°‡ªìπÀ≈—°  à«π°“√µ√«®∑“ßÀâÕߪؑ∫—µ‘°“√‡∫◊ÈÕßµâπ·≈–°“√µ√«® 摇»…Õ◊ËπÊ §«√æ‘®“√≥“µ“¡§«“¡‡À¡“– ¡¢ÕߺŸâªÉ«¬ ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π Õ“®®–¡’Õ“°“√Õ◊ËπÊ πÕ°‡Àπ◊Õ®“°Õ“°“√¥â“π∑“߇¥‘πÕ“À“√‰¥â ‚√§≈”‰ â·ª√ª√«π‡ªìπ‚√§∑’Ë«‘π‘®©—¬‚¥¬Õ“»—¬ª√–«—µ‘ Õ“°“√ ·≈–Õ“°“√· ¥ß ‡ªìπÀ≈—° ‰¡à¡’§«“¡®”‡ªìπµâÕß∑”°“√ ◊∫§âπ‡æ‘Ë¡‡µ‘¡ ‡π◊ËÕß®“°º≈¢Õß°“√ ◊∫§âπ‡æ‘Ë¡ ‡µ‘¡‰¡à‰¥âæ∫‚√§·µ°µà“ß°—∫°≈ÿࡪ√–™“°√ª°µ‘ ¡’‡æ’¬ß∫“ß·π«∑“ß°“√¥Ÿ·≈√—°…“ (guidelines)1 ∑’Ë·π–π”°“√ ◊∫§âπ‡∫◊ÈÕßµâπ∫“ßÕ¬à“ß«à“Õ“®¡’§«“¡®”‡ªìπ ”À√—∫ºŸâªÉ«¬ ‚√§π’È2-4 ‚¥¬ºŸâªÉ«¬‰¡à§«√®–¡’Õ“°“√·≈–Õ“°“√· ¥ß‡µ◊Õπ (alarm features)3, 5 „πºŸâªÉ«¬∫“ß√“¬ °“√ ◊∫§âπ Õ“∑‘ complete blood count (CBC), stool examination, ESR, C-reactive protein ‡ªìπµâπÕ“®¡’§«“¡®”‡ªìπ4  ”À√—∫°“√  ◊∫§âπ‡∫◊ÈÕßµâπ∑’Ë¡’‚√§∑’˧≈⓬§≈÷ß°—∫‚√§π’È Õ“∑‘ °“√µ√«®Õÿ®®“√–‡æ◊ËÕ«‘π‘®©—¬‚√§ 欓∏‘≈”‰ â„πºŸâªÉ«¬∑’Ë¡’Õ“°“√‚√§≈”‰ â·ª√ª√«π™π‘¥∑’Ë¡’Õ“°“√∑âÕ߇ ’¬‡¥àπÀ√◊Õ ¡’Õ“°“√ ≈—∫∑—Èß∑âÕߺŸ°·≈–∑âÕ߇ ’¬·≈–·∫∫º ¡‡¥àπ3, 6  ”À√—∫ºŸâªÉ«¬∑’Ë¡’Õ“°“√ ‡∫◊ÈÕßµâπ∑’Ëπà“ ß —¬«à“®–‡ªìπ‚√§Õ◊Ëπ ·π–π”„Àâµ√«®‡æ‘Ë¡‡µ‘¡À√◊Õª√÷°…“·æ∑¬å ºŸâ‡™’ˬ«™“≠‚√§≈”‰ â·ª√ª√«π  “¡“√∂∑’Ë®–æ∫Õ“°“√„π¥â“πÕ◊Ëπ Ê πÕ°‡Àπ◊Õ Õ“°“√∑“߇¥‘πÕ“À“√√à«¡‰¥â ‡™àπ ÕàÕπ‡æ≈’¬, πÕπ‰¡àÀ≈—∫, fibromyalgia, ª«¥À≈—ß, ªí  “«–∫àÕ¬ ·≈–¡’Õ“°“√‡®Á∫ª«¥¢≥–¡’‡æ» —¡æ—π∏å (dyspareunia), §«“¡‡§√’¬¥, ´÷¡‡»√â“ ·≈–¡’ somatization ¢âÕ √ÿª∑’Ë 9. ºŸâªÉ«¬∑’Ë¡’Õ“°“√ª«¥∑âÕßÀ√◊Õ‰¡à ∫“¬„π∑âÕ߇√◊ÈÕ√—ß∑ÿ°√“¬·æ∑¬åºŸâ¥Ÿ·≈§«√  Õ∫∂“¡§«“¡ —¡æ—π∏å¢ÕßÕ“°“√ª«¥∑âÕß/‰¡à ∫“¬„π∑âÕß°—∫°“√‡ª≈’ˬπ·ª≈ß ¢Õߧ«“¡∂’Ë¢Õß°“√∂à“¬Õÿ®®“√–·≈–≈—°…≥–¢ÕßÕÿ®®“√–  ◊∫‡π◊ËÕß®“°‚√§≈”‰ â·ª√ª√«π‡ªìπ‚√§∑’Ë„Àâ°“√«‘π‘®©—¬‚¥¬Õ“»—¬Õ“°“√ª«¥∑âÕß À√◊Õ‰¡à ∫“¬„π∑âÕ߇√◊ÈÕ√—ß√à«¡°—∫¡’°“√¢—∫∂à“¬∑’ˇª≈’ˬπ·ª≈߉ª À√◊ÕÕ“°“√ª«¥∑âÕß
  • 15. 14 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 À√◊Õ‰¡à ∫“¬„π∑âÕß∑’Ë¥’¢÷ÈπÀ≈—ß°“√∂à“¬Õÿ®®“√– ∂÷ß·¡âºŸâªÉ«¬®–¡’Õ“°“√‡©æ“–À√◊Õ®– ¡’Õ“°“√ª«¥∑âÕßÀ√◊Õ‰¡à ∫“¬„π∑âÕ߇©æ“–∫√‘‡«≥≈‘Èπªïò°Áµ“¡ ‚¥¬°“√«‘π‘®©—¬·≈– ·¬°™π‘¥¢Õß‚√§π’È¡’§«“¡®”‡ªìπµâÕß√Ÿâ§«“¡∂’Ë¢Õß°“√∂à“¬Õÿ®®“√–·≈–≈—°…≥–¢Õß Õÿ®®“√–1 ´÷Ëß®– “¡“√∂∑”„Àâ·¬°™π‘¥‡ªìπ 4 ™π‘¥ µ“¡¢âÕ √ÿª∑’Ë 3 ¢âÕ √ÿª∑’Ë 10. ºŸâªÉ«¬∑’˧«√‰¥â√—∫°“√µ√«®∑“ßÀâÕߪؑ∫—µ‘°“√À√◊Õ°“√µ√«®‡æ‘Ë¡‡µ‘¡‰¥â·°à ºŸâªÉ«¬∑’Ë¡’≈—°…≥–‡µ◊Õπ¥—ßµàÕ‰ªπ’È 10.1ºŸâªÉ«¬∑’Ë¡’Õ“°“√√ÿπ·√ß 10.2ºŸâªÉ«¬∑’Ë¡’πÈ”Àπ—°≈¥≈ߺ‘¥ª°µ‘ (≈¥≈ß¡“°°«à“À√◊Õ‡∑à“°—∫√âÕ¬≈– 10 „π 3 ‡¥◊Õπ) 10.3ºŸâªÉ«¬∑’ˇ√‘Ë¡¡’Õ“°“√‡¡◊ËÕÕ“¬ÿ 50 ªï¢÷Èπ‰ª 10.4ºŸâªÉ«¬∑’Ë¡’Õ“°“√∂à“¬‡ªìπ‡≈◊Õ¥À√◊Õ¡Ÿ°‡≈◊Õ¥ 10.5‚≈À‘µ®“ß®“°¢“¥∏“µÿ‡À≈Á° «‘µ“¡‘π∫’ 12 À√◊Õ‚ø‡≈µ∑’ˉ¡à “¡“√∂Õ∏‘∫“¬ ‰¥â®“° “‡ÀµÿÕ◊ËππÕ°∑“߇¥‘πÕ“À“√ 10.6ºŸâªÉ«¬∑’Ë¡’Õ“°“√ª«¥À√◊Õ·πàπ∑âÕß√∫°«π¢≥–πÕπÀ≈—∫ 10.7µ√«®√à“ß°“¬æ∫≈—°…≥–º‘¥ª°µ‘ ‡™àπ µ—∫‚µ °âÕπ„π∑âÕß ´’¥ ‡À≈◊Õß ‡ªìπµâπ 10.8¡’‰¢â 10.9ª√–«—µ‘¡–‡√Áß≈”‰ â„À≠à„π§√Õ∫§√—«∑’ˇªìπ≠“µ‘ “¬µ√ß (first degree relatives) °“√Õ“»—¬≈—°…≥–¢ÕßÕ“°“√·≈–Õ“°“√· ¥ß‡µ◊Õπ„π·π«∑“ß°“√¥Ÿ·≈ºŸâªÉ«¬ ‚√§≈”‰ â·ª√ª√«π¢Õߪ√–‡∑»‰∑¬‰¥â„™â·π«∑“ß°“√¥Ÿ·≈ºŸâªÉ«¬‚√§π’È¢Õ߇Շ™’¬¡“ ª√–°Õ∫5 „π°√≥’∑’˺ŸâªÉ«¬¡’≈—°…≥–‡µ◊Õπ·π–π”«à“§«√µ√«®‡æ‘Ë¡‡µ‘¡À√◊Õª√÷°…“·æ∑¬å ºŸâ‡™’ˬ«™“≠
  • 16. 15§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 ¢âÕ √ÿª∑’Ë 11. ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π∑’ˉ¡à¡’≈—°…≥–‡µ◊Õπ¡’‚Õ°“ ‡°‘¥¡–‡√Áß≈”‰ â„À≠à ‰¡àµà“ß®“°ª√–™“°√∑—Ë«‰ª °“√»÷°…“¢Õß Cash ·≈–§≥–7 æ∫«à“ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π¡’§«“¡™ÿ°¢Õß ‚√§¡–‡√Áß≈”‰ â„À≠à∑’Ë√âÕ¬≈– 0-0.51 ¢≥–∑’˧«“¡™ÿ°¢Õß‚√§π’È„πª√–™“°√∑—Ë«‰ªÕ¬Ÿà∑’Ë √âÕ¬≈– 0-6 ´÷Ë߉¡à¡’§«“¡·µ°µà“ß°—π ¢âÕ √ÿª∑’Ë 12. ‚√§≈”‰ â·ª√ª√«π‡ªìπ‚√§‡√◊ÈÕ√—ß À√◊Õ‡ªìπÊÀ“¬Ê ºŸâªÉ«¬¡—°¡’Õ“¬ÿ¬◊𬓫 ‰¡àµà“ß®“°ª√–™“°√∑—Ë«‰ª ·µà®–¡’§ÿ≥¿“æ™’«‘µ∑’Ë¥âÕ¬°«à“ °“√»÷°…“À≈“¬°“√»÷°…“8, 9 æ∫«à“ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π¡’§ÿ≥¿“æ™’«‘µ∑’Ë ¥âÕ¬°«à“ª√–™“°√∑—Ë«‰ª Õ“∑‘ °“√»÷°…“¢Õß Lu ·≈–§≥–8 „πºŸâªÉ«¬™“«®’π∑’ˇªìπ ‚√§≈”‰ â·ª√ª√«πæ∫«à“ºŸâªÉ«¬‡æ»À≠‘ß¡’·π«‚πâ¡À¬ÿ¥ß“π¡“°°«à“¡’ªí≠À“°“√πÕπ (sleep disturbance) ¡“°°«à“ºŸâªÉ«¬™“¬  à«π°“√»÷°…“¢Õß Rey ·≈–§≥–9 °Áæ∫ «à“„πºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π∑’˪√÷°…“·æ∑¬å ·≈–∑’ˉ¡à‰¥âª√÷°…“·æ∑¬å≈â«π¡’ §ÿ≥¿“æ™’«‘µ∑’Ë¥âÕ¬°«à“°≈ÿà¡∑’ˉ¡à¡’‚√§ ¢âÕ √ÿª∑’Ë 13. ≈—°…≥–°“√∂à“¬Õÿ®®“√–„πºŸâªÉ«¬≈”‰ â·ª√ª√«π¡’ª√–‚¬™πå„π°“√°”Àπ¥ ·π«∑“ß°“√ ◊∫§âπÀ“ “‡Àµÿ¢ÕßÕ“°“√ („π°√≥’∑’Ë¡’¢âÕ∫àß™’È) ·≈–·π«∑“ß°“√ „À⬓√—°…“ ·π–π”„Àâ ◊∫§âπ‡æ‘Ë¡‡µ‘¡„πºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«πµ“¡™π‘¥¢Õß‚√§π’È3, 10 ‚¥¬ ‡©æ“–™π‘¥∑’ˇªìπ·∫∫∑âÕ߇ ’¬‡¥àπ„Àâ√–«—ß‚√§°≈ÿà¡∑’ËÕ“®¡’Õ“°“√∑âÕ߇ ’¬‡√◊ÈÕ√—߉¥â ‡™àπ giardiasis, tropical sprue, hyperthyroidism, inflammatory bowel disease (IBD) ‡ªìπµâπ ‡ªÑ“À¡“¬¢Õß°“√√—°…“ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π§◊Õ ≈¥Õ“°“√·≈–‡æ‘Ë¡§ÿ≥¿“æ ™’«‘µ¢ÕߺŸâªÉ«¬3, 5 ¥—ßπ—Èπ°“√®”·π°ºŸâªÉ«¬‚√§π’ȇªìπ 4 ™π‘¥§◊Õ ≈”‰ â·ª√ª√«π ™π‘¥ ∑âÕ߇ ’¬‡¥àπ, ≈”‰ â·ª√ª√«π ™π‘¥∑âÕߺŸ°‡¥àπ, ≈”‰ â·ª√ª√«π ™π‘¥∑âÕ߇ ’¬ ≈—∫ ∑âÕߺŸ° (IBS-M), ≈”‰ â·ª√ª√«π™π‘¥‰¡à™—¥‡®π (IBS-U) ®–∑”„Àâ°“√√—°…“´÷Ëß
  • 17. 16 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 ¡ÿà߇πâπ∑’˵âÕß°“√≈¥Õ“°“√¢ÕߺŸâªÉ«¬‡ªìπÀ≈—° ∑”‰¥â –¥«°·≈–ßà“¬µàÕ°“√®—¥¬“Õ’° √«¡‰ª∂÷ß∑”„Àâ°“√»÷°…“«‘®—¬‚√§π’ȇªìπ‰ª„π·π«∑“߇¥’¬«°—πÕ’°¥â«¬‡™àπ ºŸâªÉ«¬∑’Ë¡’ Õ“°“√∑âÕ߇ ’¬‡¥àπÕ“®„™â¬“´÷Ëߪ√–°Õ∫‰ª¥â«¬¬“ antispasmodics, loperamide ·≈– alosetron ‡ªìπµâπ ¢âÕ √ÿª∑’Ë 14. °“√µ√«®∑“ßÀâÕߪؑ∫—µ‘°“√·≈–°“√µ√«®æ‘‡»…∑’Ë¡’ª√–‚¬™πå„π°“√·¬°‚√§ Õ◊Ëπ∑’Ë∑”„À⇰‘¥Õ“°“√§≈⓬Փ°“√¢Õß‚√§≈”‰ â·ª√ª√«π ‰¥â·°à 14.1 °“√µ√«®æ◊Èπ∞“π CBC, ESR, stool exam 14.2 °“√µ√«®æ‘‡»…√–∫∫∑“߇¥‘πÕ“À“√ ‰¥â·°à barium enema, upper GI study with small bowel follow through, gastroscopy, sigmoidoscopy, colonoscopy, ultrasono-graphy À√◊Õ CT scan ¢Õß™àÕß∑âÕß, πà“®–∑” H2-breath test  ”À√—∫ small bowel bacterial overgrowth, lactose malabsorption, gastro- intestinal transit study ·≈– anorectal function tests 14.3 °“√µ√«®Õ◊ËπÊ ‡™àπ thyroid function tests, serum cortisol, serum calcium, electrolytes ‡ªìπµâπ °“√µ√«®‡æ‘Ë¡‡µ‘¡∑“ßÀâÕߪؑ∫—µ‘°“√π—Èπ®–¡’ª√–‚¬™πå„πºŸâªÉ«¬‚√§≈”‰ â ·ª√ª√«π‚¥¬‡©æ“–∂â“¡’≈—°…≥–‡µ◊Õπ ‚¥¬®–¡’·π«∑“ß°“√ ◊∫§âπµ“¡≈—°…≥–¢Õß ™π‘¥¢Õß‚√§≈”‰ â·ª√ª√«π∑’˺ŸâªÉ«¬π—Èπ¡’ªí≠À“3  ”À√—∫ Asian guideline ·π–π”«à“ ∂â“√—°…“ºŸâªÉ«¬‰ª 12  —ª¥“Àå·≈â« ºŸâªÉ«¬¬—ߧߡ’Õ“°“√‰¡à¥’¢÷Èπ·π–π”«à“ §«√ àßµàÕ ºŸâªÉ«¬ª√÷°…“·æ∑¬å‡©æ“–∑“ß‚√§√–∫∫∑“߇¥‘πÕ“À“√ ¢âÕ √ÿª∑’Ë 15. ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π∑’˧«√ àßµàÕ‰ªæ∫·æ∑¬å‡©æ“–∑“ß‚√§√–∫∫ ∑“߇¥‘πÕ“À“√ ‰¥â·°à ºŸâªÉ«¬∑’Ë¡’¢âÕ∫àß™’È„π°“√µ√«®æ‘‡»…‡æ‘Ë¡‡µ‘¡À√◊ÕºŸâªÉ«¬∑’Ë¡’ Õ“°“√√ÿπ·√ß√—°…“·≈⫉¡à “¡“√∂§«∫§ÿ¡Õ“°“√‰¥â °“√√—°…“ºŸâªÉ«¬‚√§ IBS3, 11 π’È·∫àß°“√¥Ÿ·≈‡ªìπ 3 √–¥—∫§◊Õ „π°“√¥Ÿ·≈ºŸâªÉ«¬ ∑’Ë¡’Õ“°“√‰¡à¡“° „ÀℙⰓ√ª√—∫‡ª≈’ˬπ惵‘°√√¡ (life style modifications) °“√À≈’°‡≈’ˬßÕ“À“√À√◊Õ°“√‡ª≈’ˬπ™π‘¥¢ÕßÕ“À“√ Õ∏‘∫“¬°“√«‘π‘®©—¬·≈–°“√¥”‡π‘π
  • 18. 17§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 ¢Õß‚√§ ∑”„À⺟âªÉ«¬¡—Ëπ„®„πµ—«‚√§«à“‚√§π’ȉ¡à√⓬·√ß·µà‡√◊ÈÕ√—ß´÷ËßÕ“®¡’º≈„Àâ§ÿ≥¿“æ ™’«‘µ≈¥≈߉¥â ∂⓺ŸâªÉ«¬‡√‘Ë¡¡’Õ“°“√¡“°¢÷Èπ·π–π”„Àℙ⬓√—°…“µ“¡Õ“°“√·≈–™π‘¥ ¢Õß≈”‰ â·ª√ª√«π∑’˺ŸâªÉ«¬‡ªìπ √à«¡°—∫°“√√—°…“§«“¡‡§√’¬¥ µ≈Õ¥®π°“√µ‘¥µ“¡ ºŸâªÉ«¬Õ¬à“ßµàÕ‡π◊ËÕß  ”À√—∫√“¬∑’Ë¡’§«“¡√ÿπ·√ß¡“°·π–π”„Àâ¡’°“√¥Ÿ·≈√—°…“Õ¬à“ß µàÕ‡π◊ËÕßµ≈Õ¥®πæ‘®“√≥“ª√÷°…“∑“ß®‘µ‡«™∑—Èß°“√„™â¬“·≈–®‘µ∫”∫—¥‡æ‘Ë¡  ”À√—∫·æ∑¬å∑—Ë«‰ª°“√√—°…“„πºŸâªÉ«¬∑’Ë¡’Õ“°“√‡≈Á°πâÕ¬®π∂÷ߪ“π°≈“ß  “¡“√∂∑”‰¥â  à«π„π√“¬∑’Ë¡’Õ“°“√¡“° °“√√—°…“‚¥¬·æ∑¬å‡©æ“–∑“ß‚√§√–∫∫ ∑“߇¥‘πÕ“À“√·≈–®‘µ‡«™¡’§«“¡®”‡ªìπ ‡π◊ËÕß®“°Õ“®µâÕß¡’°“√ ◊∫§âπ‡æ‘Ë¡‡µ‘¡·≈– ‡ªìπ°“√∑”„À⺟âªÉ«¬¡’§«“¡¡—Ëπ„®„π·π«∑“ß°“√√—°…“¡“°¢÷Èπ «à“‰¥â√—∫°“√¥Ÿ·≈®“° ·æ∑¬åºŸâ¡’§«“¡‡™’ˬ«™“≠„π‚√§∑’ˇªìπ „π¢≥–∑’ËÕ“°“√¬—߉¡à¥’¢÷Èπ‡∑à“∑’˧«√ References 1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-91. 2. Svendsen JH, Munck LK, Andersen JR. Irritable bowel syndrome: prognosis and diagnostic safety. A 5-year follow-up study. Scand J Gastroenterol 1985;20:415-8. 3. Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104 Suppl 1:S1-35. 4. Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770-98. 5. Gwee KA, Bak YT, Ghoshal UC, et al. Asian consensus on irritable bowel syndrome. J Gastroenterol Hepatol 2010;25:1189-205. 6. Tungtrongchitr A, Manatsathit S, Kositchaiwat C, et al. Blastocystis hominis infection in irritable bowel syndrome patients. Southeast Asian J Trop Med Public Health 2004;35: 705-10. 7. Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol 2002;97:2812-9. 8. Lu CL, Chang FY, Lang HC, Chen CY, Luo JC, Lee SD. Gender difference on the symptoms, health-seeking behaviour, social impact and sleep quality in irritable bowel syndrome: a Rome II-based survey in an apparent healthy adult Chinese population in Taiwan. Aliment Pharmacol Ther 2005;21:1497-505. 9. Rey E, Garcia-Alonso MO, Moreno-Ortega M, Alvarez-Sanchez A, Diaz-Rubio M. Determinants of quality of life in irritable bowel syndrome. J Clin Gastroenterol 2008;42: 1003-9. 10. Mayer EA. Clinical practice. Irritable bowel syndrome. N Engl J Med 2008;358:1692-9. 11. Drossman DA, Camilleri M, Mayer EA, Whitehead WE.. AGA technical review on irritable bowel syndrome. Gastroentero-logy 2002;123:2108-31.
  • 19. 18 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 Non-pharmacological Treatment ¢âÕ √ÿª∑’Ë 16. ºŸâªÉ«¬≈”‰ â·ª√ª√«π∑’Ë¡’Õ“°“√‰¡à√∫°«π§ÿ≥¿“æ™’«‘µ °“√¥Ÿ·≈√—°…“¡’ ‡ªÑ“À¡“¬‡æ◊ËÕ √â“ߧ«“¡¡—Ëπ„®·≈–§≈“¬§«“¡«‘µ°°—ß«≈¢ÕߺŸâªÉ«¬ °“√¥Ÿ·≈√—°…“ºŸâªÉ«¬≈”‰ â·ª√ª√«π∑’Ë¡’Õ“°“√‰¡à√∫°«π§ÿ≥¿“æ™’«‘µ¡’‡ªÑ“À¡“¬ ∑’Ë ”§—≠§◊Õ √â“ߧ«“¡¡—Ëπ„®·≈–§≈“¬§«“¡«‘µ°°—ß«≈¢ÕߺŸâªÉ«¬  ‘Ëß·√°µâÕßÕ∏‘∫“¬ „À⺟âªÉ«¬∑√“∫∂÷ß natural history ¢Õß‚√§«à“‚√§≈”‰ â·ª√ª√«π ‡ªìπ‚√§∑’ˉ¡à√⓬·√ß ‰¡à¡’¿“«–·∑√°´âÕπ∑’Ë®–∑”„À⇠’¬™’«‘µ ·µà¡’°“√¥”‡π‘π‚√§∑’ˇ√◊ÈÕ√—ß ¡—°‡ªìπÊ À“¬Ê ·¡â‰¥â√—∫°“√√—°…“À≈—ß°“√√—°…“∂⓺ŸâªÉ«¬Õ“°“√‰¡à¥’¢÷Èπ®–¬‘Ëß∑”„À⺟âªÉ«¬«‘µ°°—ß«≈¡“° §◊Õ°≈—«‡ªìπ¡–‡√Áß≈”‰ â ·æ∑¬åµâÕßÕ∏‘∫“¬‡æ◊ËÕ √â“ߧ«“¡¡—Ëπ„®„À⺟âªÉ«¬«à“‚√§≈”‰ â ·ª√ª√«π‰¡à„™à‚√§¡–‡√Áß·≈–®–‰¡à°≈“¬‡ªìπ¡–‡√Áß·¡â®–¡’Õ“°“√∑’Ëπ”ºŸâªÉ«¬¡“æ∫·æ∑¬å ‡À¡◊Õπ°—π·æ∑¬åµâÕß´—°ª√–«—µ‘·≈–µ√«®√à“ß°“¬Õ¬à“ß≈–‡Õ’¬¥·≈–∑”°“√ ◊∫§âπÕ¬à“ß ‡À¡“– ¡°àÕπ∑’Ë®–„Àâ°“√«‘π‘®©—¬«à“‡ªìπ‚√§≈”‰ â·ª√ª√«π √«¡∑—Èß®–µâÕߧâπÀ“Õ¬à“ß ‡µÁ¡∑’Ë«à“‰¡àæ∫¡’≈—°…≥–‡µ◊Õπ (alarm symptoms) ´÷Ëß∫àß™’È«à“Õ“®®–¡’‚√§√⓬·√ß ‡™àπ¡–‡√Áß≈”‰ â√à«¡¥â«¬ ‡æ◊ËÕ¬◊π¬—π„À⺟âªÉ«¬¡—Ëπ„®«à“‰¡à¡’‚√§√⓬·√ß1-5 ¢âÕ √ÿª∑’Ë 17. ºŸâªÉ«¬≈”‰ â·ª√ª√«π∑’Ë¡’Õ“°“√√∫°«π§ÿ≥¿“æ™’«‘µ «—µ∂ÿª√– ß§å¢Õß°“√ √—°…“πÕ°®“° √â“ߧ«“¡¡—Ëπ„®·≈–§≈“¬§«“¡«‘µ°°—ß«≈„À⺟âªÉ«¬·≈â« §«√„Àâ °“√√—°…“‡æ◊ËÕ∫√√‡∑“Õ“°“√¢ÕߺŸâªÉ«¬§«√‡√‘Ë¡µâπ¥â«¬°“√·π–π”„Àâª√—∫‡ª≈’Ë¬π °“√ªØ‘∫—µ‘µ—«„π°“√¥”‡π‘π™’«‘µª√–®”«—π (life style modifications) °“√√—°…“‡æ◊ËÕ∫√√‡∑“Õ“°“√¢ÕߺŸâªÉ«¬§«√‡√‘Ë¡µâπ¥â«¬°“√·π–π”„Àâª√—∫‡ª≈’Ë¬π °“√ªØ‘∫—µ‘µ—«„π°“√¥”‡π‘π™’«‘µª√–®”«—π (life style modifications) ‡™àπ °“√√—∫ª√–∑“πÕ“À“√ ™π‘¥¢ÕßÕ“À“√ ¬“ §«“¡‡§√’¬¥ À≈’°‡≈’ˬߠ‘Ëß∑’Ë∑”„À⺟âªÉ«¬¡’ Õ“°“√¡“°¢÷Èπ‡ªìπµâπ ·¡â‰¡à¡’À≈—°∞“π∑“ß«‘∑¬“»“ µ√å∑’Ë π—∫ πÿπ«à“°“√ª√—∫ ‡ª≈’ˬπ°“√ªØ‘∫—µ‘µ—«¡’ª√–‚¬™πå„π°“√√—°…“ ·µà°“√·π–π”„Àâª√—∫‡ª≈’ˬπ°“√ªØ‘∫—µ‘ µ—«Õ“®∑”„ÀâÕ“°“√¥’¢÷Èπ„πºŸâªÉ«¬∫“ß√“¬·≈–™à«¬≈¥§«“¡∂’Ë„π°“√°≈—∫‡ªìπ´È” ‰¥â¥â«¬6
  • 20. 19§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 ¢âÕ √ÿª∑’Ë 18. °“√„Àâ°“√«‘π‘®©—¬‚√§‡™‘ß∫«°·≈–°“√¡’§«“¡ —¡æ—π∏å∑’Ë¥’√–À«à“ß·æ∑¬å ·≈–ºŸâªÉ«¬¡’§«“¡ ”§—≠µàÕº≈ ”‡√Á®¢Õß°“√√—°…“ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π °“√µ√–Àπ—°∂÷ß·≈–«‘π‘®©—¬‚√§≈”‰ â·ª√ª√«π¥â«¬§«“¡¡—Ëπ„®‡ªìπ ‘Ëß ”§—≠∑’Ë ·æ∑¬å®– √â“ߧ«“¡¡—Ëπ„®·°àºŸâªÉ«¬·≈– ”§—≠µàÕº≈ ”‡√Á®¢Õß°“√√—°…“ºŸâªÉ«¬‚√§≈”‰ â ·ª√ª√«π ‡¡◊ËÕºŸâªÉ«¬¡’§«“¡¡—Ëπ„®„π°“√¥Ÿ·≈√—°…“¢Õß·æ∑¬å®– àߺ≈„À⇰‘¥§«“¡  —¡æ—π∏å∑’Ë¥’√–À«à“ß·æ∑¬å·≈–ºŸâªÉ«¬ ´÷Ëß®–¡’§«“¡ ”§—≠µàÕº≈ ”‡√Á®¢Õß°“√√—°…“ ‡π◊ËÕß®“°‚√§≈”‰ â·ª√ª√«π¡’°“√¥”‡π‘π‚√§∑’ˇ√◊ÈÕ√—ß ¡—°‡ªìπÊÀ“¬Ê ºŸâªÉ«¬®”‡ªìπµâÕß ‰¥â√—∫°“√¥Ÿ·≈√—°…“µ‘¥µàÕ°—π√–¬–¬“«·≈–µâÕ߉¥â√—∫§«“¡√à«¡¡◊ÕÕ¬à“ߥ’®“°ºŸâªÉ«¬ Õ’°¥â«¬¥—ßπ—Èπ‡¡◊ËÕºŸâªÉ«¬¡’§«“¡‡™◊ËÕ∂◊Õ·≈–§«“¡¡—Ëπ„®„πµ—«·æ∑¬å·≈⫺ŸâªÉ«¬®–√Ÿâ ÷°«à“ ·æ∑¬å‡ªìπ∑’Ëæ÷Ë߉¥âµ≈Õ¥‡«≈“∑”„À⺟âªÉ«¬§≈“¬§«“¡«‘µ°°—ß«≈≈ßÕ“®™à«¬∑”„ÀâÕ“°“√ ¥’¢÷Èπ·¡âºŸâªÉ«¬®–¬—ߧߡ’Õ“°“√Õ¬Ÿà∫â“߉¡àÀ“¬¢“¥·µàºŸâªÉ«¬®–¡’§«“¡∑ÿ°¢å∑√¡“π‡°’Ë¬«°—∫ ‚√§≈¥πâÕ¬≈ß6-9 ¢âÕ √ÿª∑’Ë 19. °“√´—°ª√–«—µ‘惵‘°√√¡°“√√—∫ª√–∑“πÕ“À“√·≈–‡§√◊ËÕߥ◊Ë¡√«¡∂÷ߧ”·π–π” ‡°’ˬ«°—∫°“√√—∫ª√–∑“πÕ“À“√·≈–‡§√◊ËÕߥ◊Ë¡ ¡’ª√–‚¬™πå„π°“√¥Ÿ·≈√—°…“ºŸâªÉ«¬ ≈”‰ â·ª√ª√«π ºŸâªÉ«¬ à«π„À≠à√Ÿâ ÷°«à“Õ“À“√∫“ßÕ¬à“ß∑”„ÀâÕ“°“√¢Õß‚√§≈”‰ â·ª√ª√«π ‡ªìπ¡“°¢÷Èπ10 ¡’°“√»÷°…“∑’ˇªìπ systematic review ´÷Ëß à«π„À≠à‡ªìπ°“√»÷°…“·∫∫ uncontrolled æ∫«à“ °“√À≈’°‡≈’ˬßÕ“À“√∑’Ë®–∑”„Àâ¡’Õ“°“√‡æ‘Ë¡¢÷Èπ‡¡◊ËÕ‡ª√’¬∫‡∑’¬∫ °—∫ placebo ºŸâªÉ«¬®–¡’Õ“°“√¥’¢÷Èπ√âÕ¬≈– 12.5-67 ´÷Ë߉¡à “¡“√∂ √ÿª‰¥â«à“‡ªìπ placebo effect À√◊Õ‰¡à11 ¡’°“√»÷°…“∑’ˇªìπrandomized control trial (RCT) æ∫«à“ °“√À≈’°‡≈’ˬßÕ“À“√∑’Ë®–∑”„Àâ¡’Õ“°“√‡æ‘Ë¡¢÷Èπ´÷Ë߬◊π¬—π‚¥¬°“√µ√«®æ∫ IgG antibody µàÕÕ“À“√™π‘¥π—Èπ ∑”„À⺟âªÉ«¬¡’Õ“°“√¥’¢÷ÈπÕ¬à“ß¡’π—¬ ”§—≠∑“ß ∂‘µ‘‡¡◊ËÕ‡ª√’¬∫‡∑’¬∫ °—∫ sham diet ‚¥¬¡’ number needed to treat (NNT) ‡∑à“°—∫ 2.512 „πªí®®ÿ∫—π ¬—ß‰¡à¡’À≈—°∞“π∑’Ë¥’‡æ’¬ßæÕ∑’Ë®–· ¥ß∂÷ߪ√– ‘∑∏‘¿“æ¢Õß°“√À≈’°‡≈’ˬßÕ“À“√∑’Ë®– ∑”„À⺟âªÉ«¬¡’Õ“°“√‡æ‘Ë¡¢÷Èπ13 ®÷߬—߉¡à·π–π”„Àâµ√«®À“ IgG antibody ‡ªìπ routine „π‡«™ªØ‘∫—µ‘∑—Ë«‰ª Õ¬à“߉√°Áµ“¡°“√·π–π”„ÀâÀ≈’°‡≈’ˬßÕ“À“√∑’Ë®–∑”„Àâ¡’Õ“°“√‡æ‘Ë¡¢÷È𠇙àπÕ“À“√√ ®—¥ Õ“À“√¡—π ¢ÕߥÕß ·Õ≈°ÕŒÕ≈å∑ÿ°™π‘¥ °“·ø πȔ՗¥≈¡ ‡ªìπµâπ
  • 21. 20 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 ∂◊Õ«à“¡’ª√–‚¬™πå‚¥¬Õ“®∑”„ÀâÕ“°“√¢ÕߺŸâªÉ«¬¥’¢÷Èπ‰¥âπÕ°®“°π’È°“√°‘πÕ“À“√§«√°‘π ∑’≈–πâÕ¬·µà°‘π„Àâ∫àÕ¬¢÷Èπ‰¡à§«√°‘π®πÕ‘Ë¡¡“°‡æ√“–«à“®–°√–µÿâπ„Àâ¡’Õ“°“√ª«¥∑âÕß ·≈–∑âÕ߇ ’¬‰¥âßà“¬ ¢âÕ √ÿª∑’Ë 20. °“√√—°…“‚¥¬‰¡à„™â¬“∑’ËÕ“®¡’ª√–‚¬™πå„πºŸâªÉ«¬≈”‰ â·ª√ª√«π‰¥â·°à °“√„™â educational self-help guidebook, psychological therapy, °“√√—°…“ ¥â«¬ “√ ¡ÿπ‰æ√ °“√Ωí߇¢Á¡ ·≈– biofeedback therapy °“√√—°…“‚¥¬‰¡à„™â¬“ (non-drug therapy) ∑’ËÕ“®¡’ª√–‚¬™πå„πºŸâªÉ«¬ ‚√§≈”‰ â·ª√ª√«π‰¥â·°à 20.1 °“√„™â educational self-help guidebook ‡ªìπ°“√„Àâ°“√»÷°…“·°à ºŸâªÉ«¬„Àâ¡’§«“¡√Ÿâ‡°’ˬ«°—∫‚√§∑—Èß„π¥â“π欓∏‘°”‡π‘¥ °“√«‘π‘®©—¬·≈–°“√√—°…“ µ≈Õ¥®π‡¢â“„®≈—°…≥–°“√¥”‡π‘π‚√§·≈–·π«∑“ß„π°“√ª√—∫‡ª≈’ˬπ°“√ªØ‘∫—µ‘µ—«∑’Ë ‡À¡“– ¡‡æ◊ËÕ≈¥Õ“°“√∑’Ë∑”„À⺟âªÉ«¬∑ÿ°¢å∑√¡“π ¡’°“√»÷°…“∑’ˇªìπ RCT ‚¥¬ ª√–‡¡‘πº≈≈—æ∏å§◊Õ symptom score, perception of improvement ·≈– primary care consultation rates º≈°“√»÷°…“∑’ËÀπ÷Ëߪïæ∫«à“„π°≈ÿà¡ self-help guidebook ¡’ºŸâªÉ«¬¡“æ∫·æ∑¬å≈¥≈ßπâÕ¬°«à“ control group 1.56 §√—ÈßµàÕªïÕ¬à“ß¡’π—¬ ”§—≠ (95% CI, 1.15-1.98) À√◊Õ≈¥≈ß√âÕ¬≈– 60 πÕ°®“°π’Èæ∫«à“„π°≈ÿà¡ self-help guidebook ºŸâªÉ«¬√“¬ß“π perceived improvement ¡“°°«à“‚¥¬¡’ mean effect ‡∑à“°—∫ 0.51 (95% CI, 0.23-0.79)14 20.2 Psychological therapy ‡π◊ËÕß®“°ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π¡—°¡’¿“«– anxiety, depression ·≈– somatization √à«¡¥â«¬15,16 ¡’°“√»÷°…“∑’ˇªìπ systematic review ·≈– meta-analysis ∑’Ë· ¥ß«à“ psychological therapy ´÷Ëߪ√–°Õ∫¥â«¬ cognitive behavioral therapy (CBT), dynamic psychotherapy ·≈– hypno- therapy ∑”„Àâ global IBS symptoms ¥’¢÷ÈπÕ¬à“ß¡’π—¬ ”§—≠‡¡◊ËÕ‡ª√’¬∫‡∑’¬∫ °—∫°“√√—°…“µ“¡ª°µ‘17-19 ‚¥¬ CBT ‡ªìπ·π«∑“ß°“√√—°…“∑’Ë¡’°“√»÷°…“¡“°∑’Ë ÿ¥ ‚¥¬‡©æ“–¡’°“√»÷°…“∑’Ë„À≠à·≈–¡’§ÿ≥¿“æ ŸßÀπ÷Ëß°“√»÷°…“∑’Ë· ¥ß«à“ CBT ‰¥â ª√–‚¬™πå∑”„À⺟âªÉ«¬Õ“°“√¥’¢÷ÈπÕ¬à“ß™—¥‡®π ¡’°“√»÷°…“∑’ˇªìπsingle-blindedstudy ‡ª√’¬∫‡∑’¬∫ CBT °—∫ patient education alone æ∫«à“ CBT ∑”„À⺟âªÉ«¬Õ“°“√ ¥’¢÷Èπ√âÕ¬≈–73´÷Ë߉¥âº≈¥’°«à“educationgroup´÷Ë߉¥âº≈√âÕ¬≈–41.3Õ¬à“ß¡’π—¬ ”§—≠
  • 22. 21§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 ∑“ß ∂‘µ‘ (NNT= 3.2)20  ”À√—∫ hypnotherapy ¡’°“√»÷°…“∑’ˇªìπ systematic review ª√–°Õ∫¥â«¬ 6 °“√»÷°…“∑’Ë¡’ control ·≈– 8 °“√»÷°…“∑’ˉ¡à¡’ control ¡’ ºŸâªÉ«¬√«¡ 644 √“¬ æ∫«à“√âÕ¬≈– 80 ¡’ global IBS symptoms ¥’¢÷Èπ ‚¥¬‡©æ“– ºŸâªÉ«¬ typical IBS ®–µÕ∫ πÕ߉¥â¥’  à«πºŸâªÉ«¬™“¬∑’Ë¡’∑âÕ߇ ’¬‡ªìπÕ“°“√‡¥àπ ·≈–ºŸâªÉ«¬ IBS ∑’Ë¡’ atypical symptoms À√◊Õ¡’ comorbid psychopathology ¡—°‰¡à§àÕ¬µÕ∫ πÕßµàÕ°“√√—°…“21 20.3 Probiotics22-25 °≈‰°Àπ÷ËߢÕß欓∏‘ √’√–«‘∑¬“¢ÕßIBS§◊Õ¡’°“√‡ª≈’Ë¬π ·ª≈ߢÕß intestinal microbiota º‘¥ª°µ‘‰ª®“°‡¥‘¡ ‚¥¬‡°‘¥§«“¡‰¡à ¡¥ÿ≈¬å¢Õß intestinal microbiota ‡™àπ ¡’°“√≈¥≈ߢÕß Lactobacilli ·≈– Bifidobacteria ´÷Ëß ‡ªìπ·∫§∑’‡√’¬∑’Ë¥’‡°‘¥ª√–‚¬™πåµàÕ√à“ß°“¬¢≥–‡¥’¬«°—π¡’·∫§∑’‡√’¬∑’ˉ¡à¥’‡æ‘Ë¡¢÷Èπ‡™àπ Clostridia ·≈– Enterobacteriaceae ‡ªìπµâπ 𔉪 Ÿà¿“«– dysbiosis, elevated luminal gas production ·≈– immune activation ¥—ßπ—Èπ‡ªÑ“À¡“¬Àπ÷ËߢÕß°“√ √—°…“ IBS ®÷ß¡ÿà߉ª∑’Ë°“√·°â‰¢§«“¡º‘¥ª°µ‘¢Õß intestinal microbiota ¡’°“√»÷°…“ ∑’ˇªìπ systematic review 3 °“√»÷°…“ (2 °“√»÷°…“‡ªìπºŸâªÉ«¬ºŸâ„À≠àÕ¬à“߇¥’¬«, 1 °“√»÷°…“‡ªìπºŸâ„À≠à·≈–‡¥Á°)2-4 æ∫«à“ probiotics ∑”„À⺟âªÉ«¬¡’ global IBS symptoms, abdominal pain ·≈– flatulence ¥’¢÷ÈπÕ¬à“ß¡’π—¬ ”§—≠·≈–ª√–‚¬™πå ∑’ˉ¥â‡ªìπ strain-specific ·≈– symptom-specific  ”À√—∫ probiotic ∑’ˇªìπ  “¬æ—π∏ÿ凥’ˬ« À≈—°∞“π∑’Ë¥’∑’Ë ÿ¥§◊Õ Bifidobacteria infantis √Õß≈߉ª§◊Õ Lacto- bacillus planetarium  à«π probiotic ∑’ˇªì𠓬æ—π∏ÿ庠¡‡™àπ E.coli-Nisle + Streptococcusfaecalis ‡π◊ËÕß®“°¡’ªí®®—¬À≈“¬Õ¬à“߇™àπ strain selection, optimum dosage, mode of action,† safety ·≈– long-term tolerability ´÷Ëß¡’º≈µàÕ º≈¢Õß°“√√—°…“®÷߬—߉¡à “¡“√∂°”Àπ¥„Àâ probiotics ‡ªìπ general recommenda- tion „π°“√√—°…“ºŸâªÉ«¬ IBS ‰¥â 20.4  “√ ¡ÿπ‰æ√ ®“°°“√»÷°…“‚¥¬ Cochrane systematic review 75 RCTs ¡’ºŸâªÉ«¬√«¡ 7,957 √“¬ æ∫«à“¡’ “√ ¡ÿπ‰æ√∫“ßÕ¬à“ßÕ“®∑”„ÀâÕ“°“√¢Õß ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π¥’¢÷Èπ‰¥â26 ¡’°“√»÷°…“∑’ˇªìπ RCT ·∫∫ multicenter ‚¥¬ »÷°…“µ”√—∫ ¡ÿπ‰æ√™◊ËÕ Iberogast ´÷Ëߪ√–°Õ∫¥â«¬ ¡ÿπ‰æ√À≈“¬™π‘¥ æ∫«à“∑”„Àâ Õ“°“√¢ÕߺŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π¥’¢÷ÈπÕ¬à“ß¡’π—¬ ”§—≠‡¡◊ËÕ‡ª√’¬∫‡∑’¬∫°—∫¬“À≈Õ° ‚¥¬ºŸâªÉ«¬∑𬓉¥â¥’·≈–‰¥âº≈¥’‰¡à«à“®–¡’ predominant symptom ·∫∫„¥27 Õ¬à“߉√ °Áµ“¡°“√ª√–‡¡‘πª√–‚¬™πå∑’Ë·∑â®√‘ߢÕß ¡ÿπ‰æ√Õ“®‰¥âº≈‰¡à·πàπÕπ ‡π◊ËÕß®“°
  • 23. 22 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 °“√»÷°…“µà“ßÊ ¡’§«“¡À≈“°À≈“¬¢Õß®”π«π·≈–™π‘¥ ¡ÿπ‰æ√∑’Ë„™â·≈–µâÕߧ”π÷ß ∂÷ßæ‘…®“°§«“¡‰¡à∫√‘ ÿ∑∏‘Ï„π ¡ÿπ‰æ√π—ÈπÊ ¥â«¬´÷Ëß∑”„À⇪ìπ¢âÕ®”°—¥¢Õß ¡ÿπ‰æ√ ∑’Ë®–π”¡“„™â„À⇰‘¥ª√–‚¬™πå„π°“√√—°…“13 20.5 °“√Ωí߇¢Á¡ ®“°°“√»÷°…“∑’ˇªìπ systematic review æ∫«à“‰¡à “¡“√∂  √ÿª‰¥â«à“°“√Ωí߇¢Á¡‰¥âª√–‚¬™πå„π°“√√—°…“‚√§≈”‰ â·ª√ª√«π ‡π◊ËÕß®“°º≈°“√√—°…“ ¡’∑—Èß∑’Ë∑”„ÀâÕ“°“√¥’¢÷Èπ·≈–‰¡à¥’¢÷Èπ ®÷ßµâÕß°“√°“√»÷°…“‡æ‘Ë¡‡µ‘¡Õ’°¡“°°àÕπ∑’Ë®– ·π–π”°“√Ωí߇¢Á¡„À⇪ìπÀπ÷Ëß„π·π«∑“ß°“√√—°…“13 20.6 Biofeedback therapy Biofeedback therapy28 À√◊Õ°“√Ωñ°‡∫àßÕÿ®®“√– ¡’√“¬ß“π«à“¡’ª√–‚¬™πå„π ºŸâªÉ«¬≈”‰ â·ª√ª√«π™π‘¥∑âÕߺŸ°‡¥àπ∑’Ë¡’ªí≠À“‡∫à߉¡à∂Ÿ°«‘∏’ (anismus) √à«¡¥â«¬ ‚¥¬æ∫«à“∂⓺ŸâªÉ«¬ “¡“√∂Ωñ°‡∫àß®π “¡“√∂‡∫àßÕÿ®®“√–‰¥â∂Ÿ°«‘∏’ Õ“°“√ª«¥·πàπ ∑âÕß®“°≈”‰ â·ª√ª√«π®–¥’¢÷Èπ  —¡æ—π∏å°—∫°“√§≈“¬µ—«¢ÕßÀŸ√Ÿ¥∑«“√Àπ—°¢≥–‡∫àß ∑’Ë¥’¢÷Èπ ¥—ßπ—ÈπºŸâªÉ«¬≈”‰ â·ª√ª√«π™π‘¥∑âÕߺŸ°‡¥àπ∑’Ë¡’Õ“°“√√∫°«π¡“°À√◊Õ¥◊ÈÕµàÕ °“√√—°…“ °“√µ√«®°“√∑”ß“π¢Õß∑«“√Àπ—° ‡™àπ anorectal manometry, balloon expulsion test À√◊Õ defecogram ‡æ◊ËÕ§âπÀ“¿“«–‡∫à߉¡à∂Ÿ°«‘∏’ (anismus) ·≈– „Àâ°“√√—°…“‚¥¬«‘∏’ biofeedback ®÷ßπà“®–¡’ª√–‚¬™πåµàÕºŸâªÉ«¬ References : 1. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002;97 (Suppl 11):S7- 26. 2. Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treat- ments for irritable bowel syndrome: a European perspective. Aliment Pharmacol Ther 2006;24:183 - 205. 3. Hammer J, Eslick GD, Howell SC, Altiparmak E, Talley NJ. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut 2004;53:666-72. 4. Ford AC, Talley NJ, Veldhuyzen van Zanten SJ, Vakil NB, Simel DL, Moayyedi P. Will the history and physical examination help establish that irritable bowel syndrome is causing my patientûs lower gastrointestinal symptoms? JAMA 2008;300:1793-805. 5. Cash BD, Schemed P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol 2002;97:2812-9. 6. American Gastroenterological Association. AGA medical position statement: Irritable bowel syndrome. Gastroenterology 2002;123:2105-7. 7. Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. Br Med J 1978;277:653-4. 8. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med 1995;122:107-12. 9. Spiegel BMR, Nalibo7 B, Mayer E, et al. The effectiveness of a model physician-patient relationship versus usual care in irritable bowel syndrome: a andomized controlled trial. Gastro- enterology 2006;130:A773. 10. Simren M, Mansson A, Langkilde AM, et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 2001;63:108-15.
  • 24. 23§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 11. Park MI, Camilleri M. Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review. NeurogastroenterolMotil 2006;18:595-607. 12. Atkinson W, Sheldon T, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomized controlled trial. Gut 2004;53:1459-64. 13. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. American College of Gastroenterology Task Force on Irritable Bowel Syndrome. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104 Suppl 1:S1-35. 14. Robinson A , Lee V, Kennedy A , et al. A randomized controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome. Gut 2006;55:643-648. 15. Whitehead WE, Palsson O, Jones KR.. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002;122:1140-56. 16. Miller AR, North CS, Clouse RE, Wetzel RD, Spitznagel EL, Alpers DH. The association of irritable bowel syndrome and somatization disorder. Ann Clin Psychiatry 2001;13:25-30. 17. Lackner JM, Mesmer C, Morley S, Dowzer C, Hamilton S. Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis .J Consult Clin Psychol 2004;72: 1100-13. 18. Ford A, Talley N, Schoenfeld P, et al. Efficacy of psychological therapies in irritable bowel syndrome: systematic and meta-analysis. Am J Gastroenterol 2008;103 (Suppl 1):S477. 19. Webb AN, Kukuruzovic RH, Catto-Smith AG, Sawyer SM. Hypnotherapy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2007 (4) CD005110. 20. Drossman D, Toner B, Whitehead W, et al. Cognitive-behavioral therapy vs. education and desipramine vs. placebo for moderate to severe functional bowel disorders. Gastroenterology 2003; 125:19-31. 21. Tan G, Hammond D, Gurrala J. Hypnosis and irritable bowel syndrome: a review of efficacy and mechanism of action. Am J Clin Hypnosis 2005;47:161-178. 22. Whelan K. Probiotics and prebiotics in the management of IBS: a review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Care 2011;14:531-7. 23. McFarland LV, Dubin S. Meta-analysis of probiotics for the treatment of IBS. World J Gastroenterol 2008;14:2650-61. 24. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of IBS; a systematic review. Am J Gastroenterol 2009;104:1033-49. 25. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of IBS: a systematic review. Gut 2010;59:325-32. 26. Liu J, Yang M, Liu Y, Wei M, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006 ;(1):CD004116. 27. Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Ali- ment Pharmacol Ther 2004;19:271-279. 28. Patcharatrakul T, Gonlachanvit S. Outcome of biofeedback therapy in dyssynergic defecation patients with and without irritable bowel syndrome. J Clin Gastroenterol 2011; 45(7):593-598.
  • 25. 24 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 Pharmacological Treatment ¢âÕ √ÿª∑’Ë 21. ¬“∑’Ë¡’ª√–‚¬™πå„π°“√√—°…“ºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π‰¥â·°à antispasmodics, fiber, anti-diarrheal, laxatives, antibiotics, probiotics, lubiprostone, linaclotide,anti-depressants(TCAandSSRI)·≈–¬“∑’ËÕÕ°ƒ∑∏‘Ϻà“π√–∫∫ serotonin À√◊Õ 5-HT receptor °“√√—°…“≈”‰ â·ª√ª√«πªí®®ÿ∫—π¬—߇πâπ∑’Ë°“√√—°…“µ“¡Õ“°“√‡ªìπÀ≈—° à«π¬“ ∑’ËÕÕ°ƒ∑∏‘Ϻà“π serotonin receptors π—Èπ°Á “¡“√∂„™â‰¥âµ“¡¢âÕ∫àß™’È 21.1. °“√√—°…“Õ“°“√ª«¥∑âÕß  “¡“√∂„™â¬“∑’Ë≈¥Õ“°“√ª«¥‡°√Áß (antispasmodics) ‰¥â ‰¡à«à“®–‡ªìπ hyoscine, mebeverine ·µà‡π◊ËÕß®“°¬“‡À≈à“π’È ¡’®”Àπà“¬¡“π“π·≈â« °“√»÷°…“∑’ˇ§¬∑”‡¡◊ËÕπ“π·≈â«π—Èπ ¡—°¡’¢π“¥‡≈Á° ‰¡à ¡∫Ÿ√≥å „π‡™‘ß RCT ·≈–Õ“®¡’ publication bias ·¡â¡’ºŸâ∑” meta-analysis · ¥ß„Àâ‡ÀÁπ ª√–‚¬™πå·≈â«°Áµ“¡1 πÕ°®“°π—Èπ¡’¬“∑’Ë¢÷Èπ∑–‡∫’¬π„πª√–‡∑»Õ’° ‡™àπ Trimebutine (´÷Ë߇ªìπ opioid antagononist), pinaverium (Dicetel ) ·≈– dicyclomine (dicycloverine) ·µà°Á‰¡à¡’À≈—°∞“π«à“¡’ª√–‚¬™πåÕ¬à“ß™—¥‡®π Õ¬à“߉√°Áµ“¡¡’ºŸâªÉ«¬∫“ß√“¬∑’˵Õ∫ πÕß µàÕ°“√√—°…“‡™àπ°—π  à«π¬“ ‡™àπ alverine (Spasmonal ), fenoverine (Spasmopriv ) ‡§¬¡’ ®”Àπà“¬„πª√–‡∑» ·µàªí®®ÿ∫—π‰¥â∂Õπ∑–‡∫’¬π‰ª·≈â« ¬“∑’Ë¡’º≈µàÕ pain modulation °Á‡≈◊Õ°„™â‰¥â ‡™àπ tricyclic antidepressant ·≈– SSRI2 ·µà¬“°≈ÿà¡ GABA analogue ‡™àπ gabapentin ·≈– pregabalin ¬—ß ‰¡à¡’°“√»÷°…“„π IBS 21.2. °“√√—°…“Õ“°“√∑âÕ߇ ’¬ ‡≈◊Õ°„™â¬“µàÕ‰ªπ’ȉ¥â ● Antidiarrheal drugs ‡™à𠬓º ¡ diphenoxylate À√◊Õ loperamide ‚¥¬¬“ “¡“√∂≈¥§«“¡∂’Ë ∑”„Àâª√‘¡“≥Õÿ®®“√–, ≈—°…≥–Õÿ®®“√–¥’¢÷Èπ‰¥â ·µà‰¡à¡’º≈ µàÕÕ“°“√ª«¥∑âÕß ·≈– global assessment ¥’¢÷ÈππâÕ¬3,4 ●  à«π codeine ‰¡à·π–π”„Àâ„™â‡æ√“–𔉪 Ÿà abuse ‰¥â ● 5-HT3 antagonists ‡™àπ alosetron, ramosetron
  • 26. 25§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 Alosetron ¬“¬—߉¡à‰¥â¢÷Èπ∑–‡∫’¬π„πª√–‡∑»‰∑¬ ·¡âæ∫«à“‰¥âº≈¥’¡“° ·µà‡π◊ËÕß®“°æ∫º≈¢â“߇§’¬ß§◊Õ ischemic colitis ·≈–¡’∫“ß√“¬‡ ’¬™’«‘µ ºŸâº≈‘µ®÷ß ®”°—¥„Àâ·æ∑¬å —Ëß„™â‡©æ“–°√≥’¡’¢âÕ∫àß™’È·≈–ºŸâªÉ«¬∑√“∫º≈¢â“߇§’¬ß·≈–¬‘π¬Õ¡„™â ‡∑à“π—Èπ·≈–‡©æ“–„π À√—∞Õ‡¡√‘°“ª√–‡∑»‡¥’¬«≈à“ ÿ¥æ∫«à“ºŸâªÉ«¬°≈ÿà¡π’È “¡“√∂„™â¬“ „π√–¬–¬“«‰¥âÕ¬à“߉¥âº≈·≈–ª≈Õ¥¿—¬5 Ramosetron ¢÷Èπ∑–‡∫’¬π„πª√–‡∑»·≈â« æ∫«à“‰¥âº≈¥’¡“°„πºŸâªÉ«¬™“¬ ·≈– °”≈—ß¡’°“√»÷°…“„π«ß°«â“ßµàÕ‰ª6 °“√„™â¬“ªØ‘™’«π–Õ“®¡’ª√–‚¬™πå„π°“√√—°…“ IBS-D ‰¥â ‚¥¬¡’ ¡¡µ‘∞“π«à“ ºŸâªÉ«¬Õ“®¡’°“√µ‘¥‡™◊ÈÕ·ΩßÀ√◊Õ‡ªìπ°“√ª√—∫ ‘Ëß·«¥≈âÕ¡®ÿ≈™’æ„π≈”‰ âÀ√◊ÕºŸâªÉ«¬Õ“®¡’ small intestinal bacterial overgrowth À√◊Õ tropical sprue Õ¬Ÿà ¬“ªØ‘™’«π–∑’Ë¡’°“√»÷°…“ªí®®ÿ∫—π¡’‡æ’¬ß¢π“π‡¥’¬«§◊ÕRifaximin ‡¡◊ËÕªï2011 ¡’°“√»÷°…“ phase III ∑’Ë· ¥ß„Àâ‡ÀÁπ«à“ Rifaximin ‰¥âº≈¥’„πºŸâªÉ«¬ non IBS-C ‚¥¬∑”„ÀâÕ“°“√√«¡¥’¢÷È𠪫¥∑âÕß ∑âÕßÕ◊¥¥’¢÷Èπ µ≈Õ¥®π≈—°…≥–Õÿ®®“√–∑’ˇÀ≈« ‡ªìππÈ”°Á¥’¢÷Èπ¥â«¬7 21.3. °“√√—°…“Õ“°“√∑âÕߺŸ° ‡≈◊Õ°„™â¬“µàÕ‰ªπ’ȉ¥â ● Fiber „¬Õ“À“√„Àâº≈¥’„π√“¬∑’ˉ¥â√—∫„¬Õ“À“√µàÕ«—ππâÕ¬°«à“‡°≥±å À√◊Õ°≈ÿà¡∑’˵âÕß°“√„¬Õ“À“√¡“°°«à“Õ—µ√“‡©≈’ˬ À√◊ÕºŸâ∑’Ë√—∫ª√–∑“π„¬Õ“À“√‰¡à  ¡Ë”‡ ¡Õ8-10 Õ¬à“߉√°Áµ“¡À“°ºŸâªÉ«¬‰¡à‰¥âµâÕß°“√„¬Õ“À“√‡æ‘Ë¡¢÷Èπ°«à“∑’˧«√‰¥â°Á¡—°¡’ Õ“°“√¢â“߇§’¬ß‡™àπ ∑âÕßÕ◊¥ ¡’≈¡„π∑âÕß À“°‡ªìπ‰ª‰¥â§«√‰¥â√—∫„¬Õ“À“√„π√Ÿª·∫∫ ∏√√¡™“µ‘ ‡™àπ®“°º—° º≈‰¡â ¡“°°«à“„π√Ÿª∑’Ë¢÷Èπ∑–‡∫’¬π‡ªìπ¬“À√◊Õº≈‘µ¿—≥±å‡ √‘¡ Õ“À“√ ● Laxatives‰¡à¡’À≈—°∞“π‡™‘ßª√–®—°…å„π°“√„™â¬“ conventional laxatives (‡™àπ magnesium salt, lactulose, bisacodyl, senna) „πºŸâªÉ«¬ IBS ·µàæ∫«à“ ¡’°“√„™â¬“°≈ÿà¡π’ÈÕ¬à“ß°«â“ߢ«“ß ·≈–‡ªìπ∑’ˬա√—∫∑—Èß„πºŸâªÉ«¬·≈–·æ∑¬å  à«πpolyethyleneglycol¡’°“√»÷°…“¢π“¥‡≈Á°·µà°Áæ∫«à“‰¥âº≈¥’°«à“Õ“°“√ ¢â“߇§’¬ßπâÕ¬°«à“ lactulose11 ● Lubiprostone´÷Ëßæ∫«à“°“√„™â·¡â„π√–¬–¬“«°Á‰¥âº≈¥’ª≈Õ¥¿—¬·≈–ºŸâªÉ«¬ ∑π°“√√—°…“‰¥â¥’ ¬“ºà“π°“√√—∫√Õß®“° US FDA ·≈â«·≈–‡ªìπ‡æ’¬ß¢π“π‡¥’¬«∑’Ë
  • 27. 26 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 √—∫√Õß„Àâ„™â„π IBS-C ‰¥â∑—Ë«‰ª‰¡à¡’¢âÕ®”°—¥À√◊Õ¢âÕ∫àß™’ȇ©æ“– ¢≥–π’È√Õ¢÷Èπ∑–‡∫’¬π „πª√–‡∑»‰∑¬12 ● 5-HT4 agonist Tegaserod ‡ªì𬓰≈ÿà¡π’È∑’ˇ§¬¢÷Èπ∑–‡∫’¬π„πª√–‡∑» ·≈–æ‘ Ÿ®πå«à“‰¥âº≈¥’ ª≈Õ¥¿—¬ ·µàµàÕ¡“ºŸâº≈‘µ·≈–®”Àπà“¬¢Õ¬°‡≈‘°‰¡à®”Àπà“¬ ®“°∑’Ë¡’°“√»÷°…“ ∑∫∑«πºŸâªÉ«¬∑’ˇ¢â“√à«¡°“√∑¥ Õ∫∑“ߧ≈‘π‘°®”π«π¡“°æ∫«à“ºŸâ∑’ˉ¥â√—∫¬“¡’Õ—µ√“ ‡°‘¥¿“«–·∑√°´âÕπ·≈–Õ—µ√“µ“¬®“°‚√§À—«„®·≈– stroke ¡“°°«à“13 ● Prucalopride ¬“π’È¢÷Èπ∑–‡∫’¬π·≈â«∑—Èß„π·≈–µà“ߪ√–‡∑»‡æ◊ËÕ„™â√—°…“ chronicconstipation´÷Ëß„Àâº≈¥’·≈–ª≈Õ¥¿—¬¢≥–π’È¡’¢âÕ¡Ÿ≈«à“‰¥âº≈¥’„πºŸâªÉ«¬IBS- C ·µà¬—߉¡à‰¥â¢÷Èπ∑–‡∫’¬π°“√√—°…“„π¢âÕ∫àß™’Èπ’È ● Linaclotide ªí®®ÿ∫—π¢÷Èπ∑–‡∫’¬π„π À√—∞Õ‡¡√‘°“‡æ◊ËÕ√—°…“ IBS-C ·≈â«14 ·µà¬—߉¡à¡’„™â„πª√–‡∑»‰∑¬ ● Cisapride ªí®®ÿ∫—πºŸâº≈‘µ¬“µâπµ”√—∫∂Õπ∑–‡∫’¬π‰ªπ“π·≈â« „πª√–‡∑» ¡’®”Àπà“¬‡ªì𬓠generic ‡∑à“π—Èπ °“√»÷°…“º≈¢Õß cisapride „π IBS-C ¡’‰¡à¡“° ¡’‡æ’¬ß°“√»÷°…“‡¥’¬«∑’Ëæ∫«à“¥’°«à“ placebo17 ·µàÀ≈—ß®“°π—Èπ·≈–®“° systematic review18 æ∫«à“‰¡à‰¥âº≈¥’°«à“ placebo ● Mosapride ‡∑à“∑’Ë ◊∫§âπ‰¥â¡’‡æ’¬ß°“√»÷°…“‡¥’¬«19 ‡ªìπ°“√»÷°…“·∫∫‡ªî¥ „πºŸâªÉ«¬ 10 √“¬ æ∫«à“™à«¬„ÀâÕ“°“√‚¥¬√«¡¥’¢÷Èπ‰¥â ¢âÕ √ÿª∑’Ë 22. ‰¡à¡’¢âÕ∫àß™’È„π°“√„™â¬“≈¥°√¥„πºŸâªÉ«¬≈”‰ â·ª√ª√«π∑’ˉ¡à¡’Õ“°“√¢Õß °√¥‰À≈¬âÕπÀ√◊Õ°√–‡æ“–Õ“À“√∑”ß“πº‘¥ª°µ‘ (ª«¥· ∫∑âÕß∫√‘‡«≥≈‘Èπªïò) ºŸâªÉ«¬≈”‰ â·ª√ª√«π∑’ˉ¡à¡’Õ“°“√¢Õß°√¥‰À≈¬âÕπÀ√◊Õ°√–‡æ“–Õ“À“√ ∑”ß“πº‘¥ª°µ‘ (ª«¥· ∫∑âÕß∫√‘‡«≥≈‘Èπªïò) °“√„™â¬“√–ß—∫°“√À≈—Ëß°√¥¡’∫∑∫“∑πâÕ¬ ®“°°“√ ◊∫§âπ æ∫«à“ 22.1. ‰¡à¡’°“√»÷°…“∂÷ß∫∑∫“∑¢Õ߬“√–ß—∫°“√À≈—Ëß°√¥ ‰¡à«à“®–‡ªìπ H2- receptor antagonist À√◊Õ PPI „πºŸâªÉ«¬≈”‰ â·ª√ª√«π‡≈¬ 22.2. Õ¬à“߉√°Áµ“¡ æ∫«à“ºŸâªÉ«¬Õ“®¡’Õ“°“√¢Õß∑—Èß≈”‰ â·ª√ª√«π·≈–
  • 28. 27§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 ‚√§°√¥‰À≈¬âÕπÀ√◊Õ functional dyspepsia ‡À≈◊ËÕ¡´âÕπ‰¥â„π¢≥–‡¥’¬«°—π ‚¥¬ ¡’§«“¡™ÿ°Õ¬Ÿà√“« 11-27 %15 ºŸâªÉ«¬¡—°¡’Õ“°“√¡“°°«à“ºŸâ∑’Ë¡’¿“«–Àπ÷Ëß¿“«–„¥ ‡æ’¬ßÕ¬à“߇¥’¬« ®÷ßæ∫‰¥â¡“°„π ∂“π欓∫“≈√–¥—∫µµ‘¬¿Ÿ¡‘ ·≈–¡—°¡’ psychiatric comorbidity16 Õ—πÕ“®‰¥â√—∫ª√–‚¬™π宓°°“√ª√–‡¡‘π·≈–√—°…“∑“ß®‘µ‡«™ à«πÕ“°“√ ¢Õß·µà≈–¿“«–·π–π”„Àâ√—°…“·¬°®“°°—π Reference 1. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth musclerelaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15:355-61. 2. Jackson JL, OûMalley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108:65-72. 3. Lavo B, Stenstam M, Nielsen A-L. Loperamide in treatment of irritable bowel syndrome - A double-blind placebo controlled study. Scand J Gastroenterol Suppl 1987;22:77-80. 4. Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology 1980;79:1272- 5. 5. Nicandro JP, Shin P, Chuang E. Evaluation of treatment continuation with alosetron by IBS-D severity criteria. Curr Med Res Opin 2012;28:449-56. 6. Lee KJ, Kim NY , Kwon JK , et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil 2011;23:1098-104. 7. PimentelM, Lembo A, Chey WD, et al. Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation. New Engl J Med 2011;364:22-32. 8. Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet 1994;344:39-40. 9. Prior A, Whorwell PJ. Double blind study of ispaghula in irritable bowel syndrome. Gut 1987;28:1510-13. 10. Bijkerk CJ, Muris JWM, Knottnerus JA, Hoes AW, De Wit NJ. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;19:245-51. 11. Attar A, Lemann M, Ferguson A, et al. Comparison of a low dose polyethylene glycol electro- lyte solution with lactulose for treatment of chronic constipation. Gut 1999;44:226-30. 12. Chey WD, Drossman DA, Johanson JF, Scott C, Panas RM, Ueno R. Safety and patient out- comes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2012;35:587-99. 13. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev 2007:CD003960. 14. Wensel TM, Luthin DR. Linaclotide: a novel approach to the treatment of irritable bowel syn- drome. Ann Pharmacother 2011;45:1535-43. 15. Suzuki H, Hibi T. Overlap syndrome of functional dyspepsia and irritable bowel syndrome - are both diseases mutually exclusive? J Neurogastroenterol Motil 2011;17:360-5.
  • 29. 28 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 16. Piacentino D, Cantarini R, Alfonsi M, et al. Psychopathological features of irritable bowel syndrome patients with and without functional dyspepsia: a cross sectional study. BMC Gastroenterol 2011;11:94. 17. Van Outryve M, Milo R, Toussaint J, Van Eeghem P. çProkinetic-treatment of constipation- predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol 1991;13:49-57. 18. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analy- sis. Am J Gastroenterol 2009;104:1831-43. 19. Nakamura M, Ohmiya N, Miyahara R, et al. Are symptomatic changes in irritable bowel syn- drome correlated with the capsule endoscopy transit time? A pilot study using the 5-HT4 recep- tor agonist mosapride. Hepatogastroenterology 2011;58:453-8.
  • 30. 29§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 Psychiatric problems „π IBS ¢âÕ √ÿª∑’Ë 23. ¿“«–§«“¡º‘¥ª°µ‘∑“ß®‘µ‡«™‡™àπ‡§√’¬¥«‘µ°°—ß«≈À√◊Õ´÷¡‡»√Ⓡªìπ¿“«– ∑’Ëæ∫∫àÕ¬„πºŸâªÉ«¬‚√§≈”‰ â·ª√ª√«π ·≈–§«√‰¥â√—∫°“√√—°…“Õ¬à“߇À¡“– ¡ §«“¡º‘¥ª°µ‘∑“ß®‘µ‡«™ ‡™àπ anxiety, depression ·≈– somatization „πºŸâªÉ«¬ Irritable Bowel Syndrome (IBS) ¢âÕ¡Ÿ≈¢Õß Lee ·≈–§≥–1 ´÷Ëß»÷°…“„πª√–™“°√∑—Ë«‰ª∑’ËŒàÕß°ß®”π«π2,005√“¬æ∫«à“ºŸâªÉ«¬∑’Ë¡’generalanxiety disorder (GAD) ¡’Õ—µ√“°“√æ∫ IBS ‰¥â¡“°°«à“ºŸâ∑’ˉ¡à¡’ GAD 4.7 ‡∑à“ ·≈–ºŸâªÉ«¬ IBS ¡’Õ—µ√“°“√æ∫ GAD ‰¥â¡“°°«à“ºŸâ∑’ˉ¡à¡’Õ“°“√ IBS ‰¥â∂÷ß 5 ‡∑à“ ¢âÕ¡Ÿ≈°“√»÷°…“¢Õß Choung PS ·≈–§≥–2 æ∫«à“ºŸâªÉ«¬∑’Ë¡’ somatic symptom score  Ÿß ¡’Õ—µ√“°“√‡°‘¥‚√§ IBS ‰¥â Ÿß°«à“ºŸâ∑’Ë¡’ somatic symptom score µË” ‰¥â∂÷ß 4 ‡∑à“ º≈°“√»÷°…“¢Õß Henningsen ·≈–§≥–3 ‚¥¬∑” meta-analysis æ∫«à“ ºŸâªÉ«¬∑’Ë¡’Õ“°“√¢Õß IBS ¡’Õ—µ√“°“√æ∫ anxiety ·≈– depression ‰¥â¡“°°«à“ ∑’Ëæ∫„π§πª°µ‘ À√◊ÕºŸâªÉ«¬∑’Ë¡’Õ“°“√‡π◊ËÕß®“°¡’ organic cause „πºŸâªÉ«¬ IBS ∑’Ë¡“ª√÷°…“·æ∑¬å®–¡’Õ—µ√“°“√æ∫anxiety‰¥â Ÿß°«à“ºŸâªÉ«¬IBS∑’ˉ¡à‰¥â¡“æ∫·æ∑¬å „π√“¬ß“π¢Õß Gros ·≈–§≥–4 æ∫«à“ºŸâªÉ«¬ panic disorders, GAD ·≈–ºŸâªÉ«¬ ∑’Ë¡’ major depression ¡’Õ—µ√“°“√‡°‘¥Õ“°“√¢Õß IBS ‰¥â¡“°°«à“ ‚¥¬∑’˺ŸâªÉ«¬ ∑’ˇªìπ social anxiety disorder, specific phobia ·≈– obsessive-compulsive disorder ¡’Õ“°“√¢Õß IBS ‰¡àµà“ß®“°§πª°µ‘ §«“¡√ÿπ·√ß·≈–§«“¡∂’Ë¢ÕßÕ“°“√ IBS „πºŸâªÉ«¬ GAD ®–¡“°°«à“„π°≈ÿࡺŸâªÉ«¬Õ◊ËπÊ √“¬ß“π¢Õß Creed ·≈–§≥–5 æ∫«à“ºŸâªÉ«¬ IBS ∑’Ë¡’ marked somatization Õ“°“√¢Õß IBS ®–¥’¢÷Èπ‚¥¬°“√√—°…“ ¥â«¬ psychotherapy À√◊Õ antidepressant ¡“°°«à“°“√√—°…“‚¥¬«‘∏’ª°µ‘ °“√»÷°…“‚¥¬ Friedrich ·≈–§≥–6 ´÷Ë߇ªìπ°“√∑” meta-analysis æ∫«à“°“√„™â¬“ antidepressant (TCA ·≈– SSRI) „π°“√√—°…“ IBS ∑’Ë¡’ depression √à«¡¥â«¬ æ∫«à“¬“ antidepressant ∫“ߢπ“πÕ“®®–∑”„ÀâÕ“°“√¢Õß IBS ¥’¢÷Èπ ‚¥¬‰¡à¡’ §«“¡ —¡æ—π∏å°—∫º≈¢Õ߬“µàÕÕ“°“√ depression ∑’ˇ°‘¥√à«¡ ‚√§ IBS ‰¡à‰¥â‡ªìπ‚√§∑“ß®‘µ‡«™·µàºŸâªÉ«¬IBS¡’‚Õ°“ ∑’Ë®–æ∫§«“¡º‘¥ª°µ‘
  • 31. 30 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 ∑“ß®‘µ‡«™‰¥â¡“°°«à“ª√–™“°√∑—Ë«‰ª¥—ß°≈à“«¡“¢â“ßµâπ ºŸâªÉ«¬ IBS ∑’Ë¡’ªí≠À“ ∑“ß®‘µ‡«™§«√‰¥â√—∫°“√¥Ÿ·≈√—°…“√à«¡‰ª¥â«¬°—π∑—Èß Õߪí≠À“ References 1. Lee S, Wu J, Ma YL, Tsang A, Guo WJ, Sung J. Irritable bowel syndrome is strongly associated with generalized anxiety disorder: a community study. Aliment Pharmacol Ther 2009;30:643- 51. 2. Choung RS, Locke R, Zinsmeistr AR, Schleck CD, Talley NJ. Psychosocial distress and somatic symptoms in community subjects with irritable bowel syndrome: a psychological component is the rule. Am J Gastroenterol 2009;104:1772-9. 3. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosomatic Medicine 2003;65:528-33. 4. Gros DF, Antony MM, McCabe RE, Swinson RP. Frequency and severity of the symptoms of irritable bowel syndrome across the anxiety disorders and depression. J Anxiety Disorders 2009;23:290-6. 5. Creed F, Tomenson B, Guthrie E, et al. The relationship between somatization and outcome in patients with severe irritable bowel syndrome. J of Psychosomatic Res 2008;64:613-20. 6. Friedrich M, Grady SE, Wall GC. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. Clin Ther 2010;32:1221-33. ¢âÕ √ÿª∑’Ë 24. °“√ «π≈â“ß≈”‰ âÕ“®∑”„ÀâÕ“°“√≈”‰ â·ª√ª√«π¥’¢÷Èπ™—Ë«§√“«·µàº≈¥’À√◊Õ º≈‡ ’¬√–¬–¬“«¬—߉¡à¡’¢âÕ¡Ÿ≈∑“ß°“√·æ∑¬å™—¥‡®π „πºŸâªÉ«¬≈”‰ â·ª√ª√«π∑’Ë¡’Õ“°“√∑âÕߺŸ°‡ªìπª√–®”°“√ «π≈â“ß≈”‰ â Õ“®∑”„ÀâÕ“°“√¥’¢÷Èπ™—Ë«§√“«·µà‰¡à§«√∑”‡ªìπª√–®”‡π◊ËÕß®“°‰¡à¡’¢âÕ¡Ÿ≈∑“ß°“√ ·æ∑¬å∑’Ë∫àß∫Õ°∂÷ߺ≈¥’À√◊Õº≈‡ ’¬√–¬–¬“« „πºŸâªÉ«¬≈”‰ â·ª√ª√«π∑’Ë¡’Õ“°“√§àÕπ‰ª∑“ß∑âÕ߇ ’¬°“√ «π≈â“ß≈”‰ â‰¡àπà“ ®–‰¥âª√–‚¬™πå„¥ Ê
  • 33. 32 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012 𓬷æ∑¬å°‘µµ‘ ®—π∑√å‡≈‘»ƒ∑∏‘Ï ‚√ß欓∫“≈»√’π§√‘π∑√å ¢Õπ·°àπ ·æ∑¬åÀ≠‘ß®‘π¥“√—µπå ‡®’¬‡®…Ø“°ÿ≈ ‚√ß欓∫“≈æ√–¡ß°ÿƇ°≈â“ °√ÿ߇∑æ¡À“π§√ ·æ∑¬åÀ≠‘ß‚©¡»√’ ‚¶…‘µ™—¬«—≤πå ‚√ß欓∫“≈√“¡“∏‘∫¥’ °√ÿ߇∑æ¡À“π§√ ·æ∑¬åÀ≠‘ß∞π‘ “ æ—™√µ√–°Ÿ≈ ‚√ß欓∫“≈®ÿÓ≈ß°√≥å °√ÿ߇∑æ¡À“π§√ 𓬷æ∑¬å∏‡π» ®—¥«—≤π°ÿ≈ ‚√ß欓∫“≈ ¡‡¥Á®æ√–∫√¡√“™‡∑«’ ≥ »√’√“™“ ™≈∫ÿ√’ 𓬷æ∑¬å∏‡π» ™‘µ“æπ“√—°…å ‚√ß欓∫“≈¡À“√“™π§√‡™’¬ß„À¡à ‡™’¬ß„À¡à 𓬷æ∑¬åπæ«ÿ≤‘ °’√µ‘°√≥å ÿ¿—§ ‚√ß欓∫“≈ ¡‡¥Á®æ√–∫√¡√“™‡∑«’ ≥ »√’√“™“ ™≈∫ÿ√’ ·æ∑¬åÀ≠‘ßπ‘»“ ‡πµ‘π“∂ ÿπ∑√ ‚√ß欓∫“≈ ß¢≈“π§√‘π∑√å  ß¢≈“ 𓬷æ∑¬å∫—≠™“ ‚Õ«“∑Ó√æ√ ‚√ß欓∫“≈ ß¢≈“π§√‘π∑√å  ß¢≈“ ·æ∑¬åÀ≠‘ß∫ÿ…∫“ «‘«—≤π凫§‘π ‚√ß欓∫“≈®ÿÓ≈ß°√≥å °√ÿ߇∑æ¡À“π§√ ·æ∑¬åÀ≠‘ß¡≥±‘√“ ¡≥’√—µπ–æ√ ‚√ß欓∫“≈»‘√‘√“™ °√ÿ߇∑æ¡À“π§√ 𓬷æ∑¬å√—∞°√ «‘‰≈™π¡å ‚√ß欓∫“≈∏√√¡»“ µ√å °√ÿ߇∑æ¡À“π§√ ·æ∑¬åÀ≠‘ß«√πÿ™ ®ß»√’ «— ¥‘Ï ‚√ß欓∫“≈®ÿÓ≈ß°√≥å °√ÿ߇∑æ¡À“π§√ ·æ∑¬åÀ≠‘ß«√¡π ‡®’¬¡»√’æß…å ‚√ß欓∫“≈æÿ∑∏™‘π√“™ æ‘…≥ÿ‚≈° 𓬷æ∑¬å«“π‘™ ªî¬π‘√—π¥√å ‚√ß欓∫“≈æ√–¡ß°ÿƇ°≈â“ °√ÿ߇∑æ¡À“π§√ ·æ∑¬åÀ≠‘ß«‚√™“ ¡À“™—¬ ‚√ß欓∫“≈®ÿÓ≈ß°√≥å °√ÿ߇∑æ¡À“π§√ 𓬷æ∑¬å»µ«√√… ∑Õß «— ¥‘Ï ‚√ß欓∫“≈¡À“√“™π§√‡™’¬ß„À¡à ‡™’¬ß„À¡à 𓬷æ∑¬å»√—≥¬å «√√≥¿“ π’ ‚√ß欓∫“≈ √√æ ‘∑∏‘ª√– ß§å Õÿ∫≈√“™∏“π’ 𓬷æ∑¬å»ÿ¿™—¬ »√’»‘√‘√ÿàß ‚√ß欓∫“≈æ≠“‰∑ »√’√“™“ ™≈∫ÿ√’ 𓬷æ∑¬å ¡™“¬ ≈’≈“°ÿ»≈«ß»å ‚√ß欓∫“≈»‘√‘√“™ °√ÿ߇∑æ¡À“π§√ 𓬷æ∑¬å ¬“¡ »‘√‘π∏√ªí≠≠“ ‚√ß欓∫“≈√“™«‘∂’ °√ÿ߇∑æ¡À“π§√ 𓬷æ∑¬å ‘π Õπÿ√“…Æ√å ‚√ß欓∫“≈∫”√ÿß√“…Æ√å °√ÿ߇∑æ¡À“π§√ ·æ∑¬åÀ≠‘ß ÿæ√ µ√’æß…å°√ÿ≥“ ‚√ß欓∫“≈√“¡“∏‘∫¥’ °√ÿ߇∑æ¡À“π§√ 𓬷æ∑¬å ÿ√‘¬– ®—°°–æ“° ‚√ß欓∫“≈√“¡“∏‘∫¥’ °√ÿ߇∑æ¡À“π§√ 𓬷æ∑¬å ÿ‡∑æ °≈™“≠«‘∑¬å ‚√ß欓∫“≈®ÿÓ≈ß°√≥å °√ÿ߇∑æ¡À“π§√ 𓬷æ∑¬åÕÿ¥¡ §™‘π∑√ ‚√ß欓∫“≈»‘√‘√“™ °√ÿ߇∑æ¡À“π§√ √“¬π“¡ºŸâ‡¢â“√à«¡ª√–™ÿ¡ —¡¡π“æ‘®“√≥“ Guideline for Management of Irritable bowel syndrome §√—Èß∑’Ë 1 «—π∑’Ë 22-23 ¡°√“§¡ 2554 ≥ ‚√ß·√¡¥ÿ ‘µ ∏“π’ æ—∑¬“ ®—ßÀ«—¥™≈∫ÿ√’ §√—Èß∑’Ë 2 «—π∑’Ë 23-24 ¡‘∂ÿπ“¬π 2555 ≥ ‚√ß·√¡‡™Õ√“µ—π À—«À‘π √’ Õ√å∑·Õπ¥å ª“ ®—ßÀ«—¥ª√–®«∫§’√’¢—π∏å